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ABSTRACT OF THE DISSERTATION 
 
Leveraging the Tools and Techniques of Precision Medicine 
to Better Understand the Biological Underpinnings of  
Psychiatric Disorders and Psychotropic Treatment Effects 
 
by 
 
Lauren Catherine Seaman  
Doctor of Philosophy in Chemistry 
University of California, Los Angeles, 2019 
Professor William M. Gelbart, Chair 
Professor Erika Lynn Nurmi, Co-Chair 
 
 
The dawn of a new era of medicine has begun as clinicians and researchers shift their focus to 
more individual-centric diagnostic, treatment, and disease management strategies. Precision 
medicine is a multidisciplinary approach to human health care that takes into account a person’s 
genetic makeup, behaviors, and environmental factors when evaluating pathophysiology, 
tailoring treatments, and designing novel therapeutic moieties. In this dissertation I break down 
the critical subfields of this discipline to explain and apply the emerging tools and techniques we 
now have at our disposal to better understand the underlying biology of complex human 
psychiatric disorders. 
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We begin with pharmacokinetics and pharmacodynamics, two branches of precision medicine 
that are involved directly with the temporal dynamics of pharmaceutical therapies and aid in 
disentanglement of how the body processes drugs versus how the drugs affect our bodies. I 
discuss detailed research across three separate drugs; risperidone, methamphetamine, and 
nicotine, integrating quantitative metabolic studies, genetic assessment, neuroimaging, and 
receptor analysis to clearly define inter-patient variability in risk and response.  
 
Following this is work I accomplished in the realm of gene and environment interactions in 
young children experiencing anxiety disorders, which over time, led to what I hold as my largest 
contribution to the personalized medicine field; microbiome and host interactions. I am 
attempting to unlock a more direct, biological mechanism to something known as antipsychotic-
induced weight gain (AIWG) through the examination of bile acids and the gut microbiome and 
their crosstalk and interplay with host physiology. Results are abundant throughout this 
document and each study presented here within brings a unique piece of the precision medicine 
puzzle to the table. 
 
Pharmacokinetics, pharmacodynamics, genomic technology, gene-environment interactions, 
and the host-microbiome axis are the salient concepts in my toolbox of personalized medicine 
techniques that I believe can be leveraged in a variety of combinations to accomplish large 
goals in the medical and biotechnology fields. Whether it be through careful patient assessment 
with companion diagnostics, proper medication selection based on risk vs. reward value in 
harmony with an individual’s personal makeup, perseverance of high level disease progression 
and treatment monitoring, or even one day tailoring drug discovery to the highly specific 
receptors and biological pathways involved in these grievous diseases, it is clear precision 
medicine will pave the way for a better life for many people in the future. 
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Chapter 1  
An Introduction and Overview of the World of Personalized Medicine 
 
Personalized medicine—two simple words with a hidden universe of meaning, potential, and 
hope. It takes other names, such as precision medicine, stratified medicine, or theranostics, but 
in the end, all represent the same overarching goal; to tailor medical decisions, pharmaceutical 
interventions, and even long-term care and disease management to each unique individual. 
While this is not a new philosophy, as Hippocrates once said, “It is more important to know what 
sort of person has a disease than to know what sort of disease a person has”, the rapid 
advancement of diagnostic and informatic technologies has pushed the field back into the 
limelight of the medical world. These novel approaches revolve around understanding the 
molecular hierarchy of disease, specifically focusing broad scope genomics, and the 
development of the personalized medicine concept was first coined in this context but continues 
to expand to encompass many specific measures. In fact, over the last 10 years, the focus of 
the medical treatment world has shifted from “reaction” to “prevention” and can be clearly 
observed in the 870% increase of personalized medicine drugs, treatments and diagnostics 
products available in the market over this time period.1  
 
This increased momentum is most dominant in the growing biotech field, and drug development 
pipelines are full of targeted treatments; 42% of all compounds have the potential to be 
personalized medicines.2 While effective and tailored drug molecules are the pot of gold at the 
end of the rainbow, we must first understand how these substances address the issue of inter-
patient variability. What better place to start than the most basic building blocks of life – our 
DNA? As every single human being differs to some extent in their genetic sequence, or 
2 
 
genome, it stands to reason that this avenue would be critical in evaluating as how we respond 
to treatment at both the population and individual levels.3 Since successful completion of the 
Human Genome Project in 2003, which encompassed complete nucleotide base pair 
sequencing as well as phenotypic linking, more than 1,800 genes directly related to disease 
have been discovered, characterized and can be targeted in condition-specific clinical testing.4 
Researchers have capitalized on this improved understanding of population history, and over 
the years, we have built on this genetic technology. Modern advances allow for further 
examination of a patient’s fundamental biology and regulatory genome variation through RNA 
expression and protein synthesis, which can lead to downstream mechanistic insights for 
treatment planning and drug development.5  
 
Since these concepts can be applied to transformative health care and are based on the 
complex dynamics of systems biology, it is necessary to first evaluate simple nucleotide genetic 
mutations and how they may be connected to certain diseases. One of the most invaluable tools 
used in precision diagnostics is the genome-wide association study (GWAS). These studies are 
based on the millions of single nucleotide polymorphisms (SNPs) and other genetic variations 
that humans display and asks if the allele of interest in one of these variants is found more 
frequently than expected in individuals with a certain disease.6 These broad scope assays are 
vital, as common and complex diseases are influenced by multiple genes, and the likelihood of 
developing certain ailments is one of the most powerful predictive measures. In addition, an 
individual’s genetic makeup partially influences how well or poorly they respond to certain 
pharmaceutical interventions, and therefore has the potential to entirely alter their course of 
treatment. 
 
3 
 
Interlacing a person’s genetics with their treatment response has evolved into the field known as 
pharmacogenomics (PG), which will be discussed in detail in the Genomic Technology of 
Chapter 3. Briefly, since an individual’s genetic information can be utilized in this approach, it 
aims to combat the typical “one size fits all” medication prescribing and dosing methods. The 
lynchpins of PG are the genes directly involved with drug metabolism, notably cytochrome 
P450s7, VKORC18, and TPMT,9 and their allelic variations are linked closely to how an 
individual will respond to an active compound or drug metabolite. Enzymatic structural changes 
caused by mutations in these genes can make a drug more or less effective in different 
individuals, and even minute alterations can drastically impact the safety of a pharmaceutical. 
These genetic markers display clinically important consequences in the average population, and 
are an invaluable tool being leveraged for personalized medicine. 
 
While these genomic markers are a critical foundation of the personalized medicine field, there 
are a number of factors that must be tested and considered when treating individuals with any 
type of therapy. Companion analyses and diagnostics are the remaining slices of the 
personalized medicine pie and help researchers and medical professionals understand the 
underlying biology of specific diseases and conditions. Here we must define a new term, 
“theranostics”, which is the effort to develop more specific and individualized therapies for 
various ailments, and to combine diagnostic and therapeutic capabilities into a single agent.10 
Briefly, theranostics takes advantage of both particles (x-ray, free radical, nanotechnology) and 
imaging/devices (MRI, ultrasounds, fluorescence microscopy) to provide point-of-care therapy 
delivery while being able to examine and evaluate the effects of a drug in real time. This 
approach to treatment can engender better prognoses for many morbid diseases in a wide 
range of patient subpopulations.  
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Based on the desired target, this conglomerate of strategies can be varied immensely, but 
typically include identifying unique biomarkers related to the disease of interest. These 
“biomarkers”, or biological markers, refer to objective indications of a medical state that are 
observed from outside the patient and can be measured accurately and reproducibly.11 These 
non-subjective and quantitative phenotypes related to illness are one of the most sought-after 
aspects of personalized medicine research, as they can offer unambiguous data to demonstrate 
whether interventions are effective, ineffective, safe, or unsafe. When these biomarkers are 
used as outcomes in drug trials, they can be considered surrogate endpoints for clinically 
meaningful results.12 Additionally, biomarkers have started to be incorporated in preventative 
care, for example, pre-screening for lung13  and breast cancer14 related gene mutations and the 
protein production gene linked to Alzheimer’s disease.15 In all cases, discerning biomarker data, 
either epidemiological, therapeutic, and/or pathophysiological, allows for the improvement of the 
drug development process, in addition to a deeper understanding of the biological hierarchy of 
many grievous diseases. 
 
With this arsenal of tools in place, we can finally discuss the current state of the field of 
personalized medicine, and how it is contributing directly to interventions in the biomedical 
realm. The first and foremost sector impacted by these scientific advancements is that of drug 
development, and as I briefly mentioned above, this industry has seen tremendous growth with 
the addition of personalized medicine tactics. Because of the heterogenous nature of most 
diseases, utilizing genomic information to combat one-sized-fits all drug therapies has quickly 
become one of the most effective strategies of targeted drug design. This shift has resulted in a 
boom in the biotechnology or “biotech” industry that involves living systems or organisms in the 
development of products and devices.16  And while biotech is used in numerous other sectors 
such as food production, agriculture, and fuel, it’s prevalence in medicine and pharmaceuticals  
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allows for implementation of novel genomic data and techniques. Large pharmaceutical focused 
biotech companies such as Amgen and Genetech boast missions of “curing grievous diseases” 
instead of just treating the symptoms, and believe these cures exists inside of our own unique 
biological traits. 
 
Diseases such as cancer, Alzheimer’s, asthma, diabetes, heart disease, and HIV are all heavy 
hitters when it comes to human mortality, and in conjunction with their enigmatic pathological 
mechanisms, they become prime targets in the personalized medicine field. Identifying genetic 
determinates of these common diseases through GWAS can provide valuable knowledge about 
the architecture, even though the vast majority of disease-associated loci have yet to be 
biologically explained. A vanguard example of this personalized medicine technique is that of 
cancer genomics. A total of 1,762,450 new cases of cancer, along with 606,880 unique deaths 
from cancer are expected to occur in 2019 in the United States alone.17 However, these 
fatalities are down over 27% since their peak in 1991, thanks to early detection diagnostics and 
patient tailored treatments.  Appropriately coined “oncogenomics”, high through-put sequencing 
methods are used to characterize genes,18 identify genome hybridization,19 detect copy number 
variation in oligonucleotides,20 perform karyotyping,21  and reveal chromosomal breakpoints 
(BAC-end sequencing).22 These technologies allow for a significantly better understanding of 
cancer, particularly in the realm of tumor heterogeneity, and can improve prognosis for 
thousands of individuals that may not find success in the treatments typically applied to the 
general population. 
 
Cancer certainly isn’t the only field to benefit from the proliferation of the “omics” aspect of 
precision medicine, which takes groups of biological molecules and chemicals that inform us 
about the structure, function, and dynamics of an organism and aims to collectively characterize 
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and quantify these systems. The suffix “-ome” describes a totality in biology, and large areas 
like genome, the proteome, and the metabolome encompass a plethora of knowledge that 
unless broken down can be overwhelming for researchers to utilize in personalized and targeted 
project development. We’ve already covered the importance of personal genomics, but it is 
worth mentioning that other biochemical branches such as epigenomics, which is concerned 
with chemical modification on DNA due to environmental factors,23 proteomics, the large-scale 
analysis of proteins and their structures and functions,24 and metabolomics, that systematically 
evaluates the unique chemical fingerprints of metabolites25 are helping shape the personalized 
medicine landscape. The ability of classify derangements that underlie disease is the future of 
comprehensive diagnosis, progression monitoring, and new therapeutic discovery. 
 
With these base biological foundations, the potential of the field can truly grow. So finally, to 
wrap up the current horizon of this exciting research, we can exemplify this by discussing 
artificial intelligence (AI) in precision medicine. A true paradigm shift is occurring with the 
advancement of AI, machine learning, and the development of neural networks.26 Patient 
information, such as vitals, clinical symptoms, laboratory test results, personality phenotypes, 
etc., is being collected on a near constant basis, providing millions of data that have the 
potential to be employed by both physicians and researchers. One can imagine it would require 
significant computer power and detailed algorithms to not only organize this valuable 
commodity, but also to parse it into meaningful scientific connections. The innovation of 
biostatistical methods and AI programs can improve the quality of patient care, enable cost-
effective strategies both in healthcare and drug development, increase overall efficiency in 
prescriptions and testing predictions, and reduce readmission and mortality rates.27 So while it is 
hard to say with confidence that AI is the final frontier, it is clear that there would be no 
personalized medicine without these technological wonders. 
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Unfortunately, with any wonderful area of science, there are challenges and pitfalls that while 
difficult, can also inspire us to push further into our understanding and advance the field in many 
aspects. Of course, as PM is practiced more widely and continues to grow, the main difficulty 
comes when dealing with regulations, patient privacy and confidentiality, and intellectual 
property rights, which will all be discussed in more detail in the final chapter of this thesis. 
However briefly, the Food and Drug Administration (FDA) in the United States is responsible for 
overseeing all pharmaceutical and chemically based therapeutic modalities, and in order to 
incorporate aspects such a genetic and biomarker information in clinical use and drug 
development, regulatory science standards need to be updated.28 This is of vital importance to 
ensure quality control, accuracy, precision, and reliability in our endeavors to create a better 
standard of care for many diseases. And perhaps the most critical issue with the widespread 
implementation of PM is the protection of the patients it hopes to aid. Due to the unique nature 
of individualized genetic information, this poses a significant challenge in both managing the 
psychological effects patients might experience, as well as what constitutes personal health 
information for confidentiality purposes. As the discipline continues to evolve, we are 
responsible for addressing these concerns and implementing adequate tools in order to 
accelerate the adoption of stratified medicine to further aspects and fields of generalized 
medicine.   
 
By now, you have most likely surmised that personalized medicine is a truly interdisciplinary 
area of research, bounding a variety of scientific fields and technologies. This is why I chose to 
explore the potential of a variety of individual aspects of PM in order to expand my knowledge 
as a scientist beyond just that of simply organic chemistry. I have always been conscious of our 
impact, as both scientists and humans, on the planet and its environment, and what we will be 
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able to both accomplish and leave behind to improve the quality of life of our species. As I 
began to pursue my graduate studies here at UCLA, I considered how my science might have 
real-world impact, and I quickly realized that my background in organic chemistry would provide 
a formidable foundation for translational research. Rapidly this crystallized into the realization 
that I would need to acquire a better understanding of a variety of biological sciences, and so I 
sought out mentorship from many talented individuals in a myriad of departments in order to 
nurse my desire to paint a complete picture of targeted medicine and drug design. I found 
myself in the laboratory of Dr. Erika Nurmi, a brilliant psychiatrist with a passion for helping 
others and advancing the fundamental science we use to do so. Through 6 years of intensive 
research and training, I believe I have created a cohesive story of how personalized medicine 
can be utilized to understand, treat, and change how we approach a variety of diseases. Let me 
briefly walk you through what that entailed, and what this dissertation will aim to convey. 
Chapter 2 will set the stage in the realm of pharmacokinetics (PK) – which is succinctly defined 
as the time course/movement of a drug throughout the body, examining aspects of absorption, 
distribution, metabolism, and excretion. I was able to participate in research of two separate 
drugs and their pharmacokinetic properties, methamphetamine and risperidone, specifically 
leveraging a unique cytochrome p450 enzyme genotype to better understand deleterious side 
effects, and how they might be attenuated. Chapter 3 examines the reverse side of the PK coin, 
pharmacodynamics (PD), where now we are concerned with how a drug affects the body, 
instead of how the body affects a drug. Here I learned about neurobiology, and the 
consequences of cigarette smoking and nicotine on neurochemical balances due to brain 
structure and function. While PK and PD are the bread and butter for not only personalized 
medicine, but also targeted drug design, it is also important to consider genomic technology and 
within that pharmacogenetics (PG), and I do so in Chapter 4. PG is the branch of pharmacology 
that is concerned with the effects of genetic variation on reactions to pharmaceuticals, and here 
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I was able to bring a huge component of personal genomics to the table. Continuing this theme, 
we come to Chapter 5, which is all about the work I accomplished in the realm of gene and 
environment interactions, which over time, led to what I hold as my largest contribution to the 
personalized medicine field – Chapter 6; microbiome and host interactions. Here I spent years 
attempting to unlock a more direct, biological mechanism to something known as antipsychotic-
induced weight gain (AIWG) through the examination of bile acids and the gut microbiome and 
their crosstalk and interplay with host physiology. 
 
My story ends on a hopeful note; a putative mechanism of how this unwanted side effect of 
AIWG, which also has strong ties to cardiometabolic syndrome, one of the most profound 
diseases of our era, works on a biochemical level, and how we can leverage this information to 
better inform therapeutic treatment of various psychiatric diseases with not only antipsychotics, 
but other psychotropic drugs as well. I am currently running a replication study of a promising 
preliminary finding in this area that was recently funded by the NICHD, and I cannot express 
how excited I am for the potential my work has to impact the lives of so many people that may 
suffer from similar conditions. Each chapter represents a piece of the puzzle for my own 
personalized medicine story, and each unique situation taught me invaluable science and skills 
that I will utilize as I pursue my career as a scientist and research in this paramount field. I invite 
you to buckle up, strap in, and enjoy the rollercoaster ride that is the following PhD dissertation. 
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Chapter 2  
Pharmacokinetics  
 
General Background 
In my quest to better understand and contribute to the growing field of personalized medicine, I 
worked on a variety of scientific projects in specific categories of this overarching concept. The 
roots were established first in the field of pharmacokinetics, a branch of pharmacology which is 
simply the study of drug absorption, distribution, metabolism, and excretion.29 Stemming from 
the ancient Greek pharmakon meaning “drug” and kinetikos meaning “moving, putting in 
motion”, pharmacokinetics (PK) employs a conglomerate of techniques to determine the fate of 
a pharmaceutical substance once given to a living organism, and aims to understand how the 
organism itself affects this active drug compound. In combination with pharmacodynamics, 
which will we discuss in a later chapter, PK helps inform and influence medicinal dosing levels 
to maximize therapeutic benefits while minimizing adverse side effects. 
 
One can imagine that the human body is a complex system, and a drug must undergo multiple 
steps and transformations as it is being liberated, absorbed, distributed, metabolized, and/or 
excreted (LADME). Liberation refers to the process of the release of the biologically active 
compound from the pharmaceutical formulation. Absorption is simply how that substance enters 
blood circulation, and distribution is the subsequent distribution or dissemination throughout the 
various organs, tissues, and bodily fluids. Metabolism, which can be referred to as 
biotransformation or inactivation as well, occurs when the organism recognizes the drug as a 
foreign entity and begins the irreversible transformation of the parent compound into chemically 
and structurally different metabolites. Lastly, there is excretion, where any leftover original drug 
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and its metabolites are removed from the body through avenues such as urine, feces, or 
perspiration.30 
 
All the above phases are individually susceptible to physio-chemical interactions between the 
active drug substance and the organism in question. Both compartmental and non-
compartmental mathematical modelling for these connections is used to express unique 
equations for a milieu of pharmacokinetic properties. Parameters such as dose, clearance, 
bioavailability, elimination half-life, concentration, and fluctuation are just a few of the vital 
measurements that are typically completed during the PK branch of modern drug development. 
In fact, PK is so crucial to avoid a potential compound’s attrition before or during clinical trials, 
the industry has focused countless efforts into improving the understanding of these drug 
characteristics, and candidate failure in this branch has dropped to only 5% in recent years.31 
While lack of safety or efficacy are the most common causes for a drug getting the axe, 
attempting to overcome poor bioavailability or uncover predictive kinetic behavior can dictate the 
overall success of a program32, making PK one of the first lines of defense against development 
failure. 
 
Because of the importance of PK analysis in both drug development and clinical applications, it 
is worth discussing the main avenues of measurement for this subfield. Having the ability to 
develop strong associations between drug concentrations and their pharmacological responses 
allows both doctors and personalized medicine researchers to apply PK principles to patients on 
a case-by-case basis. A drug’s active effect in the body is often directly related to its 
concentration in various peripherals or tissue. This is potential proxy of the concentration at 
inaccessible direct receptor binding sites, a concept known as kinetic homogeneity; as the 
concentration of a compound increases in plasma, serum, urine, or saliva, the concentration in 
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most tissues will increase proportionally.33 With this information, we can construct a 
concentration vs. time profile for any given pharmaceutical, and hypersensitive bioanalytical 
methods are necessary for this purpose. 
 
The gold standard analytical technique used in PK is mass spectrometry. While I will be 
discussing mass spectrometry and related methods in great detail later in chapter 6, a brief 
overview will help paint the picture of why it is such a critical component to PK in development 
settings. There are three essential steps in this type of measurement: ionization, separation, 
and mass detection.34 First, individual molecules in a small sample are broken apart, or ionized, 
in the ion source of the machine where they typically become cations through the loss of an 
electron. Because of this, the ions can be sorted and separated according to their atomic mass 
and charge state. Commonly, this is accomplished through column chromatography with either 
gas or liquid as a mobile phase and can be tailored to the specific molecular properties of the 
items of interest. Finally, as the ions pass to the detector of a machine, which measures the 
relative abundance of each species, and this data can be analyzed further to parse apart critical 
information about the compound originally injected. The high selectivity and sensitivity of mass 
spectrometry allows for detection of xenobiotics in complex bodily matrices such as those 
mentioned above at very low concentrations with reliability. 
 
An Introduction to Cytochrome P450 
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With a strong understanding of how pharmacokinetics is critical to multiple aspects of 
pharmaceuticals, I began to explore the application of these principals to different areas of 
personalized medicine. As previously discussed, there are 5 major areas of focus in PK, 
represented by LADME. When I began my graduate work, I had the opportunity to explore the 
metabolism piece of pharmacokinetics in a couple of various ways, while learning techniques 
and concepts that would help drive the story of how personalized medicine can shape our future 
endeavors. It is necessary to flesh out the 
discussion of metabolism in order to better 
understand how the upcoming studies 
function in their entirety. Metabolism, in the 
broadest definition of the word, is the sum of 
all chemical reactions that happen 
intercellularly in living organisms. To give a 
sense of how complex this collective of pathways is, Figure 2-1 demonstrates the core 
metabolic functions of just ONE eukaryotic cell.  
 And in lieu of attempting to tackle explaining this entire miniature universe, I will focus on 
catabolic metabolism, as this relates to only the reactions involved in breaking down 
compounds, providing the strongest foundation for what happens to a drug once it enters the 
body. Xenobiotics, or chemical moieties found within an organism that are not naturally 
produced by that organism, are quickly targeted by catabolic processes, mainly located in the 
Figure 2-1. An artistic diagram of the 
core metabolic pathways in a eukaryotic 
cell, such as the cells that make up the 
human body. Each line is a reaction, 
and each circle is a reactant or product. 
 
Image credit: "Metabolism diagram," by 
Zlir'a (public domain). 
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liver. Many of these molecular transformations that occur within cells require multiple steps, 
energy, and enzymes to accomplish.35  Ingested or injected drugs are either activated (or 
inactivated) by these hepatic enzymes to form metabolites, which are then conjugated and 
excreted in either bile or urine.36 Commonly, this occurs in an enzyme complex called the 
microsomal biotransformation, of which the main component is a heme containing cytochrome 
monooxygenase, also known as cytochrome P450’s. (CYPs)  
 
CYP proteins/enzymes are predominantly oxidization catalysts and membrane associated in 
nature and add one oxygen atom to a variety of small and large molecule substrates. In 
humans, the CYP family accounts for 75% of total drug metabolism, transforming thousands of 
compounds that act as substrates in a variety of tissues throughout the body.37 This is in part 
because the active site of a cytochrome P450 contains a heme-iron center that is tethered 
directly to the protein via cysteine-thiolate flanking residues38, allowing for a wide array of 
reactions to undergo catalysis. These CYP enzymes are present in most tissues of the human 
body, and additionally play critical roles in the breakdown of endogenous chemicals. There are 
57 human genes divided among 18 families of cytochrome p450 genes and the proteins they 
encode, making these loci prime functional targets for genetic evaluation and penetrance 
understanding.39  In order to avoid lengthy explanation of these salient metabolic tools, the CYP 
families are listed in detail in Table 2-1. 
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Pharmacokinetic 
Metabolism and 
CYP2D6 
And while some CYPs 
metabolize very few, or 
sometimes just even 
one, substrates, both 
CYP3A4 and CYP2D6 
account for over 34% 
and 25% of drug 
deactivation and bioactivation respectively.40 These two enzymes can be both inhibited or 
induced by pharmaceuticals, resulting in clinically significant drug-drug interactions that may 
results in unanticipated adverse reactions, but also potentially beneficial therapeutic outcomes. 
Because of this, it is of critical importance to understand the genetic variability at these loci and 
how this variance functionally impacts individual’s abilities to metabolize certain drugs; a strong 
Family Members Names
CYP1
3 subfamilies, 3 genes, 
1 pseudogene
CYP1A1, CYP1A2, CYP1B1
CYP2
13 subfamilies, 16 genes, 
16 pseudogenes
CYP2A6, CYP2A7, CYP2A13,
 CYP2B6, CYP2C8, CYP2C9,
 CYP2C18, CYP2C19, CYP2
D6, CYP2E1, CYP2F1, CYP2
J2, CYP2R1, CYP2S1, CYP2
U1, CYP2W1
CYP3
1 subfamily, 4 genes, 
2 pseudogenes
CYP3A4, CYP3A5, CYP3A7, 
CYP3A43
CYP4
6 subfamilies, 12 genes, 
10pseudogenes
CYP4A11, CYP4A22, CYP4B
1, CYP4F2, CYP4F3, CYP4F
8, CYP4F11, CYP4F12, CYP
4F22, CYP4V2, CYP4X1, CY
P4Z1
CYP5 1 subfamily, 1 gene CYP5A1
CYP7 2 subfamilies, 2 genes CYP7A1, CYP7B1
CYP8 2 subfamilies, 2 genes CYP8A1, CYP8B1
CYP11 2 subfamilies, 3 genes
CYP11A1, CYP11B1, CYP11
B2
CYP17 1 subfamily, 1 gene CYP17A1
CYP19 1 subfamily, 1 gene CYP19A1
CYP20 1 subfamily, 1 gene CYP20A1
CYP21
2 subfamilies, 1 gene, 1 
pseudogene
CYP21A2
CYP24 1 subfamily, 1 gene CYP24A1
CYP26 3 subfamilies, 3 genes
CYP26A1, CYP26B1, CYP26
C1
CYP27 3 subfamilies, 3 genes
CYP27A1, CYP27B1, 
CYP27C1
CYP39 1 subfamily, 1 gene CYP39A1
CYP46 1 subfamily, 1 gene CYP46A1
CYP51
1 subfamily, 1 gene, 3 
pseudogenes
CYP51A1
Table 2-1. Humans 
have 57 genes and 
more than 59 
pseudogenes 
divided among 18 
families of 
cytochrome P450 
genes and 43 
subfamilies. This is a 
summary of the 
genes and of the 
proteins they 
encode. 
(http://drnelson.uths
c.edu/human.P450.t
able.html) 
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foundation of pharmacokinetics and pharmacogenetics as a whole. The research opportunities I 
encountered in my early years of graduate school allowed me to dive into the world of CYP2D6 
specifically, and it is important to understand the basic science and genetics behind perhaps the 
most well-characterized metabolic enzyme. 
 
Serendipitously, CYP2D6 is primarily expressed in the liver, which is the central hub for all drug 
processing and excretion in the human body, but also has a strong presence in areas of the 
central nervous system41, allowing for pivotal drug-host interactions. Biochemically, CYP2D6 act 
through the mechanism of hydroxylation, demethylation, and dealkylation of specific functional 
groups.42 But what makes this enzyme intriguing is the fact that CYP2D6 is characterized by a 
high inter-individual variability in catalytic activity mainly caused by genetic polymorphisms43 and 
copy number variation.44 Appropriately named, the CYP2D6 allele is what mediates these 
deviations in phenotypes, and individuals possessing certain allelic variants will manifest 
normal, decreased, absent, or excessive CYP2D6 function.45 There are four distinct metabolizer 
classes, and their nomenclature, phenotypes and related genotypes can be seen in Table 2-2. 
These denominations will be used throughout the two case studies in this chapter. 
The second year of my graduate research career, I had the opportunity to be a part of a project 
examining the effects of 
Classification Genotype Phenotype
Ultrarapid Metabolizer 
(UM)
3 or more fully 
functioning genes 
(CNV)
Increased 
enzymatic activity
Extensive Metabolizer 
(EM)
2 wild type, fully 
function genes
Normal activity
Intermediate 
Metabolizer (IM)
1 wild type allele, 1 
non-
functioning/defective 
allele
Decreased 
activity
Poor Metabolizer 
(PM)
2 non-functioning 
alleles/1 or more 
deleted gene
No enzymatic 
activity
Table 2-2. The four 
metabolizer status 
classifications for the 
CYP2D6 gene and related 
enzyme. Genotype at this 
locus and functionally 
related phenotype are also 
displayed for each 
variation. Enzymatic 
activity directly impacts 
drug metabolism rate. 
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methamphetamine (MA) usage on neurodegeneration. CYP2D6 is selectively responsible for 
the metabolism of MA, thus individuals with genetic variation and therefore altered metabolizer 
classes may experience differing responses to the drug as well as to the deleterious side 
effects. Detailed information and findings from this work can be seen in the upcoming PK case 
study #1. Additionally, I was also involved in a pharmacokinetic project aimed at autistic youth in 
my 3rd year as a graduate student. Here we were interested in whether or not CYP2D6 
genotype had an effect on these patient’s response to a second-generation antipsychotic, 
risperidone, metabolized by this enzyme. This study also added CYP3A4/5 analysis into the mix 
to paint a more complete PK picture. More background and results of this research can be 
found in PK case study #2. Overall, I feel these two studies provided me with a robust 
background on pharmacokinetics, and allowed me to begin to truly apply these principles to my 
overarching goal of a better understanding of personalized medicine. 
 
Case Study #1: CYP2D6, brain structure, and cognitive function in methamphetamine 
dependence* 
A Dean, LC Seaman, ED London, EL Nurmi 
*This work is currently unpublished. 
Background / Specific Research Aims 
Methamphetamine (MA) use disorder is a highly prevalent public health problem, both nationally 
and worldwide. Cognitive dysfunction is a common sequela of MA use; however, individual 
susceptibility to cognitive impairment is highly variable and the mechanism of degeneration is 
largely unknown. Metabolism of MA is dependent on the cytochrome p450 2D6 (CYP2D6) 
enzyme, which is inactivated by common polymorphisms. Previous research has found that 
CYP2D6 extensive metabolizers (EMs), with two wild-type or functional alleles, have higher 
rates of cognitive impairment than intermediate/poor metabolizers (IM/PMs) with at least one 
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non-functional allele. We hypothesized that this may result from the elevated exposure of EMs 
to toxic metabolic byproducts. To evaluate this hypothesis, we examined whether EMs, relative 
to IM/PMs, display other markers of neurotoxicity such as differences in cerebral gray matter 
volume. 
 
 
This project sought to evaluate whether methamphetamine-dependent participants with different 
variants of the cytochrome P450 gene (cytochrome P450, family 2, subfamily D, polypeptide 6; 
CYP2D6) exhibit differential rates of cognitive impairment and abnormalities in brain structure. 
The CYP2D6 gene codes for one of the primary enzymes responsible for methamphetamine 
metabolism. Depending on the functionality of inherited CYP2D6 alleles, individuals vary in how 
readily they metabolize methamphetamine, ranging from poor (two non-functional alleles) to 
Figure 2-2. Methamphetamine is metabolized by the liver enzyme CP2D6. The drug can 
either undergo hydroxylation to form p-hydroxymethamphetamine or dealkylation to form 
amphetamine. These represent the two major metabolites. 
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extensive metabolism (two functional alleles). Previous research has found that CYP2D6 
extensive metabolizers have higher rates of cognitive impairment than intermediate/poor 
metabolizers.46 The authors hypothesized that, because extensive metabolizers are exposed to 
a greater load of metabolic byproducts (e.g., amphetamine, 4-hydroxymethamphetamine) than 
intermediate/poor metabolizers, metabolic byproducts may be more neurotoxic than the parent 
methamphetamine compound. Our project sought to further evaluate this hypothesis by 
examining whether extensive metabolizers display other markers of neurotoxicity relative to 
intermediate/poor metabolizers; namely, abnormalities in cerebral gray matter volume and white 
matter integrity. At the time of the grant submission, we already had structural MRI and CYP2D6 
genotype on 57 methamphetamine-dependent subjects; with this R21, we sought to add 24 
more methamphetamine-dependent subjects to this dataset to evaluate hypotheses. We 
hypothesized that: 1) methamphetamine-dependent participants who are extensive 
metabolizers (based on CYP2D6 genotype) would have significantly lower cognitive scores than 
intermediate/poor metabolizers (but not significantly different estimates of premorbid IQ); and 2) 
relative to intermediate/poor metabolizers, extensive metabolizers would have alterations in 
gray matter volume and white matter integrity which have previously been hypothesized to be 
associated with neurotoxicity (i.e., reduced cortical gray matter and reduced fractional 
anisotropy in the frontal lobe). 
 
General Methods 
Subjects:  
Otherwise healthy, adult (18-55 years old) methamphetamine-dependent individuals, n=86. 
Inclusion criteria: DSM-IV-TR MA dependence by Structured Clinical Interview. Must test 
positive for MA metabolite in urinalysis during first screen. Caucasian or Hispanic. Exclusion 
20 
 
criteria: History of Axis I psychiatric disorder other than MA dependence or nicotine dependence 
(due to high co-morbidity) or evidence of a serious neurological or medical condition. 
Imaging: 
Structural MRI was acquired on the testing day using a Siemens Sonata 1.5 tesla system with a 
standard 32-channel phased array head coil. A high-resolution whole-brain T1-weighted 
anatomical sequence (MP-RAGE) was collected for spatial normalization and voxel-based 
morphometry. Diffusion tensor imaging (DTI) data was obtained using 30 gradient directions at 
b=1000, 5 repeats of b=0 (no diffusion weighting), with 2.5x2.5x2.5 mm resolution. Scanning 
time took approximately 30 minutes. 
 
Neuropsychological Assessment: 
The neuropsychological battery shown in Table 3 was completed on the testing day after 
participants sustained 5 days of abstinence. This collection of tests was designed to tap multiple 
cognitive domains, with an emphasis on tests of executive function, memory and processing 
speed. Inclusion of normative data for performance comparison purposes. Assessment took 
approximately 2.5 hours to complete. 
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NEUROPSYCHOLOGICAL BATTERY DOMAIN 
COGNITIVE TESTS 
Wechsler Test of Adult Reading  Premorbid IQ estimation 
Rey Auditory Verbal Learning Test   Verbal learning and memory 
Brief Visuospatial Memory Test-Revised   Visual learning and memory 
Continuous Performance Test – 2   Visual attention/inhibitory control 
Stroop Test  Executive functioning/inhibitory 
control 
Finger Tapping Test  Motor speed 
Verbal Fluency   Language and executive 
functioning 
Wisconsin Card Sorting Test   Executive functioning/concept 
formation 
Trailmaking Test   Psychomotor speed and set-
shifting 
Victoria Symptom Validity Test  Effort/motivation 
INVENTORIES 
Time/date last drug use Recency of drug, cigarette & 
caffeine use 
Alcohol breathalyzer  Exclude alcohol intoxication 
Stanford Sleepiness Scale  Alertness 
Beck Depression Inventory-II  Depressive symptoms 
Amphetamine Cessation Symptom Assessment                              
Scale  
Meth withdrawal and craving 
Positive and Negative Affect Schedule  Emotional States 
  
 
Genetic Testing: 
Blood samples were collected, and genomic DNA was extracted. The two most common 
variants in Caucasian and Hispanic populations account for 94% of the genetic variation in 
CYP2D6, rs1065852 and rs3892097. TaqMan SNP genotyping assays were used to genotype 
these loci in all individuals with 93.69% sensitivity, >99% specificity, and >99% positive predict 
value. 
 
Statistical Analyses:  
Table 2-3. Neuropsychological battery of tests utilized in the reported MA study. 
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No significant differences in age, sex, ethnicity, level of education, or smoking were observed 
between the EM and IM/PM groups. Differences in performance on cognitive measures were 
assessed by t-test (one-tailed) for equivalence of the means. 
 
Studies & Results 
During the period of this grant, we completed assessments on 29 methamphetamine-dependent 
participants. The participants received a 1.5 T structural MRI scan, provided a blood sample for 
CYP2D6 genotyping and were administered a comprehensive neurocognitive battery. 
Combined with existing data from former participants, we now have CYP2D6 genotype and 
structural MRI from 86 methamphetamine-dependent subjects (extensive metabolizers n = 60; 
intermediate/poor metabolizers n = 26), with smaller subsets having been administered various 
cognitive tests.  
 
The extensive metabolizer and intermediate/poor metabolizer subjects are generally well-
matched on demographic variables. The two groups do not differ with respect to age, gender, 
education, premorbid IQ (Shipley Vocabulary Test), or ethnicity (p’s > .05). Further, the 
extensive and intermediate/poor metabolizers do not significantly differ on measures of 
methamphetamine and nicotine use, including years of heavy methamphetamine use, age of 
onset of methamphetamine use, days of methamphetamine used in the last 30 days, grams of 
methamphetamine used in the last week, cigarette smoker status (yes/no) or pack years of 
cigarette smoking (p’s > .05).  
 
Because of unavailable data in former participants, only a subset of the subjects have been 
administered cognitive tests, with the largest subsets having been administered the Stop Signal 
Test (SST; extensive metabolizers n = 47; intermediate/poor n = 23) and the Wisconsin Card 
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Sorting Test (WCST; extensive metabolizers n = 44; intermediate/poor n = 18). The extensive 
metabolizers had a significantly slower go reaction time on the SST than intermediate/poor 
metabolizers (t(68) = -2.016; p = .048); however, the two groups did not differ in stop signal 
reaction time (SSRT, p > .05). On the WCST, relative to intermediate/poor metabolizers, the 
extensive metabolizers had a higher percentage of perseverative errors (t(60) = 1.745; p = 
0.017), shown in Figure 2-3. Other WCST indices did not significantly differ between the groups 
(p’s > .10).  
 
 
 
We next compared the extensive and intermediate/poor metabolizer groups on measures of 
cerebral gray matter volume. Images were preprocessed (segmented, modulated and 
Figure 2-3. MA users who are CYP2D6 extensive (EM) vs. intermediate/poor (PM/IM) 
metabolizers show increased perseverative errors on the WCST.  
Utilizing the Wisconsin Card Sorting Task (WCST) as a measure of cognitive ability, we 
observed a significant and marked increase of percentage of perseverative errors in the EM 
participants, almost double that seen in PM/IM individuals. (p=0.014, Cohen’s d effect size = 
1.4) This data supports our prediction of greater cognitive decline in EM individuals, due to 
the increase of toxic MA metabolism byproducts that are reaching the brain. 
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smoothed) using the voxel-based morphometry (VBM) toolbox in SPM8. Statistical analyses 
were conducted using FSL’s Randomise (http://www.fmrib.ox.ac.uk/fsl/randomise, version 5.1) 
to implement voxelwise permutation-based nonparametric inference for ANCOVA with age and 
gender as covariates. Given the association of WCST performance with frontal lobe integrity in 
meta-analytic data47, statistical models were applied to data in an explicit mask of gray matter in 
the frontal lobe based on an atlas rendered in Montreal Neurological Institute (MNI) 152 space 
(see Figure 2-4).48, 49 Threshold-free cluster enhancement 50 was used to correct for multiple 
comparisons, and a statistical threshold of p < 0.05, corrected for the entire search volume, was 
applied to each of the resulting statistical maps.  
 
 
 
 
Results revealed that, relative to intermediate/poor 
metabolizers, the extensive metabolizers had less gray matter volume in the right 
cingulate/paracingulate gyri (see Figure 2-5). In contrast, there were no regions in which the 
N=23 
N=49 
Figure 2-4. MA users who are 
extensive (EM) vs. poor/intermediate 
(PM/IM) metabolizers show an 
increased median reaction time on the 
of SST, as measured by go-reaction 
response. Consistent with our 
predictions, the significant increase in 
go-reaction time displayed by EM 
individuals on the Stop Signal Task 
(SST) (p=0.036, Cohen’s d effect size = 
2.0) reflects dysfunction in response 
inhibition and impulsive action. 
Speculatively, because the SST has a 
mix of stop and go trials, a delayed 
reaction time on a go trial would indicate 
a difficulty in adaptation and executive 
functioning, potentially due to neurotoxic 
damage in the prefrontal cortex. 
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extensive metabolizers had greater gray matter volume than the intermediate/poor 
metabolizers.  
Lastly, group differences in estimates of white 
matter integrity (i.e., fractional anisotropy; FA) 
were evaluated using Diffusion Tensor Imaging 
(DTI) data processed and analyzed in FSL. Analyses were conducted using tract-based spatial 
statistics (TBSS) within a thresholded FA “skeleton” of white matter tracts. Voxel-wise statistics 
were conducted within the FA skeleton, using threshold-free cluster enhancement and 
permutation testing in FSL’s Randomise. Age and gender were included as covariates of no 
interest.  
 
At corrected thresholds, the extensive and intermediate/poor metabolizers did not exhibit 
differences in FA, regardless of contrast selection (i.e., extensive > intermediate/poor or 
intermediate/poor > extensive). At reduced statistical levels (p < .15, corrected), the most 
appreciable differences suggested that extensive metabolizers have greater FA than 
intermediate/poor metabolizers in regions of the corpus callosum, anterior commissure, and left 
Figure 2-5. MA users who are 
extensive (EM) vs. poor/intermediate 
metabolizers (PM/IM) display decreased 
cerebral gray matter volume. EMs 
(n=57) exhibited reduced gray matter 
volume in the right anterior cingulate 
gyrus relative to IM/PMs (n=26) by 
threshhold free cluster enhancement 
(p<0.05, corrected) controlled for age 
and gender. Sagittal slice (in yellow) in 
the upper left corner shows the frontal 
lobe mask used as a region of interest. 
There were no brain regions where 
EM’s displayed higher grey matter than 
PM/IM’s. These findings support our 
hypothesis that the metabolized 
products of MA, amphetamine and 4-
hydroxymethamphetamine, are more 
toxic to neuronal cells than the parent 
compound. 
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cerebral white matter (Figure 2-6). However, these differences were not observed at traditional 
levels of significance. 
 
 
Significance & Conclusions 
The present data provide some support for the hypothesis that, based on CYP2D6 genotype, 
extensive metabolizers are more susceptible to methamphetamine-induced neurotoxic effects 
than intermediate/poor metabolizers. Specifically, relative to intermediate/poor metabolizers, 
extensive metabolizers exhibited worse performance on a test of executive function (Wisconsin 
Card Sorting Test perseverative errors, p = 0.017) and had less gray matter volume in the right 
cingulate/paracingulate gyri (p<.05, corrected). Since extensive metabolizers have a higher 
degree of exposure to the metabolic byproducts of methamphetamine (e.g., amphetamine and 4-
hydroxymethamphetamine)51 than intermediate/poor metabolizers (extensive metabolizers 
readily metabolize methamphetamine while intermediate/poor metabolizers are more likely to 
excrete methamphetamine unchanged), these data may suggest that the metabolic byproducts 
Figure 2-6. Observed changes in 
fractional anisotropy between extensive 
(EM) and intermediate/poor (IM/PM) 
metabolizers. 
IM/PMs (n=23) tended to have lower 
fractional anisotropy (FA), a measure of 
white matter integrity, than EMs (n=39) 
at reduced statistical thresholds 
(p<0.15, corrected) in regions of the 
corpus callosum, anterior commissure, 
and cerebral white matter. While it might 
be contrary to initial hypotheses, when 
taken together with our results above, 
this finding suggests that FA scores 
may not be indicative of neurotoxicity 
and that low FA itself may not reflect 
neuronal damage or cognitive disability. 
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are more toxic than the parent compound. This is consistent with in vivo studies showing that 4-
hydroxymethamphetamine is more toxic to rat neuronal cells than methamphetamine. 52 Should 
these data be replicated, possible harm-reduction strategies could be explored to reduce the 
toxicity of methamphetamine for users who are engaged in the early stages of behavioral 
treatment (e.g., administration of CYP2D6 inhibitors). 
 
There were no significant differences between extensive and intermediate/poor metabolizers on 
a measure of white matter integrity (fractional anisotropy; FA). Nonsignificant trends in some 
regions were contrary to hypotheses; extensive metabolizers exhibited higher FA than 
intermediate/poor metabolizers. Although this may suggest that FA scores were not indicative of 
neurotoxicity, it should be noted that low FA may not be synonymous with neuronal damage. For 
example, cigarette smokers have been shown to have higher FA than nonsmokers in several 
white matter tracts.53 Likewise, increased FA is associated with attention- deficit hyperactivity 
disorder (ADHD;)54 and visuospatial deficits in Williams syndrome.55 In HIV+ individuals, both 
decreased and increased FA have been found relative to healthy control subjects, depending on 
the specific brain region.56 As such, current nonsignificant findings in FA may not indicate the 
absence of neurotoxicity. 
 
Our data strongly support the hypothesis that CYP2D6 extensive metabolizers are more 
vulnerable to methamphetamine-induced neurotoxic effects than those with impaired enzymatic 
activity, resulting from common gene polymorphisms. This could be due to the fact that MA 
metabolites are more toxic to the underlying neurocircuitry and neuronal cells than the parent 
compound, and future toxicity studies can now address this issue. 
 
We were unable to test for gene deletions or duplications with our methods, which decreases the 
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sensitivity of our test, so that it is possible that a small number of IM/PM individuals may have 
been missed or misclassified. While our pilot study was not powered to support correction for 
multiple testing for 10 cognitive measures, effect sizes are large and warrant replication in a larger 
population. 
 
However, by demonstrating an association between CYP2D6 genotype and cognitive decline and 
brain abnormalities, we propose an identifiable risk factor for cognitive dysfunction in MA 
dependence. Subsequently, this risk factor has the potential to be utilized by clinicians for both 
early intervention and individualized treatment planning, while also aiding in the development of 
harm reduction strategies (i.e., the use of CYP2D6 inhibitors) to prevent cognitive damage related 
to MA relapse while individuals are in treatment. 
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INTRODUCTION 
 
The antipsychotic risperidone (RSP) is safe and effective for the acute and intermediate-term 
treatment of severe and challenging behaviors such as aggression, self-injury, and extreme mood 
lability that are commonly associated with autism spectrum disorder.57, 58 Individual treatment 
benefit and adverse events, such as antipsychotic-induced weight gain (AIWG), however, are 
highly variable. Identifying predictors of therapeutic response and adverse event risk could guide 
treatment selection and may reveal fundamental mechanisms for prevention or treatment. 
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Available data support the hypothesis that drug response and risk for some adverse events is 
heritable, determined in part by individual genetic differences. For AIWG, investigations using 
family study designs show heritability for this adverse effect may be as high as 60-80%.59, 60 Both 
genome-wide and candidate gene studies have identified common genetic variants to function as 
predictors, but the amount of variance in AIWG explained by these findings remains modest. 61-63 
The strongest published associations have implicated common variants of MC4R, leptin, and 
HTR2C as partial predictors of AIWG64. Attempts to identify genetic associations for other adverse 
events such as extrapyramidal and tardive dyskinesia (TD) have only been. 65, 66 While a genome-
wide association study identified 5 potential genes impacting antipsychotic treatment response in 
schizophrenia,67 established moderators of genetic response in ASD are lacking.68   
 
A significant limitation in the vast majority of pharmacogenetic studies of antipsychotic treatment 
has been the failure to include drug pharmacokinetic (PK) information in the examination of 
genetic effects. This is especially relevant in studies of drug distribution, metabolism, excretion 
(DME), and transporter gene variants, where mutations may directly impact plasma and tissue 
drug concentrations. RSP, like most antipsychotics, undergoes extensive first-pass hepatic 
metabolism (hydroxylation) to 9-hydroxyrisperidone (9-OH-RSP, paliperidone). Hydroxylation is 
primarily catalyzed by cytochrome P450 2D6 (CYP2D6), with cytochrome P450 3A4/5 
(CYP3A4/5) representing a secondary pathway of metabolism.69 Interest in the possible effects 
of genetic variants of these drug metabolizing enzymes is heightened by the observations that 
they are both expressed in brain.70 Although 9-OH-RSP was often presumed to possess 
equivalent pharmacodynamic properties to RSP, it is now recognized that RSP has substantially 
higher affinity for 5-HT2A and α1 and α2 adrenergic receptors.71, 72 Therefore, differences in 
adverse events could be influenced by shifts in the ratio of RSP/9-OH-RSP, as well as the sum 
of plasma RSP and 9-OH-RSP (active moiety) concentrations. In addition, both RSP and 9-OH-
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RSP are substrates and inhibitors of members of the adenosine-triphosphate-binding cassette 
(ABC) superfamily of transport proteins, including the multidrug resistance-1 protein P-
glycoprotein (MDR1 or P-gp), encoded by the ABCB1 gene,73 and the breast cancer resistance 
protein (BCRP), encoded by the ABCG2 gene,74 both of which influence drug efflux across 
membranes in the intestines, blood-brain-barrier, and renal tubules. Genetic variants in ABCB1 
and ABCG2 may be additional sources of variability in therapeutic and adverse effects of 
psychotropics such as RSP. Lastly, NR1I2 encodes the nuclear receptor pregnane X (PXR) that 
is a transcriptional regulator of multiple genes involved in the absorption, distribution, metabolism, 
and extraction of drugs and other xenobiotics, including the cytochrome P450s and ABC drug 
transporters.75, 76 NR1I2 polymorphism rs7643645 (A>G) was correlated with a 2.8 fold lower 
risperidone total active moiety concentration when comparing GG to AA genotypes (p = 0.031).77  
 
Multiple mutations in relevant drug metabolism enzymes (DME) and transporter genes are 
common across all human populations, and allele frequencies vary according to genetic 
background. CYP2D6 is polymorphic, with over 100 functional variants identified. Absent CYP2D6 
metabolic capacity (“Poor Metabolizers” or PMs) occurs in 5-10% of Caucasians as a result of 
inheriting two nonfunctional alleles, with the alleles CYP2D6*3, *4, *5, *6 representing 95% of 
responsible variants underlying PMs. Decreased CYP2D6 function (“Intermediate Metabolizers” 
or IMs) can be observed in those individuals with one nonfunctional allele, or in individuals 
possessing other mutations which convey reduced enzyme activity (e.g., CYP2D6*10 allele).78  
Gene deletion and duplication occurs in approximately 7% and 5% if the American population 
respectively.44 Gene duplication (3 or more copies) of functional alleles results in ultrarapid 
metabolizer status (UMs). CYP3A4/5 is also polymorphic, but with fewer variants, although some 
6% of Caucasians, 22% of Asians, and 26% of African Americans have been found to carry the 
CYP3A4*20 variant, an insertion-mediated frameshift resulting in loss of enzyme activity. Other 
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relatively common CYP3A4 variants which also reduce enzymatic activity include the CYP3A4*1B 
and *3 alleles, found in 4-5% and 1% of Caucasians respectively. Similarly, the genes encoding 
drug transporters are known to have common variants. ABCB1 and ABCG2 have identified 
variants which influence expression and/or substrate affinity, and which can be found in as many 
as 20% of Caucasians. NR1I2 variants are also common. 
 
Studies examining the impact of differing CYP2D6 and CYP3A4/5 genotypes on RSP 
pharmacokinetics have yielded mixed findings, but most extant studies are underpowered to 
detect genetic effects, or contain confounding factors such as smoking, wide age ranges, and 
varying exposure lengths. Extensive Metabolizer (EM, or wild type) subjects did not differ from 
PM subjects in the sum of plasma RSP and 9-OH-RSP concentrations (active moiety) in several 
reports.79-84 Nevertheless, differences in RSP and 9-OH-RSP concentrations,80 and higher ratios 
of RSP/9-OH-RSP in PMs79-81, 83 have been found between CYP2D6 PMs versus EMs, in the 
absence of differences in active moiety levels. However, some contrasting reports from larger 
samples have observed higher RSP and active moiety plasma concentrations in impaired 
metabolizers (heterozygous and homozygous for inactive CYP2D6 alleles) versus EMs.85-87 Using 
population PK analyses, one of the largest studies showed that CYP2D6 allele groups linked to 
metabolizer phenotype classification predicted 52% of the variance of RSP concentrations, while 
the area under the curve (AUC) values for activity moiety concentrations were significantly (28%) 
higher for CYP2D6 PMs versus combined EM/UMs and versus IMs. 87 None of these studies 
examined downstream beneficial or adverse clinical drug effects.  
 
Few reports have examined effects of CYP3A4/5, ABC-family variants, and RSP 
pharmacokinetics to confidently establish PK or pharmacodynamic relationships. No CYP3A4/5 
effects were observed for any RSP PK parameters in three studies.79, 88, 89 However, one study 
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noted that carriers of the CYP3A4 SNP rs35599367 A-allele to have a 30% reduction in 9-OH-
RSP clearance,87 and in another report, the CYP3A5*3 allele conferred higher active moiety and 
9-9-OH-RSP concentrations,80 which remained significant even after correcting for 2D6 
genotypes.  For ABCB1, three studies have found significant effects of the ABCB1 SNP 
rs1045642 (C3435T) on active moiety concentrations;79, 84, 85 two of these studies also noted 
effects of additional ABCB1 variants. In addition, a haplotype comprised of 3 SNPs (rs1128503, 
rs1045642, and rs2032583) in ABCB1 was associated with significantly different 9-OH-RSP and 
active moiety concentrations; the haplotype predicted 11% of active moiety concentrations.79 
However, one report failed to find PK effects of ABCB1 variants. None of these studies examined 
resultant clinical drug effects in relation to PK. 
 
Studies testing associations between CYP2D6, 3A4/5, and ABCB1 genotypes and clinical effects, 
such as response and weight gain, have yielded mixed results. Reports on CYP2D6 have 
generally not found associations with clinical response.82, 85, 90, 91 In a positive cohort study of 40 
children with ASD, disruptive behaviors were rated as improved, no change, or worsened; UMs 
(n=2) showed no response or adverse effects, whereas PMs (n=2) experienced improvement and 
greater adverse effects.92 One report of a sample of 116 outpatients treated with various 
antipsychotics (including 26 receiving RSP) for psychosis noted a greater proportion of 
responders were CYP2D6 EMs versus non-responders (67% versus 46%, p = 0.023). I can’t find 
this reference In a smaller study, EMs also showed greater improvement. I can’t find this reference 
However, a monotherapy RSP study of adults with schizophrenia found CYP2D6 PMs showed 
greater PANSS-Total score reduction (p = 0.029).93 Two reports have identified associations 
between efficacy and CYP3A4/5 variants. In the Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE) study, a marginal effect for clinical response was seen for CYP3A5  
genotypes in 175 subjects treated with RSP (p = 0.04).94 A study in 130 patients with 
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schizophrenia receiving RSP monotherapy reported minor A-allele homozygotes of CYP3A4*1G 
versus other genotypes experienced significantly less percent improvement in PANSS score 
(28% versus 42/43%, p = 0.021), however this result did not survive statistical correction.(Du et 
al., 2010) Drug transporter variants may be associated with the clinical efficacy of RSP. Greater 
reductions in behavior and sociability problems in children with autism treated with RSP were 
observed in ABCB1 1236T-allele (rs1128503) carriers (p = 0.002), although the magnitude of 
difference was small (4.7%).90 Likewise, TT homozygotes at this SNP experienced greater 
improvement of psychotic symptoms in adults with schizophrenia.95 
 
Adverse events and relationships to DME variants have also been reported. Lane et al (2006) 
found that CYP2D6*10 EMs gained 1.14 and 0.80 kg less than those heterozygous and 
homozygous for CYP2D6*10 respectively after 6 weeks of RSP exposure. Similarly, null alleles 
(*4) were also associated with weight gain in several other studies.96, 97 In contrast, a study of 45 
children with autism treated with RSP for up to 12 months found that both CYP2D6 UMs and PMs 
showed smaller increases in waist circumference than EMs; PMs did not differ from EMs in BMI 
increases.90 While other reports have noted associations between CYP2D6 and ABCB1 variants 
with adverse effects and intolerance of RSP,85, 86, 98, 99  only one study has reported an association 
between ABCB1 variants and RSP-associated weight gain only in females.100 Several studies 
have found significant relationships between RSP PK (specifically active moiety concentrations) 
and adverse events of akathisia, tremor, and other “neurologic” symptoms.87 A meta-analysis of 
20 studies with varying antipsychotics found no association between TD and CYP2D6, however 
when analyses were re-examined using prospective studies only, homozygous and heterozygous 
individuals with CYP2D6 reduced function alleles showed an increased odds ratio of 1.83 – 2.08 
for TD versus EM patients, and mutant allele carriers also possessed increased risk for 
parkinsonian symptoms (OR = 1.64).101 In a sample of 325 outpatients receiving chronic RSP, 
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CYP2D6 PMs were 3.1-fold more likely to experience moderate to severe adverse drug 
reactions98 and discontinued RSP due to adverse events at a 6-fold greater rate than EMs. 
Similarly, variants in ABCB1 have been associated with RSP-induced extrapyramidal 
symptoms.85, 99 Finally, RSP-induced prolactin elevation in children was associated with number 
of functional CYP2D6 alleles;102 however, this result was not replicated by later reports.90, 103-105  
 
Taken together, aside from some associations with adverse events such as EPS and possibly 
AIWG, the extant literature on the impact of CYP2D6, CYP3A4/5, and ABCB1 mutations on 
risperidone PK, efficacy, and adverse events is inconclusive and incomplete, given the relative 
absence of integrated analyses of RSP PK with genetic and clinical outcomes. We are unaware 
of a single study of investigating DME genetics with RSP PK and clinical response in children, 
despite its widespread clinical use in pediatric psychiatry. Given the lack of consistent and 
integrated prior data, we sought to concurrently test the impact of common PK variants on plasma 
RSP levels and treatment outcomes in a sample of children receiving standard RSP monotherapy. 
 
 
METHODS 
 
Subjects 
The research was conducted under the auspices of the National Institute of Mental Health 
(NIMH) RUPP Autism Network using two protocols approved by individual site Institutional 
Review Boards and by a NIMH Health Data Safety Monitoring Board.106, 107 Written informed 
consent (and assent from the child, when capable) was obtained from a parent or guardian prior 
to enrollment. In the earlier study, youth (ages 5 to 17 years) meeting DSM-IV criteria for autistic 
disorder accompanied by severe irritability (aggression, tantrums, and/or self-injurious 
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behaviors) defined by a score of > 18 on the Aberrant Behavior Checklist (ABC) Irritability 
subscale were treated for 8 weeks with risperidone monotherapy or placebo.(McCracken et al., 
2002) Only 10% of subjects had previously received (ineffective) antipsychotic treatment. Those 
subjects deemed non-responders who had been randomized first to placebo in the 8-week 
acute phase were offered open-label treated with risperidone according to an identical titration 
and assessment protocol. The Aman et al. study applied similar inclusion and exclusion criteria 
(except age range of 4 – 13 years) and all subjects received RSP monotherapy, titrated similarly 
to the 2002 RUPP study, with or without behavior management for up to 24 weeks. Of the 225 
total outpatients enrolled from the two trials, weekly measures of weight, height, BMI, and 
genotype data were available for a combined 184 subjects from their initial 8-week acute 
exposure to RSP. Plasma samples for RSP and 9-OH-RSP drug levels were available from 120 
subjects and were analyzed using combined liquid chromatography/mass spectrometry 
according to previously published protocols; sample loss was primarily due to inadequate 
samples and blood draw refusals.  
 
Clinical response was assessed by changes in parent-reported behavior on the Aberrant 
Behavior Checklist-Community Version (ABC).(Aman, Singh, Stewart, & Field, 1985) The ABC 
is a widely-used outcome measure in clinical trials involving individuals with intellectual and 
developmental disabilities. It contains five subscales defined by factor analysis: Irritability, 
Hyperactivity, Stereotypic Behavior, Social Withdrawal, and Inappropriate Speech. The 
Irritability subscale was one of the primary endpoints for the two clinical trials. Weight and height 
were obtained weekly, and weight was transformed to standardized z-scores using 
anthropometric indices based on the 2000 CDC growth charts using the CDC SAS program, as 
previously described.108 Adverse events were assessed using a parent-reported checklist of 
items, as well as by spontaneous report from parents to the study physicians.  
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Genotyping 
Genomic DNA was extracted from whole blood using QiaAmp DNA Blood Mini Kits (Qiagen, 
Valencia, CA). Genotyping was performed using the TaqMan genotyping platform (Life 
Technologies, Grand Island, NY) with Qiagen Type-it Fast SNP Probe PCR Kit according to 
manufacturer’s protocols. All markers were in Hardy-Weinberg Equilibrium, 10% of the dataset 
was genotyped in duplicate with perfect concordance, and allele frequencies were consistent 
with those reported by the HapMap Consortium. Genes chosen for analysis were those known 
to regulate risperidone metabolism (CYP2D6, CYP3A4/5, NR1I2) and influence absorption and 
disposition (ABCB1, ABCG2, NR1I2). The four most common functional SNPs in CYP2D6 that 
are associated with >90% of IM and PM phenotypes in Caucasian and African American 
individuals were genotyped (rs1065852 [missense], rs3892097 [splice donor], rs16947 
[missense], rs28371706 [missense]) and gene copy number variation (CNV) was determined 
using Taqman real-time PCR. Activity score was assigned by summing the number of null (0), 
partial (0.5), and wild-type (1) alleles plus or minus CNV duplication or deletion. For metabolizer 
status assignment, EMs had a score of 1.5-2, IMs 0.5-1, PMs 0 and UMs>2.109  We did not test 
for rare polymorphisms/alleles, since these, if present at all, would have represented only a tiny 
percent of our sample. Similarly, common functional variants in CYP3A4/5 (rs2740574, 
rs55785340, rs4987161, and rs776746) and NR1I2 (rs7643645, rs1523130, rs2472677) were 
selected and classified as EM, IM, or PM according to the existing literature;110 (PharmGKB, 
https://www.pharmgkb.org/view/vips.jsp). Three known functional variants in ABCB1 
(C1236T/rs1128503,  C3435T/rs1045642, rs4148740 and G2677T/rs2032582 by strong linkage 
disequilibrium (r2=0.8) with rs1128503) and 7 tag SNPs across the coding region of ABCG2 
were also included in the analyses (rs2725248, rs3114020, rs17731538, rs2231142, 
rs13137622, rs7681519, rs2725256).  
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Statistical Analysis 
Because the distributions of RSP, 9-OH-RSP, and active moiety concentrations were skewed, 
those data were log-transformed to normalize distributions to meet the assumptions of the 
statistical model. ANOVA analysis was conducted with RSP PK concentrations as the 
dependent variable and genotype as a fixed factor. Potentially confounding covariates such as 
sex, age, dose, race and ethnicity were entered in the initial model; those identified as non-
significant were thereafter dropped from the final model. Due to race effects, analyses were 
repeated within racial groups. Statistical significance was set as p <0.05. Given the exploratory 
nature of the study, p values are reported as their uncorrected value; the effects of statistical 
correction for multiple tests per hypothesis are reported in the text. To examine change in 
treatment outcome over time, a repeated measures linear mixed model was employed (e.g., 
weighted z-score from baseline and ABC subscales). Genotype, visit (as a continuous variable), 
and interaction of genotype by visit were entered as predictors. Frequency of adverse events in 
genotype groups was examine by chi square analysis. 
 
RESULTS 
 
Risperidone PK: Demographic Influences 
 
The RUPP and RUPP-PI groups were compared using the appropriate Chi-square, ANOVA, or 
t-test to ensure comparable samples. The samples were mostly comparable, with the exception 
of the mean younger age of the RUPP-PI sample (90.6 + 29.9 months versus 102.3 + 31.9 
months, p = 0.06), and a slightly higher mean daily dose for the RUPP-PI study (2.1 + 0.6 
mg/day versus 1.8 mg/day, p = 0.019), and, reflecting the above, the baseline mean body 
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weights and mean risperidone dose (mg/kg/day) were significantly different. The RUPP sample 
also contained a higher proportion of Hispanic subjects and a trend towards fewer Black 
subjects; separate analyses by ancestry are reported. All analyses included age, sex, ancestry, 
and dose as covariates. Interestingly, RSP plasma level was not correlated with age (r=0.029, 
p=0.75), sex (F=1.096, p=0.337) or dose (r=-0.053, p=0.564). As clinicians followed a protocol 
of flexible dosing, the latter may be explained by apparent implicitly detected CYP metabolizer 
phenotype. After covarying for baseline age and weight, both strong determinants of dose, 
those with at least one functional CYP2D6 or CYP3A4 enzyme received a mean dose of 0.076 
mg/kg/day or 2.1 mg daily, while those with no functional CYP2D6 or 3A4 were prescribed 
0.069 mg/kg/day or 1.8 mg daily (p=0.047). Inference of impaired metabolizer status by 
prescribing clinicians has been similarly noted in a prior report.111 
 
 
 
 
RUPP 
(n=34) 
RUPP-PI 
(n=86) 
Combined 
(n=120) 
P-value 
Gender [n (%) male]   85.3 (%)   83.7 (%) 101 (84.2%) 
2 =0.045, 
p=0.832 
Baseline age [months] 102.3 ± 31.9   90.6 ± 29.9   93.9 ± 30.8 
T=1.90, 
p=0.06 
Baseline BMI   18.3 ± 5.0   17.7 ± 3.0   17.9 ± 3.8 
T=0.89, 
p=0.37 
Ethnicity [n (%)] 
  White, non-Hispanic  
  Black, non-Hispanic  
  Native American  
  Asian or Pacific Islander  
  Hispanic 
  Black, Hispanic  
  Other 
 
21 (61.8%) 
  2 (5.9%) 
  0 
  1 (2.9%) 
  6 (17.6%) 
  0 
  4 (11.8%) 
 
61 (70.9%) 
14 (16.3%) 
  2 (2.3%) 
  4 (4.7%) 
  4 (4.7%) 
  1 (1.2%) 
  0 
 
82 (68.3%) 
16 (13.3%) 
  2 (1.7%) 
5 (4.2%) 
10 (8.3%) 
  1 (0.8%) 
  4 (3.3%) 
 
 
2 = 0.95, 
p=0.33 
X2 = 2.68, 
p=0.10 
 
 
X2 = 5.38, 
p=0.02 
40 
 
Baseline weight [mean kgs]   34.0 ± 17.9   28.9 ± 10.9   30.7 ± 14.2 
 T=2.37, 
p=0.019 
Final dose [mg/kg/d]   0.06 ± 0.03   0.08 ± 0.03   0.07 ± 0.03 
T=-4.08, 
p=6.7x10-5 
Final dose [mg/d]     1.8 ± 0.6     2.1 ± 0.6     2.0 ± 0.6 
T=-2.71, 
p=0.007 
Risperidone [nmol/L]   27.3 ± 38.9   18.5 ± 37.7   21.0 ± 38.1 
T=1.13, 
p=0.26 
9-OH-risperidone [nmol/L]   42.5 ± 30.9   51.4 ± 49.4   48.9 ± 44.9 
T=-0.98 
p=0.24 
Total Active Moiety [nmol/L] 69.8 ± 60.5 69.9 ± 81.4 69.8 ± 75.8 
T=-0.008, 
p=0.99 
Mean weight gain [kg]     2.8 ± 2.0     2.6 ± 1.5     2.7 ± 3.9 
T=1.40, 
p=0.16 
 
 
Risperidone PK: Pharmacogenetics 
CYP2D6. Concentrations for RSP, 9-OH-RSP, and total active moiety (RSP + 9-OH-RSP), as 
well as the RSP/9-OH-RSP ratio are reported in Table 1 for the separate studies and the 
combined sample. Observed mean concentrations were comparable to those reported in the 
literature;79, 83, 85 however, levels showed marked variability. CYP2D6 activity score (AS)109was 
the strongest determinant of RSP levels (see Figure 2-7). Of the 119 subjects with valid 
CYP2D6 genotypes, 24 (20%) had wildtype activity (AS = 2) at the CYP2D6 locus, having two 
normal function alleles and 6 subjects (5%) had duplications resulting supernormal activity (AS 
> 2). Two (2%) subjects were poor metabolizers with no enzyme function (AS = 0). The majority 
of subjects (N=87, 73%) had some combination of reduced function or null alleles: 13 (11%) 
with AS = 0.5, 28 (24%) with AS = 1, and 46 (39%) with AS = 1.5 (see Figure 2-8). CYP2D6 AS 
predicted RSP parent drug level (p=7.71 x 10-6) and the ratio of RSP/9-OH-RSP (p=8.71 x 10-9), 
Table 2-4. Characteristics of the RUPP, RUPP-PI, and Combined RUPP Autism 
Risperidone Pharmacokinetic/Pharmacogenetic Samples 
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controlling for age, sex, ancestry, total daily dose, and plasma processing batch. In addition to 
total daily dose (p=0.019), parent drug (RSP) level (p=8.13 x10-12) was the strongest predictor of 
9-OH-RSP concentration. Given this observation, parent drug level was added to the model, 
revealing a significant effect of AS on 9-OH-RSP (3.01 x10-4).  
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As noted in previous literature, CYP2D6 *4 and *10 alleles resulted in the highest RSP levels. 
Consistent with prior reports suggesting substrate specificity, *17 does not appear to be a 
reduced function allele for RSP transport in our sample. In the case of two reduced function 
alleles, a duplication of one of the partial alleles was apparently able to compensate for impaired 
function with increased quantity, resulting in wildtype RSP levels. While classic UMs (AS > 2) 
showed only slightly reduced RSP levels compared to EMs, total active moiety was more than 
halved in individuals with an AS of 3. (see Figure 8).  
 
CYP3A4/5. The multiple rare CYP3A4 polymorphisms tested were invariant in our sample, and 
therefore CYP3A4 did not contribute to RSP PK variability. At the CYP3A5 locus, 25 subjects 
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(21%) possessed one allele conveying impaired function and 80 subjects (67%) possessed two 
reduced function alleles. After covarying for CYP2D6 effects in the total sample, CYP3A5 
showed a marginal contribution to only RSP parent drug level (p = 0.02). Ancestry effects, 
discussed below, were prominent.  
 
Other PK Genes. Carriers of the minor allele at NR1I2 rs1523130 show higher levels of 9-OH-
RSP (p=0.044) in a dominant pattern independent of CYP2D6 or CYP3A4 genotype. No other 
PK effects of NR1I2 variants were observed. Transporter gene variants in ABCB1 and ABCG2 
had no effect on plasma drug levels. 
 
Risperidone PK: Ancestry Effects 
 
The range of RSP level was much greater in Caucasians, with a range of 254 compared to 92 in 
non-Caucasians, likely reflecting the prevalence of CYP2D6 inactivating polymorphisms. Given 
the large differences identified in minor allele frequencies between Caucasian and non-
Caucasian populations, we performed separate exploratory analyses of the effects of CYP2D6 
and CYP3A5 variation in these two groups. Since all Caucasians (N=84) in our sample carried 
impaired activity alleles at CYP3A5, not all phenotypes were represented (N EM = 0, IM = 14 
and PM = 67), and CYP3A5 variation did not account for variability within the Caucasian sample 
(p = 0.15). In Caucasians, RSP concentrations were strongly predicted by CYP2D6 genotype 
alone (p = 1.1 x10-5). Conversely, in this underpowered sample of non-Caucasians (N=36), 
RSP concentration was determined predominantly by CYP3A5 genotype (p = 0.005), with a 
marginal influence of CYP2D6 status (p=0.035), and contrary to findings in Caucasians, a 
marginally significant effect of dose (p=0.004).  
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Risperidone PK: Clinical Outcomes 
 
Pairwise correlational analyses were performed to assess the possible relationships between 
PK concentrations and clinical outcomes. Individual values for RSP, 9-OH-RSP, total active 
moiety, and for the RSP/9-OH-RSP ratio (all log-transformed) were examined against change 
from baseline to Week 8 for the five clinical efficacy ABC subscales. Of the total of 20 tests, 
ABC-I (irritability subscale) change was positively correlated with RSP ratio (r=0.22, p=0.015) 
and negatively correlated with 9-OH-RSP level (r=-0.18, p=0.047). ABC-III (stereotypy subscale) 
was also negatively correlated with 9-OH-RSP level (r=-0.22, p=0.016). None of the PK values 
were significantly correlated with RSP-associated weight gain (BMI Z-scores, all p values >0.3). 
From the Adverse Events Report Form, we examined relationships between RSP PK 
concentrations and the presence or absence of side effects. In 23 children with reported 
extrapyramidal symptoms (EPS), symptoms were positively associated with levels of 9-OH-RSP 
(p=0.021) and total active moiety (p=0.014). Sedation, which was commonly reported in 95 
children, was positively associated with RSP Ratio (p=0.047). Drooling was positively 
associated with higher daily RSP doses (2.16 ± 0.59 mg/d vs. 1.92 ± 0.62 mg/day, p=0.015). 
 
Risperidone Pharmacogenomics: Clinical Outcomes 
 
Genotype groups at each locus were analyzed as possible predictors of clinical efficacy and 
adverse event outcomes. Neither CYP2D6 nor CYP3A4/5 metabolizer status was significantly 
associated with changes on treatment response endpoints, as measured by the five ABC 
subscales, or side effects, including weight gain, sedation, EPS, tremor, and drooling. While not 
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significant, our data suggests that CYP2D6 PMs may show both attenuated response and 
increased side effects; however, these analyses were severely underpowered given only 2 PMs 
in our sample. CYP2D6 PMs showed half to one quarter the improvement in ABC-I, -II, and IV 
compared to IM/EMs (Cohen’s D effect sizes = 0.8-0.9). Similarly, PMs had nearly twice the 
degree of weight gain as IM/EMs (BMI-Z score 1.1 verses 0.6 respectively, D = 0.8). 
Variant rs7681519 in the ABCG2 transporter gene is the only genetic variant globally associated 
with dimensional ABC score. Homozygotes for the minor allele showed an enhanced response 
(ABC-I p = 0.07, D = 0.5; ABC-II p=0.04, D = 0.6; ABC-III p = 0.03, D = 0.6; ABC-IV p = 0.02, D 
= 0.6; ABC-V p = 0.001, D = 0.9). Consistent with the direction of effects discussed above, 
minor allele ABCG2 homozygotes were also protected from AIWG (p=0.04). The C-allele at 
NR1I2 rs1523130 was associated with enhanced ABC-I response (p=0.02, dominant pattern, D 
= 0.5). ABCB1 rs4148740 minor alleles showed greater weight gain (p = 0.002, recessive 
pattern, D = 1.6). With regard to other adverse effects, all participants who reported tremor 
(14/14) were carriers of the C-allele at NR1I2 rs1523130 (p=0.039) and 92% of those reporting 
EPS (p=0.017) and 86% of those reporting drooling (p=0.044) were common allele 
homozygotes at ABCG2 rs2231142. 
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DISCUSSION 
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This study represents one of the most comprehensive attempts to delineate the role of multiple 
DME and drug transporter genes on antipsychotic pharmacokinetics and clinical effects of 
treatment and is especially unique given our sample of children and adolescents. There are 
several main findings.  
 
Plasma RSP levels showed only weak association with clinical outcomes. With the exception of 
marginal effects of 9-OH-RSP on irritability, stereotypy and EPS, no efficacy or side effect 
associations, including with weight gain, were evident. Speculatively, negative effects of 9-OH-
RSP on outcome and adverse effects may imply that paliperidone may not achieve equal 
efficacy to RSP for ASD irritability and stereotypy and may be more likely to produce EPS. In 
line with these data, NR1I2 rs1523130 was associated with both 9-OH-RSP levels and 
irritability. Sedation, on the other hand, was associated with RSP to 9-OH RSP ratio, suggesting 
the opposite relationship. BMI changes were independent of RSP plasma levels.  
 
The paucity of association between RSP PK values and clinical outcomes we observed is 
surprising but in agreement with literature reports. Extant data has suggested possible 
relationships between drug level and the presence of neurologic symptoms. We speculate that, 
given the mechanism of action of RSP as an antagonist of dopamine 2 and serotonin 2A 
receptors, PK values, especially of active moiety, above a certain threshold are sufficient for 
inducing clinical change, and that a “dose-response” relationship between exposure and other 
clinical effects, positive or negative, may require much higher exposures to be detected.  
 
Despite some contradictory findings in the literature, our data confirms the primary and 
significant role of CYP2D6 in determining RSP concentrations, especially in Caucasians. The 
CYP2D6 poor metabolizer genotype group displayed 702% higher RSP and 133% higher total 
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active moiety concentrations. Significant but more modest associations were also observed for 
the effects of CYP3A5 genotypes on RSP and active moiety concentrations, which 
predominated over CYP2D6 in non-Caucasian subjects in predicting drug levels. RSP 
metabolism appears to be handled by different CYP metabolic pathways across ancestry. As 
fully functional CYP3A5 alleles are apparently rare in Caucasians but CYP2D6 variation is 
common, the finding that CYP2D6 variation is the primary driver of RSP variability is not 
surprising. Inactive copies of CYP3A4 are common in populations of African ancestry, 
emphasizing the importance of compensation by CYP3A5. Since CYP2D6 PM alleles are less 
common in non-Caucasian populations, CYP2D6 contributes less to non-Caucasian variation. 
Larger and more diverse samples would be needed to further stratify effects according to 
ancestry. These findings are consistent with prior reports of the predominant role of CYP2D6 
genotype on RSP concentration85-87 and contribution of CYP3A5 variants to RSP and active 
moiety concentrations80, 87 in adults, suggesting that conflicting studies may have been 
underpowered or influenced by population background differences, especially with regard to 
genetic ancestry.79, 88, 89   
 
Contrary to a few other published reports, we found no impact of ABC-family gene variants on 
RSP pharmacokinetics. The absence of associations between variants in ABCB1 with RSP PK 
endpoints is difficult to reconcile with the two reports finding effects of multiple ABCB1 variants 
on 9-OH-RSP and active moiety concentrations,79, 85 even though we genotyped at least one of 
the SNPs (rs1045642, C3435T) found previously to be predictive of PK differences. The fact 
that other groups have also been unable to identify RSP PK effects of ABCB1 genotypes 
suggests that any true effects are relatively small.87  It is conceivable that developmental 
differences may influence the relationship between these gene variants and RSP PK, given the 
pediatric age range of our sample.  
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Despite a strong effect of CYP2D6 on plasma RSP, CYP2D6 genotype did not predict outcome. 
Given the few relationships noted between RSP PK and clinical effects, this is not surprising. 
Genetic predictors of RSP response outcomes are undoubtedly far more complex than genetic 
determinants of plasma concentration, requiring sample sizes in the tens of thousands for 
unequivocal discovery. PMs in our study may have in fact suffered worse outcomes and 
adverse effects; however, our study was underpowered to statistically test this relationship. 
While neither of the metabolic CYP genes were related to outcomes, transporter proteins were 
nominally associated. One possible interpretation of this finding is that plasma concentration, 
which is largely related to CYP enzymes, is less important than brain exposure, which is 
dependent on transporter proteins, in determining outcomes. The consistent association of 
NR1I2 and transporter variants across measures of efficacy and adverse effects in the absence 
of RSP PK associations might reflect their potential role in influencing brain exposure. The fact 
that the same genes and variants (ABCG2 and NR1I2) were associated with therapeutic 
outcomes and adverse effects adds credence to these results.  
 
ABCG2 intronic SNP rs7681519 and NR1I2 5’UTR SNP rs1523130 appear to tag regulatory 
DNA blocks, as evidenced by numerous promoter and enhancer marks, evidence of DNase 
protection and regulatory protein binding, and functional gene regulation based on eQTL 
databases (haploreg). Interestingly, the G-allele of ABCG2 rs7681519 is in strong LD (r2=0.78, 
D’=0.99) with the C-allele of rs2725263, empirically shown to produce increased expression of 
ABCG2.112 Based on this strong association, carriers of the G-allele of rs7681519 should have 
reduced brain exposure to RSP given the increased ABCG2 efflux pump expression at the BBB. 
Similarly, the T-allele of NR1I2 rs1523130 has also been previously shown to increase RSP 
clearance and in our sample was observed to predict reduced response and greater side 
50 
 
effects.87 ABCG2 rs2231142 is a missense variant resulting in an amino acid change from 
glutamine to lysine; common alleles have been previously associated with higher RSP levels 
and greater adverse effects,113 which we also observed in our analysis. Linkage disequilibrium 
(LD) between SNPs within ABCG2 is <0.4, reflecting independent associations. ABCB1 
rs4148740 is an intronic variant tagging enhancer marks, sites of protein binding and motif 
changes. Minor alleles, associated with increased AIWG in our sample and have previously 
been associated with remission of major depression and increased adverse effects of 
antidepressants transported by ABCB1, suggesting that it is a functional variant producing 
greater psychotropic exposure.114-116  
 
These data add to extant knowledge of moderators of RSP pharmacokinetics in humans. 
Consistent with in vitro and in vivo studies, we confirmed the importance of CYP2D6 and 
CYP3A5 genetic variants in determining steady state concentrations of RSP and active moiety. 
Our sample was larger than the majority of similar reports and participants demonstrated 
excellent treatment compliance, were mostly treatment-naive, and were all non-smokers and 
medically healthy, which presumably aided our ability to discern important but subtle effects of 
gene variants on RSP pharmacokinetics and outcome.  
 
Our study has several limitations. Although our sample is larger than the majority of similar 
studies, it still lacks sufficient power to test variants of low frequency or small effect, as well as 
interactions between multiple loci. As a sample of children with ASD, the clinical effects under 
observation may not extrapolate to the treatment of psychosis or other clinical conditions. Our 
RSP PK estimates are only based on single trough samples, which may be insufficient to fully 
capture the range of actual exposures as compared to repeated sampling studies. A large 
number of tests were performed (tests of 14 genetic variants, 4 (not independent) plasma 
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measures, 5 treatment outcomes and 5 adverse effects). Few of these findings would survive 
correction for multiple testing.   
 
There have been considerable efforts to identify clinically significant moderators and predictors 
of benefits and adverse effects of RSP and other antipsychotics, which in theory could yield 
more personalized and effective management. However, the results of these efforts have been 
mostly disappointing. Moderator analyses of clinical benefit in the two RSP studies of children 
with ASD that formed the sample studied in this report only identified one significant moderator, 
baseline severity of irritability, out of 33 variables tested. Similar attempts to identify genetic 
predictors of antipsychotic response have not yet uncovered significant predictors of outcome, 
with the possible exception of studies of AIWG, where prior studies have noted replicated and 
robust associations with variants in MC4R and other genes involved in energy balance. In 
theory, genetic variants that directly impact the distribution and metabolism of the drug 
represent reasonable candidates to test for their impact on clinical outcomes. Although we 
demonstrated significant associations with RSP PK values and identified several nominal 
associations between gene variants and clinical outcomes, additional studies are needed to 
confirm these associations. More research on the mechanisms and magnitude of clinical effects 
of drug transporter gene variants is especially needed. Overall, the prediction of clinical effects 
of medications such as RSP are complex, and will require considerably more effort to achieve 
clinical application. These important efforts, however, may eventually help to identify patients 
who would benefit most from RSP therapy or are at highest risk for adverse outcomes. 
 
 
Chapter 2 Wrap-Up 
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Overall, the completion of these two projections based heavily in pharmacokinetics not only 
taught me in-depth knowledge of LADME principles, but also helped me learn an enormous 
amount of the liver-based metabolism of pharmaceutical drugs. Specifically, cytochrome p450 
enzymes are invaluable tools in our working knowledge of drugs and xenobiotic treatments for 
human diseases, and I believe that with this strong PK foundation at the base of my 
personalized medicine pyramid, I will truly be able to apply sound scientific reasoning to my 
future targeted strategies for biological mechanistic evaluation and drug design. 
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Chapter 3  
Pharmacodynamics 
 
General Introduction 
As we saw in chapter 2, one of the most powerful tools we have in understanding 
pharmaceuticals is that of pharmacokinetics; because being able to identify the ways our own 
body will process and affect the drug is over half of the battle. The second piece to this puzzle 
comes in the form of a field known as pharmacodynamics (PD). I touched briefly on these 
principles in chapter 1, but we can consider PK and PD a sort of yin and yang relationship. 
Where PK is in the most basic sense how the body will affect a drug or drug like substance, PD 
is how that substance or its metabolites will interact with and affect the human body. 
 
Pharmacodynamics stems from two Greek words: pharmakon, meaning drug, and dynamikos, 
representing force or power. Whether or not we are talking about pharmaceutical moieties or 
even drugs of abuse, people take these substances to achieve a desired biological, 
physiological, and/or pharmacological responses. Because of this, most drugs are developed 
based on the PD theory that the compound will interact with a native biological structure (i.e. a 
receptor, an enzyme, a transporter, etc.) and that this interaction manifests as a specific effect 
on the body.117  The majority of drugs either mimic or inhibit normal biochemical processes or 
inhibit pathological processes of microbial organisms, and there are 7 main drug interactions 
that researchers consider when developing a novel drug.118 
1. Stimulating action / receptor agonism 
2. Depressing action / receptor agonism 
3. Blocking / antagonizing action 
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4. Stabilizing action 
5. Exchanging / replacing native substance action 
6. Direct beneficial chemical reaction 
7. Direct harmful chemical reaction 
 
In general, PD endpoints and measures are essential for establishing the benefit-to-risk ratio for 
any therapeutic intervention. These systematically evaluate a drug’s activity in the body using 
biomarkers and or clinical outcomes to quantify both efficacy and safety.119  Pharmacodynamics 
places emphasis on dose-response relationships, which is the direct cause and effect of drug 
concentration and represents a large sphere of the temporal dynamics involved in this field. As 
we consider drugs as ligands for their biochemical receptors, it is also possible to measure the 
receptor binding and consequent effect, informing about the therapeutic window and duration of 
action of a constituent.120  
 
Identifying and Implementing Pharmacodynamic Biomarkers 
 
The bulk of pharmacodynamics is focused around the concept of biomarkers, which are most 
commonly endogenous macromolecules that can be measured in bodily fluids. These provide a 
more direct biological link to disease and clinical response, but pose significant challenges due 
to heterogeneity, varying levels of activity, and immunoreactivity.121  However, they are vital in 
the bigger picture of personalized medicine, as they allow for earlier and more robust drug 
safety and efficacy measures as well as accurate patient stratification.122 They propel our 
understanding of how drugs, both novel and already established, work on a cellular level, and in 
combination with targeted bioanalytics and PK/PD modelling, can ensure proper 
55 
 
pathophysiological validation of various human diseases and improve the way medicine 
approaches and treats these issues.  
 
My graduate advisor, Dr. Erika Nurmi, worked closed with a researcher who was deeply 
interested in the effects that nicotine has on neuroinflammation, Dr. Arthur Brody. I had the 
opportunity in my 3rd and 4th years of graduate school to work closely with both of them on two 
separate but related pharmacodynamic projects focusing on cigarette smoking. We can 
consider nicotine the drug in these scenarios, as although it is derived from the tobacco plant, it 
is still a stimulant and potent parasympathomimetic alkaloid that acts as a receptor agonist as 
most nicotinic acetylcholine receptors.123 It is the main psychoactive compound in cigarettes 
currently available on the market and has a high addiction liability in the general population, but 
this mechanism of action is still somewhat poorly understood.124   
 
We leveraged a biomarker for neuroinflammation, the expression of translocator protein 
(TSPO), which is quantifiable through positron emission topography (PET) imaging to better 
understand nicotine’s direct effects on the brain after individuals smoke a cigarette. In the first 
study, represented below as PD Case Study #1, we demonstrated that smokers have impaired 
inflammatory functioning compared with non-smokers and that the extent of this effect could be 
determined by an individuals genotype at the TSPO locus. To better understand how this 
mechanism operated on a more neurochemical level, the second study, PD Case Study #2, 
evaluated the effect of overnight smoking abstinence on this same TSPO biomarker, 
implementing dynamic imaging of both satiated and abstinent smokers for comparison. Results 
showed that chronic cigarette smoking was indicative of global impairment of microglial 
activation that can persist throughout the duration of a smoker’s life. More background 
explanation, PD details, results, and discussion can be found directly below in each case study. 
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PD Case Study #1 : Effect of Cigarette Smoking on a Marker for Neuroinflammation: A 
[11C]DAA1106 Positron Emission Tomography Study * 
 
*This study is currently published in Neuropsychopharmacology 125 
 
Brody AL, Hubert R, Enoki R, Garcia LY, Mamoun MS, Okita K, London ED, Nurmi EL, Seaman 
LC, Mandelkern MA. 
 
INTRODUCTION 
 
Inflammation is a critical component of normal tissue repair and is fundamental to the body’s 
defense against infection. 126 In the brain, microglia continuously scan the surrounding 
extracellular space127 in order to respond swiftly to damage or infection by becoming activated 
and participating in neuroinflammation128. In this context, activated microglia participate in 
functions such as clearance of apoptotic cells and extracellular pathogens, removal of 
degenerating neurons and extracellular proteins, and cytokine/chemokine production.128 When 
activated, microglial cellular morphology changes and the expression of the translocator protein 
(TSPO) 18 kDa is increased, thereby making the expression of TSPO a marker for 
neuroinflammation. 
 
The radioligand N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide labeled with 
carbon-11 (abbreviated as [11C]DAA1106) has emerged as a reliable second-generation 
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radiotracer for labeling TSPO129-131 with high affinity132-135 for positron emission tomography 
(PET) scanning in vivo. Because [11C]DAA1106 and other newer radiotracers have higher 
affinity for TSPO than previously used radiotracers (eg, [11C]PK11195), they are more useful 
for quantifying PET data by having the sensitivity to account for genetic TSPO predispositions 
(discussed in more detail below)136 and smaller changes in neuroinflammation.135 TSPO was 
originally called the ‘peripheral benzodiazepine receptor131’ because it was identified by 
benzodiazepine binding but was renamed to acknowledge its many potential functions and 
location in the central nervous system (as well as in the periphery).137 Specific binding of 
DAA1106 correlates with the presence of activated microglia identified by 
immunohistochemistry in situ135 and immunohistochemistry combined with autoradiography in 
brain tissue.138 
 
PET studies using [11C]DAA1106 and similar radiotracers have examined a range of conditions 
thought to be associated with neuroinflammation. This method was used recently to 
demonstrate increases in radiotracer binding in patients with Alzheimer’s disease139-144, Lewy 
body dementia145, amyotrophic lateral sclerosis146, stroke147, and non-smokers with major 
depression148, but not Parkinson’s disease149 or normal aging150. Increases in this marker have 
also been demonstrated in animal models of brain injury134, 151-153 and stroke154, along with 
subsequent normalization with time after a brain insult152, 154, 155. In contrast, a decrease in the 
marker for neuroinflammation was found with administration of propofol anesthesia (Hines et al, 
2013). 
 
Over the past 30+ years, a large body of research has addressed the effects of cigarette 
smoking on inflammation in the body126. A driving force behind this research is the known 
impairment of wound healing by smoking. Comprehensive literature reviews have 
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recommended preoperative and postoperative abstinence periods of >4 weeks in smokers 
undergoing surgical procedures157, 158. Though the mechanism by which smoking impairs wound 
healing has not been fully elucidated, cigarette smoke contains >250 toxins, many of which are 
known to affect healing158, and studies of laboratory animals exposed to cigarette smoke have 
demonstrated significant alterations (both decreases and increases) in markers of 
neuroinflammation159. Reviews of this literature indicate that the inflammatory healing response 
is attenuated in smokers by reduced inflammatory cell chemotactic responsiveness, diminished 
migratory function, and increased oxidative stress.160, 161 
 
In the absence of studies directly examining the effect of human cigarette smoking on 
neuroinflammation in vivo, we used PET scanning to determine whether cigarette smokers have 
altered binding of [11C]DAA1106, a marker for neuroinflammation, compared with non-smokers. 
We hypothesized that non-smoker vs smoker effects would occur globally throughout the brain, 
as prior research by our group162-165 and others166, 167 demonstrates widespread effects of 
smoking when studying systems (eg, the nicotinic cholinergic system) that are widely 
distributed. We also sought to examine the effect of menthol, as menthol cigarette smoking is 
common (~1/3 of US smokers) (SAMHSA, 2009) and menthol smokers have more difficulty 
quitting in standard treatment programs168-170, elevated serum nicotine/cotinine/exhaled carbon 
monoxide (CO) levels (in some171, but not all 172, 173, studies), and more severe upregulation of 
brain nicotinic acetylcholine receptors165 when compared with non-menthol cigarette smokers. 
Therefore, we also hypothesized that effects of smoking on [11C]DAA1106 binding would be 
greater in menthol than in non-menthol smokers. 
 
 
MATERIALS AND METHODS 
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Forty-five participants (30 smokers and 15 non-smokers) completed the study and had usable 
data. These participants underwent telephone and in-person screening, a bolus [11C]DAA1106 
PET scanning session, blood draws during PET to determine TSPO affinity genotype and 
plasma nicotine (and metabolite) levels, and a structural magnetic resonance imaging (MRI) 
scan, as described below. An additional 6 participants underwent PET scanning but were 
excluded due to genotype (n=4, see below) or technical PET scanning issues (n=2) (Figure 11). 
 
Participants were veterans who were recruited through Internet (eg, Craigslist) advertisements 
and posted flyers. Inclusion criteria were: (1) healthy adult (18–65 years) cigarette smokers (10–
40 cigarettes per day) who met DSM-IV criteria174 for Nicotine Dependence or non-smokers 
(<100 cigarettes lifetime and none within the past year), (2) smoking primarily  
 
(>80%) either menthol or non-menthol 
cigarettes (for the smoker group), (3) 
ability to read, write, and give voluntary 
informed consent, and (4) an exhaled CO 
⩾ or <8 ppm (and urine cotinine ⩾ or 
<200 ng/ml) during the study screening 
visit to support smoking or non-smoking 
status, respectively. Exclusion criteria 
Figure 3-1. Flow diagram showing the 
number of potential and actual 
participants at each step of the study, 
including reasons for potential 
participants being screened out of 
participation. 
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were: (1) any Axis I diagnosis (including mood, anxiety, psychotic, and substance abuse 
disorders) within the past year, (2) any current medication or history of a medical condition that 
might affect the central nervous system at the time of scanning (eg, current treatment with a 
psychotropic medication or history of severe head trauma with loss of consciousness, epilepsy, 
or other neurological diseases), (3) regular use (>1 × /week) of anti-inflammatory medication, 
such as steroidal or non-steroidal anti-inflammatory medications (eg, corticosteroids, ibuprofen, 
naproxen, aspirin, or celecoxib (Celebrex)), (4) unstable cardiovascular disease, severe liver 
disease, or renal insufficiency, which might make tolerating study procedures difficult, or (5) 
pregnancy. Occasional drug/alcohol use not meeting criteria for abuse or dependence was not 
exclusionary, but participants were instructed to abstain from drug/alcohol use for at least 48 h 
prior to PET scanning. 
 
For the telephone screening, a thorough smoking history, including age of first cigarette, 
maximum smoking habit, menthol or non-menthol cigarette use, length and dates of abstinence 
periods, previous treatments used, and current smoking habit, was obtained. A brief medical, 
psychiatric, and substance use history was also obtained during the telephone screening. 
During a subsequent in-person visit, eligibility criteria were confirmed and general 
demographics, smoking history, and symptom ratings were obtained with screening questions 
from the SCID for DSM-IV, the Smoker’s Profile Form, the Fagerström Test for Nicotine 
Dependence (FTND)175, 176 (to assess severity of Nicotine Dependence), Shiffman–Jarvik 
Withdrawal Scale (SJWS)177 (to measure craving and withdrawal), and Spielberger State Trait 
Anxiety Index (STAI)178 and Beck Depression Inventory (BDI)179 (to confirm the absence of 
potentially confounding psychiatric symptoms). A brief medical review of systems and chart 
review were also performed by a study physician (ALB or MSM), along with an exhaled CO 
measurement (Micro+ Smokerlyzer Breath CO Monitor; Bedfont Scientific, UK), urine cotinine 
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screen (The Accutest NicAlert; Jant Pharmacal, Encino, CA), breathalyzer (AlcoMatePro), urine 
toxicology screen (Test Country I-Cup Urine Toxicology Kit), and urine pregnancy test (Test 
Country Cassette Urine Pregnancy Test) to verify inclusion/exclusion criteria. 
 
Participants meeting inclusion/exclusion criteria who wished to participate underwent a 
[11C]DAA1106 PET scanning session 1 week later, using a procedure similar to the one 
developed in previous studies.144, 180, 181 At 1400 hours on the day of PET scanning, participants 
arrived at the VA Greater Los Angeles Healthcare System PET Center and underwent a brief 
clinical interview, breathalyzer, and urine cotinine, toxicology, and pregnancy screens, in order 
to verify continued meeting of inclusion/exclusion criteria (including confirmation of reports of 
drug abstinence at the time of scanning). From 1430 to 1445 hours, smokers smoked to satiety 
(2–3 cigarettes, favorite brand) in an outdoor area adjacent to the PET center. From 1445 to 
1500 hours, participants were positioned on the PET scanner and a venous line was placed. At 
1500 hours, participants received a bolus injection of 377 (±62) MBq of [11C]DAA1106 and 
underwent dynamic PET scanning of the brain for the next 90 min. PET scans were obtained 
using the Philips Gemini TruFlight PET Scanner (Koninklijke Philips Electronics N.V., 
Eindhoven, The Netherlands). [11C]DAA1106 was prepared by an established method (Wang 
et al, 2012). An investigational new drug (IND) approval from the Food and Drug Administration 
(IND 122041) was obtained to use the radiotracer [11C]DAA1106 for the study described here. 
 
A 5-ml blood sample was drawn prior to the initiation of PET scanning for genotyping of each 
individual’s TSPO affinity subtype (high [C/C], medium [C/T], or low [T/T]), because these 
affinity subtypes have been shown to affect radiotracer binding for all currently used radiotracers 
determining TSPO availability.136, 182, 183 For this sample, venous blood was drawn via a port in 
the catheter placed for radiotracer injection. Genomic DNA was extracted from whole blood 
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using the QiaAmp DNA Blood Mini Kits (Qiagen, Valencia, CA) by study collaborators (EN and 
LS) and TSPO single-nucleotide polymorphism (rs6971) genotyping using the TaqMan Allelic 
Discrimination (Thermo Fisher Scientific, Canoga Park, CA) platform was performed in 
duplicate, according to the manufacturer’s specified protocol. Quality control was ensured by 
perfect concordance of replicate samples, expected minor allele frequencies, and adherence to 
Hardy–Weinberg equilibrium. Only scans from participants with the high- or medium-affinity 
genotypes (known to be >90% of North Americans;184) were included in study analyses in order 
to avoid a potential confound. The exclusion of low-affinity binders from data analysis is 
standard practice in recent research in this field.146, 149, 185, 186 
 
In addition, blood samples were drawn 10 and 60 min after the initiation of PET scanning for 
determination of plasma nicotine/cotinine levels. Afternoon plasma cotinine has been shown to 
be a good measure of nicotine exposure for the past 24 h187. Samples were centrifuged to 
obtain plasma, packed on dry ice, and shipped to the Clinical Pharmacology Laboratory at the 
University of California, San Francisco for assay by gas chromatography by Peyton Jacob and 
colleagues. 
 
One week after the PET scanning session, an MRI scan of the brain was obtained on a 3.0-T 
scanner (Signa; GE Medical Systems, Milwaukee, WI) in order to aid in localization of regions 
on the PET scans. The MRI had the following specifications: three-dimensional Fourier-
transform spoiled-gradient-recalled acquisition with TR=30 ms, TE=7 ms, 30-degree angle, 2 
acquisitions, and 256 × 192 view matrix. The acquired volume was reconstructed as roughly 90 
contiguous 1.5-mm thick transaxial slices. 
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As in previous research by our group162, 188-190 , MRI/PET co-registration was performed using 
the Statistical Parametric Mapping software (FIL Methods Group, UK), and automated volumes 
of interest (VOIs) were determined on MRI using FSL tools for structural MRI. These automated 
VOIs were transferred from each participant’s MRI to his/her co-registered PET scan and 
visually inspected using PMOD (PMOD Technologies, Zurich, Switzerland). The primary VOI 
was whole brain (including gray and white matter) for reasons cited in the Introduction section. 
However, as automated volumes are easily attained and regional differences are possible, VOIs 
were also determined for the amygdala, caudate, hippocampus, nucleus accumbens, putamen, 
and thalamus, similar to VOIs obtained in prior research (Takano et al, 2010; Yasuno et al, 
2012). 
 
In order to obtain a quantitative measurement of VOI binding to TSPO in the brain, standardized 
uptake values (SUVs) were calculated using the standard definition of SUV=mean tissue activity 
concentration (Bq/ml)/(injected dose (Bq)/body weight (g)). Mean tissue activity concentration 
from 20 to 40 min postinjection was used, based on time activity curves demonstrating stable 
activity during this time period. SUV was used as the primary outcome measure because it 
avoids invasive arterial blood sampling and has been shown to strongly correlate with total 
volume of distribution (Vt) values191, 192, has good test–retest reproducibility, and has less 
intersubject variability than Vt for a similar radiotracer. 
 
For statistical analysis of data, an analysis of variance (ANOVA) was performed, with whole-
brain SUV as the measure of interest and both group (smokers vs non-smoker) and TSPO 
genotype (mixed or high affinity) as between-subject factors141, 142. To determine whether group 
differences were due to differences in particular brain regions, a multivariate ANOVA 
(MANOVA), using the smaller automated VOIs, was performed with the same structure as the 
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preceding ANOVA, followed by univariate ANOVAs for the individual VOIs. To quantify 
between-group differences, percentage of difference was calculated as: 100 × (SUVnon-
smokers−SUVsmokers)/SUVnon-smokers. Based on prior research reporting greater brain 
exposure to cigarette smoke in menthol than in non-menthol cigarette smokers, we also 
performed an ANOVA for whole-brain SUV with the same structure as the above test, using 
non-smoker vs menthol vs non-menthol cigarette preference as a between-subject factor. As an 
exploratory analysis, linear analyses were performed for the smoker group, with whole-brain 
SUV value as the dependent variable and independent variables related to smoking, controlling  
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Variable Non-smoker 
group (n=15) 
Whole 
smoker 
group (n=30) 
Non-menthol 
smoker 
subgroup 
(n=15) 
Menthol 
smoker 
subgroup 
(n=15) 
Age, years 47.6 (±13.8) 52.1 (±8.1) 49.9 (±8.4) 54.4 (±7.4) 
Sex (% female) 26.7 20.0 20.0 20.0 
Race/ethnicity 
(%) 
 African 
American 
26.7 46.7 33.3 60.0 
 Asian 26.7 10.0 6.7 13.3 
 Hispanic 26.7 13.3 13.3 13.3 
 White 20.0 30.0 46.7 13.3 
          
Height (inches) 68.9 (±4.0) 68.2 (±4.0) 68.3 (±4.7) 68.2 (±3.5) 
Weight (kg) 88.1 (±23.4) 84.0 (±16.2) 83.9 (±17.9) 84.1 (±14.9) 
Cigarettes per 
day 
0 (±0) 13.9 (±3.8) 13.5 (±3.8) 14.4 (±3.9) 
Exhaled carbon 
monoxide (ppm) 
1.6 (±0.6) 13.3 (±4.7) 13.0 (±4.2) 13.5 (±5.2) 
Fagerström Test 
for Nicotine 
Dependence 
(FTND) 
0 (±0) 4.0 (±2.3) 4.1 (±2.1) 3.9 (±2.4) 
Beck Depression 
Inventory 
1.0 (±1.3) 1.7 (±2.3) 1.3 (±1.8) 2.1 (±2.8) 
State Trait 
Anxiety Inventory 
58.5 (±15.0) 66.7 (±17.8) 68.3 (±18.1) 65.1 (±18.0) 
Caffeine use 
(coffee cup 
equivalents/day) 
1.1 (±1.3) 2.0 (±1.6) 2.0 (±1.7) 1.9 (±1.5) 
Alcohol drinks 
per day 
0.6 (±1.4) 1.0 (±2.1) 0.7 (±1.6) 1.3 (±2.5) 
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for TSPO genotype. Statistical tests were performed using the statistical software program  
SPSS/PASW version 24 (SPSS, Chicago, IL). 
RESULTS 
 
Study groups had no significant differences in age, sex, race/ethnicity, height, weight, 
depression/anxiety levels, or caffeine, alcohol, or marijuana use (Table 3-1). On average, the 
groups were middle-aged, mostly male, and had generally low levels of depression/anxiety and 
drug/alcohol use. No significant between-group differences were present for body weight or 
injected dose of radiotracer, which were used to calculate SUV. 
Brain region SUV values—
non-smokers 
(n=15) 
SUV values—
smokers 
(n=30) 
SUV values—
non-menthol 
smoker 
subgroup 
(n=15) 
SUV values—
menthol 
smoker 
subgroup 
(n=15) 
Whole brain 0.20 (±0.03) 0.17 (±0.04) 0.18 (±0.04) 0.16 (±0.02) 
Accumbens 
 R 0.20 (±0.03) 0.17 (±0.04) 0.17 (±0.04) 0.16 (±0.03) 
 L 0.21 (±0.03) 0.17 (±0.04) 0.17 (±0.04) 0.16 (±0.03) 
          
Amygdala 
 R 0.18 (±0.03) 0.15 (±0.04) 0.16 (±0.04) 0.13 (±0.02) 
Marijuana 
cigarettes per 
week 
0.0 (±0.0) 0.3 (±1.3) 0.5 (±1.8) 0.1 (±0.4) 
1. Table 3-1. Baseline Demographics and Rating Scale Scores for the Non-Smoker and 
Smoker Groups All values are presented as means (±SD) or percentages. Using χ2 tests for 
categorical variables and Student’s t-tests for continuous variables, no between-group (or 
between-subgroup) tests were significant, other than differences in measures of smoking 
(cigarettes per day, exhaled carbon monoxide, and FTND scores) between the smoker 
groups/subgroups and the non-smoker group (all P-values<0.0005). 
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 L 0.17 (±0.03) 0.15 (±0.04) 0.16 (±0.04) 0.14 (±0.02) 
          
Caudate 
 R 0.18 (±0.04) 0.14 (±0.03) 0.15 (±0.03) 0.14 (±0.02) 
 L 0.18 (±0.03) 0.15 (±0.03) 0.15 (±0.03) 0.14 (±0.02) 
          
Hippocampus 
 R 0.19 (±0.03) 0.16 (±0.03) 0.17 (±0.04) 0.15 (±0.02) 
 L 0.19 (±0.03) 0.15 (±0.03) 0.16 (±0.04) 0.14 (±0.02) 
          
Putamen 
 R 0.23 (±0.03) 0.19 (±0.05) 0.21 (±0.06) 0.18 (±0.03) 
 L 0.23 (±0.03) 0.19 (±0.04) 0.20 (±0.05) 0.18 (±0.03) 
          
Thalamus 
 R 0.22 (±0.04) 0.19 (±0.04) 0.20 (±0.04) 0.18 (±0.03) 
 L 0.22 (±0.03) 0.18 (±0.04) 0.19 (±0.04) 0.17 (±0.03) 
 
PET data analysis comparing smokers and non-smokers revealed a significant effect of group 
for whole-brain SUV values (ANOVA, F=8.3; df=1,41; P=0.006), due to smokers having mean 
2. Table 3-2. Standardized Uptake Values (SUVs) for the Whole Brain and Smaller 
Regions of Interest for Non-smokers and Smokers (and the Non-Menthol Smoker and 
Menthol Smoker Subgroups) Abbreviations: L=left; R=right. All values are mean±SD. All regions 
were analyzed using analysis of variance, with group (non-smoker vs smoker or non-smoker vs non-
menthol smoker vs menthol smoker) and genotype as between-subject factors. All regions were 
significant for the non-smoker vs smoker comparison at the P 0.05 level, except for the right and 
left accumbens, which approached significance (P-values=0.08 and 0.06, respectively). Similarly, all 
regions were significant for the three group comparisons (non-smoker vs non-menthol smoker vs 
menthol smoker) at the P 0.05 level. The automated regions listed here were generated using the 
FSL toolkit. 
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16.8% lower values than non-smokers (Table 3-2). Consistent with this global finding, in the 
analysis of the smaller VOIs, a significant multivariate effect of group was found (MANOVA; 
F=2.8, df=12,30; P=0.01), with all VOIs having a significant (or trend-level) between-group effect 
on univariate analysis (Table 3-2), owing to smokers having lower SUV values than non-
smokers (range 14.6–19.7%) in all VOIs studied. 
 
 
For the three-group comparison (non-smokers vs non-menthol cigarette smokers vs menthol 
cigarette smokers), the whole-brain SUV comparison was significant (ANOVA, F=6.1; df=2,39; 
P=0.005), owing to a range of values from non-smokers (highest) to non-menthol cigarette 
smokers (middle) to menthol cigarette smokers (lowest) (Table 3-2). In the multivariate analysis 
3. Figure 3-2. Mean positron emission tomography (PET) images from the study subgroups 
(non-smokers, non-menthol cigarette smokers, and menthol cigarette smokers) 
demonstrating higher [11C]DAA1106 standardized uptake values (SUVs) for non-smokers 
than the two smoker subgroups. The first three columns consist of mean SUV PET images 
(transaxial, sagittal, and coronal from top to bottom) for the three study groups/subgroups 
(n=15 each) and the far right column shows the group mean magnetic resonance image. For 
this figure representation of study results, the PET scans were spatially normalized into 
standard Montreal Neurological Institute (MNI) template space. 
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of smaller VOIs, a significant effect of group was found (MANOVA; F=1.8, df=24,56; P=0.03), 
with all VOIs having a significant between-group effect, owing to the range (from high to low) of 
SUV values from smokers to non-menthol smokers to menthol smokers (Table 3-2). In 
comparing only the non-menthol with the menthol cigarette smokers, the whole-brain SUV 
comparison did not reach significance (ANOVA; F=3.6; df=1,26; P=0.07), and similar results 
were found for the smaller VOIs (ANOVAs; Ps=0.03–0.21), possibly owing to the smaller 
samples used for comparing the non-menthol with the menthol cigarette smoker subgroups. 
 
In the exploratory analysis of smoking-related variables, a significant relationship was found 
between cigarettes per day and whole-brain SUV (F=6.3; P=0.02), indicating that higher levels 
of reported smoking were associated with lower levels of TSPO availability. Similarly, a 
significant relationship between the stimulation subscale scores of the SJWS and whole-brain 
SUV was also found (F=5.6; P=0.03), indicating that higher levels of withdrawal stimulation were 
associated with lower levels of TSPO availability. No significant associations were found for 
FTND scores, CO levels, plasma nicotine/cotinine levels, or other subscales on the SJWS. 
 
 
DISCUSSION 
 
Cigarette smokers have less [11C]DAA1106 binding than non-smokers throughout the brain, 
indicating less TSPO availability. Though several explanations for this finding are possible, a 
straightforward one is that smoking results in global impairment of microglial activation. This 
explanation is consistent with much prior research demonstrating that smokers have impaired 
inflammatory functioning in other parts of the body, which leads to compromised wound 
healing126, 156. Furthermore, the inverse correlation between [11C]DAA1106 binding and 
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participant reports of cigarette use per day indicates that the severity of impaired microglial 
activation may be related to the amount of current cigarette usage. Of note, the fact that study 
results were global (rather than regional) is also consistent with prior research demonstrating 
widespread effects of smoking on brain receptors.162, 163, 165-167, 190 These global effects of 
smoking are in line with known properties of cigarette smoke, namely, that it rapidly enters the 
body and brain due to high permeability through lung, vasculature, and brain cells.193 Taken 
together, study results may demonstrate a significant widespread brain abnormality in smokers 
in the satiated state. 
 
The negative association between SUV values and cigarettes per day, but not plasma nicotine 
levels (or other measures of smoking behavior), may indicate that components of cigarette 
smoke other than nicotine are responsible for the low level of microglial activation found here. 
Laboratory studies support this theory, with several studies demonstrating that whole tobacco 
smoke administration results in greater alterations in inflammatory markers than nicotine 
alone.194, 195 However, given the evidence that nicotine indeed impairs196, 197 or attenuates198 
some inflammatory processes, and the relatively small sample of smokers studied here in the 
correlational analysis, the exact relationship between nicotine and neuroinflammation in human 
smokers remains to be confirmed. 
 
Although impairment of neuroinflammation by smoking is a straightforward explanation of the 
study results, other explanations are possible, given the complex effects of cigarette smoking on 
the brain. Cigarette smoke contains thousands of constituents,199 with hundreds having known 
toxic effects. 200, 201 It is possible that one or more of these constituents directly interfered with 
[11C]DAA1106 binding to TSPO, which would have resulted in the difference in binding 
between smokers in the satiated state and non-smokers found here. Additionally, acute smoking 
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is known to disrupt blood–brain barrier function,202 which could have created differences in 
radiotracer binding for smokers and non-smokers for the PET time period of interest used here. 
 
In addition to the overall difference between smokers and non-smokers, the menthol cigarette 
smoker subgroup had less [11C]DAA1106 binding than the non-menthol cigarette smoker 
subgroup. This finding is consistent with prior research by our group165 showing greater 
upregulation of nicotinic acetylcholine receptors throughout almost all brain regions in menthol 
than in non-menthol cigarette smokers. Also, research by others demonstrates that menthol 
cigarette smoking is associated with more severe biological abnormalities in some171, but not 
all,172, 173 studies that have examined this issue. Therefore, as in prior research, the present 
finding may be due to greater brain exposure to cigarette smoke (leading to greater impairment 
of microglial activation) in menthol cigarette smokers, a direct effect of menthol flavoring, or 
some other mechanism. 
 
The primary limitation of this study was the absence of arterial blood sampling such that total 
distribution volume (Vt) was not ascertained. Vt may control for the potential confounds of 
between-subject differences in radiotracer metabolism and binding to vascular endothelium and 
plasma protein.149, 203, 204 Although Vt is a common outcome measure in PET studies examining 
TSPO in conditions other than tobacco dependence,205-207 recent research demonstrates that 
the less invasive SUV measure tends to correlate well with Vt within individual PET studies191, 
208 and has high test–retest reliability209. Other similar studies have used pseudo-reference 
regions for PET data analysis146, 205, 210-213 to minimize potential confounds, but this method 
would not have been appropriate here due to the hypothesized and confirmed effect of smoking 
throughout the brain. Additional limitations included a modest sample size and the fact that 
smokers were scanned in the satiated state, such that we did not determine whether results 
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were due to acute or chronic cigarette smoking. Future research could examine smokers in the 
abstinent state to determine the relationship between decreased [11C]DAA1106 binding and 
recency of smoking. 
 
In summary, cigarette smokers in the satiated state have decreased TSPO availability, which is 
related to participants’ current smoking level (higher levels of smoking were associated with less 
TSPO availability). This effect appeared to be greater for menthol than for non-menthol cigarette 
smokers. Future research could examine the time course of recovery of TSPO availability upon 
smoking cessation and the interplay between smoking, neuroinflammation, and the progression 
of diseases thought to be mediated by neuroinflammation. 
 
 
 
 
 
 
 
 
 
 
PD Case Study #2: Effect of overnight smoking abstinence on a marker for microglial 
activation: a [11C]DAA1106 positron emission tomography study.* 
 
*This study is currently published in Psychopharmacology.214 
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INTRODUCTION 
 
Microglia are the main innate immune cells in the central nervous system (CNS).215 Under 
homeostatic conditions, they continuously monitor the surrounding environment for signs of 
infection or homeostasis-perturbing events.216, 217 Microglia react to counteract such 
perturbations in order to protect neurons, which have a limited capacity to regenerate, leading to 
elevated levels of activated microglia in neurodegenerative diseases.218, 219 In this context, 
activated microglia participate in various functions, such as clearance of apoptotic cells and 
extracellular pathogens, removal of degenerating neurons and extracellular proteins, and 
cytokine/chemokine production.128 When activated, microglial cellular morphology changes and 
expression of the translocator protein (TSPO) 18 kDa is increased, thereby making expression 
of TSPO a marker for neuroinflammation. 
 
Epidemiological studies have shown that cigarette smokers have a lower risk of 
neurodegenerative diseases than the general population,220, 221 and much research has 
examined the mechanism by which smoking could diminish neuroinflammation, which 
contributes to neurodegenerative damage. Extensive pre-clinical work has shown that nicotine 
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and/or other agonists at nicotinic acetylcholine receptors (nAChRs) protect against neuronal cell 
damage222 via binding to α7 nAChRs and inhibition of microglial activation.220, 223-225 
 
The radioligand N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl) acetamide labeled with 
carbon-11 ([11C]DAA1106) has emerged as a reliable second-generation radiotracer for 
labeling TSPO129-131 with high affinity132, 133, 135, 138  for positron emission tomography (PET) 
scanning in vivo. Specific binding of DAA1106 is reported to be greater than previously used 
ligands (e.g., PK11195) but less than at least one recently developed ligand (PBR28). 136 
Specific binding of DAA1106 correlates with the presence of activated microglia identified by 
immunohistochemistry in situ135 and immunohistochemistry combined with autoradiography in 
brain tissue.138 [11C]DAA1106 was chosen for use here because of these favorable properties 
and previous experience by our group with this radiotracer.125, 226 
 
Our group recently used [11C]DAA1106 with PET scanning to compare smokers who had 
smoked to satiety (~ 15 min prior to scanning) with nonsmoking controls.125 The groups differed 
in whole brain standardized uptake values (SUVs) for the radiotracer, with smokers having 
16.8% lower values than nonsmokers (and lower mean SUVs in menthol- than nonmenthol-
cigarette smokers). Smokers also had lower SUVs (by 14.6–19.7%) in a range of smaller brain 
volumes of interest. In addition, whole-brain SUV was negatively correlated with participant-
reported cigarettes per day. These study findings were consistent with much prior research 
demonstrating that smokers have less inflammatory functioning than nonsmokers. 
 
For the study presented here, we sought to determine if the reduction in [11C]DAA1106 SUV 
(the marker for neuroinflammation) found in satiated smokers was still present in early 
(overnight) smoking abstinence. In order to study smokers in a state with potentially significant 
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differences from nonsmoking controls, overnight (> 12 h) abstinence from smoking was chosen 
as the time point of interest because nicotine would be expected to be recently eliminated from 
the body at that time (plasma half-life of ~ 2 h;124 and withdrawal symptoms (e.g., urge to smoke 
and anxiety/irritability) would be expected to be elevated.227, 228 As in our prior study, we 
hypothesized that smoker vs. nonsmoker effects would occur globally, based on prior research 
demonstrating that cigarette smoke is rapidly absorbed229 and results in saturation (or near 
saturation) of nicotinic acetylcholine receptors throughout the brain.162, 163, 190, 230 We also sought 
to examine the effect of menthol, because menthol smoking is common (~ 1/3 of US smokers) 
(SAMHSA 2009), menthol smokers have more trouble quitting in standard treatment programs 
than nonmenthol-cigarette smokers,157, 168, 169 menthol smoking has been found to lead to 
elevated serum nicotine/cotinine and exhaled carbon monoxide levels171 (though not all studies 
agree on this point;231, 232 and menthol smokers had lower mean [11C]DAA1106 SUVs than 
nonmenthol smokers in our prior study of smokers in satiety.125 
 
METHOD 
 
Forty participants (22 cigarette smokers and 18 nonsmokers) completed the study and had 
usable data. These participants underwent telephone and in-person screening, overnight 
smoking abstinence prior to the PET session (for the smoker group), a bolus [11C]DAA1106 
PET scanning session, a blood draw to determine TSPO affinity genotype, and a structural 
magnetic resonance imaging (MRI) scan, as described below. Four additional participants were 
enrolled, but were excluded because they were homozygous for the low affinity TSPO 
genotype. All participants provided written informed consent on forms approved by the 
Institutional Review Boards of either the VA San Diego Healthcare System or VA Greater Los 
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Angeles Healthcare System. A subset of the nonsmoker group in the analysis presented here 
consisted of participants who were included in our previous report (n = 13). 
 
Participants were recruited through posted flyers and the Internet (e.g., Craigslist). Inclusion 
criteria were healthy adult (18 to 65 years old) daily cigarette smokers (range 2–25 
cigarettes/day and evidence of tobacco dependence on the Fagerström test for nicotine 
dependence (FTND)) or nonsmokers (< 100 cigarettes lifetime and none within the past year), 
smoking primarily (> 80%) either menthol or nonmenthol cigarettes (for the smoker group), 
ability to give voluntary informed consent, and an exhaled CO > or < 8 ppm (and urine cotinine > 
or < 200 ng/mL) during the study screening visit to support smoking or nonsmoking status, 
respectively. Exclusion criteria were any psychiatric diagnosis (including mood, anxiety, 
psychotic, and substance abuse disorders other than tobacco use disorder) within the past 6 
months; any current medication or history of a medical condition that might affect the central 
nervous system at the time of scanning (e.g., current treatment with a psychotropic medication, 
or history of severe head trauma with loss of consciousness, epilepsy, or other neurological 
diseases); regular use (> 1×/week) of anti-inflammatory medication, such as steroidal or 
nonsteroidal anti-inflammatory medications (e.g., corticosteroids, ibuprofen, naproxen, aspirin, 
or celecoxib (Celebrex®)); unstable cardiovascular disease, severe liver disease, or renal 
insufficiency, which might make tolerating study procedures difficult; or pregnancy. Occasional 
drug/alcohol use not meeting criteria for abuse or dependence was not exclusionary, but 
participants were instructed to abstain from drug/alcohol use for at least 48 h prior to PET 
scanning. 
 
For the telephone screening, a thorough smoking history, including age of first cigarette, 
maximum smoking habit, menthol- or nonmenthol-cigarette use, length and dates of abstinence 
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periods, previous treatments used, and current smoking habit, was obtained. A brief medical, 
psychiatric, and substance use history was also obtained. During a subsequent in-person visit, 
eligibility criteria were confirmed and general demographics, smoking history, and symptom 
ratings were obtained with the FTND175, 176 (to assess severity of nicotine dependence), 
Spielberger State Trait Anxiety Index (STAI)178 , and Beck Depression Inventory (BDI)179 (to 
confirm the absence of potentially confounding psychiatric symptoms) for all participants, and 
Smoker’s Profile Form and Shiffman–Jarvik Withdrawal Scale (SJWS)177 (to measure craving 
and withdrawal) for participants scanned at UCSD. A brief medical review of systems and chart 
review were also performed by a study physician, along with an exhaled carbon monoxide (CO) 
measurement (Micro+ Smokerlyzer Breath CO Monitor; Bedfont Scientific, Ltd., UK), urine 
cotinine screen (The Accutest® NicAlert™; Jant Pharmacal Corp., Encino, CA), breathalyzer 
(AlcoMatePro), urine toxicology screen (Test Country I-Cup Urine Toxicology Kit), and urine 
pregnancy test (Test Country Cassette Urine Pregnancy Test), in order to determine if 
participants met inclusion/exclusion criteria. 
 
Participants who met inclusion/exclusion criteria and wished to participate underwent a 
[11C]DAA1106 PET scanning session 1 week later at either the University of California at San 
Diego (UCSD) Center for Molecular Imaging (n = 15; 10 overnight abstinent smokers and 5 
nonsmokers) or VA Greater Los Angeles Healthcare System (VAGLAHS) PET Center (n = 25; 
12 overnight abstinent smokers and 13 nonsmokers), using a procedure similar to the one 
developed in previous studies.143, 144, 180, 181 Smokers were instructed to abstain from cigarettes 
and other nicotine-containing products from prior to midnight on the night before PET scanning. 
The PET session was initiated in the afternoon with participants undergoing a brief clinical 
interview, breathalyzer, exhaled CO level, and urine toxicology and pregnancy screens, in order 
to verify continued meeting of inclusion/exclusion criteria (including drug abstinence at the time 
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of scanning). An exhaled CO of < 6 ppm was considered consistent with overnight abstinence. 
Following these procedures, participants were positioned on the PET scanning bed and a 
venous line was placed. They then received a bolus injection of 350 (± 53) MBq of 
[11C]DAA1106 and underwent dynamic PET scanning of the brain for the next 90 min. PET 
scans were obtained using either an ECAT HR+ PET scanner (CTI PET systems, Knoxville, TN) 
(UCSD) or a Philips Gemini TruFlight PET Scanner (Koninklijke Philips Electronics N.V., 
Eindhoven, the Netherlands) (VAGLAHS). [11C]DAA1106 was prepared by an established 
method.233 All scans consisted of eighteen 5-min frames. For the UCSD scanner, a 20-min 
transmission scan from a Ge-68 rod source was performed for attenuation correction following 
the dynamic scan. The reconstruction used a manufacturer’s OSEM algorithm with 4 iterations 
and 16 subsets. For the VAGLAHS scanner, CT scanning was performed for attenuation 
correction following the dynamic scan, and the manufacturer’s RAMLA algorithm was used for 
image reconstruction. Investigational new drug (IND) approvals from the Food and Drug 
Administration (INDs 133984 (UCSD) and 122041 (VAGLAHS)) were obtained to use the 
radiotracer [11C]DAA1106 for the studies described here. 
 
A 5-ml blood sample was drawn prior to the initiation of PET scanning for genotyping of each 
individual’s TSPO affinity subtype (high (C/C), medium (C/T), or low (T/T)), because these 
affinity subtypes affect radiotracer binding of all currently used radiotracers determining TSPO 
availability.136, 182, 183 Genomic DNA was extracted from whole blood using QiaAmp DNA Blood 
Mini Kits (Qiagen, Valencia, CA) (by E.N. and L.S.) and TSPO single-nucleotide polymorphism 
(rs6971) genotyping using the TaqMan Allelic Discrimination (Thermo Fisher Scientific, Canoga 
Park, CA) platform was performed in duplicate, according to the manufacturer’s specified 
protocol. Quality control was ensured by perfect concordance of replicate samples, expected 
minor allele frequencies, and adherence to Hardy–Weinberg equilibrium. Only scans from 
79 
 
participants with the high- or medium- affinity genotypes, present in > 90% of North 
Americans,184 were included in study analyses, in order to avoid a potential confound. The 
exclusion of homozygous low-affinity binders from data analysis is standard practice in recent 
research in this field.146, 149, 185, 186 
 
Within 1–2 weeks of PET scanning, an MRI scan of the brain was obtained, in order to facilitate 
localization of regions on the PET scans. At UCSD, high-resolution T1-weighted 3D MRIs were 
obtained on a Siemens 3 T Skyra scanner (Erlangen, Germany), with the following 
specifications: TR = 2300 ms, TE = 3 ms, 9° angle, 2 acquisitions, and 160 × 256 × 256 matrix. 
Participants who received PET scans at VAGLAHS had MRI scans with the following 
specifications: 3 T GE Medical Systems Signa scanner (Milwaukee, WI) three-dimensional 
Fourier-transform (3DFT) spoiled-gradient-recalled acquisition with TR = 30 ms, TE = 7 ms, 30° 
angle, 2 acquisitions, and 256 × 192 view matrix. 
 
As in previous research by our group, MRI/PET co-registration was performed using Statistical 
Parametric Mapping software (FIL Methods Group, UK), and automated volumes of interest 
(VOIs) were determined on MRI using FSL tools for structural MRI. These automated VOIs were 
transferred from each participant’s MRI to his/her co-registered PET scan and visually inspected 
using PMOD (PMOD Technologies Ltd., Zurich, Switzerland). The primary VOI was whole brain 
(including gray and white matter) for reasons noted above. However, since automated volumes 
are easily attained and regional differences are possible, VOIs were also determined for the 
amygdala, caudate, hippocampus, nucleus accumbens, putamen, and thalamus, similar to VOIs 
obtained in prior research.144, 181 
 
80 
 
In order to obtain semi-quantitative measurements of radiotracer binding to TSPO in brain, 
SUVs were calculated using the standard definition of SUV = mean tissue activity concentration 
(Bq/mL)/(injected dose (Bq)/body weight (g)). Mean tissue activity from 20 to 40 min post-
injection was used, based on time-activity curves from our previous study demonstrating stable 
activity during this time period. SUV was used as the primary outcome measure because it 
avoids invasive arterial blood sampling. 
 
For the statistical analysis of data, demographic and rating scale variables were compared 
between groups using Student t tests for continuous variables and Chi-square tests for 
categorical variables, in order to determine if groups were similar on these variables. For the 
central study analysis, an analysis of covariance (ANCOVA) was performed, with whole-brain 
SUV as the measure of interest and both group (overnight abstinent smoker vs. nonsmoker) 
and TSPO genotype (heterozygous or homozygous for the high affinity allele) as between-
subject factors.142, 148 Research site (UCSD vs. VAGLAHS) was included in the model as a 
nuisance covariate, in order to control for possible systematic differences in SUVs related to the 
different PET scanners or other differences in methodology at the two sites (which were 
somewhat, but not significantly, different). To determine if group differences were due to 
regional effects, a multivariate ANCOVA (MANCOVA), using the smaller automated VOIs, was 
performed with the same structure as the preceding ANCOVA, followed by univariate ANCOVAs 
for the individual VOIs. The use of an overall MANCOVA for determination of main effect of 
group (nonsmoker vs. overnight abstinent smoker) controls for multiple comparisons. For the 
smaller VOIs, means of left and right SUVs were used. For descriptive purposes, percent 
difference between study groups for both sites was calculated as: 100 * 
(SUVnonsmokers − SUVsmokers) / SUVnonsmokers. Based on prior research reporting greater 
brain exposure to cigarette smoke in menthol- than nonmenthol-cigarette smokers, we also 
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performed an ANCOVA for whole brain SUV with the same structure as the above test, using 
nonsmoker vs. menthol- vs. nonmenthol-cigarette preference as a between-subject factor, 
followed by the same analyses for smaller automated VOIs as for the preceding analysis. For 
the exploration of associations between PET data and smoking-related behavioral symptoms, 
correlations were determined for the smoker group between whole brain SUV and smoking-
related ratings (for smokers with completed rating scales), while controlling for genotype. For 
exploratory associations between SUVs and demographic variables, correlations or tests for 
associations with the same structure as in the preceding analyses were performed for age, sex, 
and race/ethnicity for the whole study sample. Statistical tests were performed using the 
statistical software program SPSS version 24 (SPSS Inc., Chicago, IL). 
 
RESULTS 
 
The nonsmoker and overnight abstinent smoker groups did not differ significantly in age 
(P = 0.24), sex (P = 0.71), race/ethnicity (P = 0.50), height (P = 0.18), weight (P = 0.25), 
depression (P = 0.16) or anxiety (P = 0.94) levels, or caffeine (P = 0.23), alcohol (P = 0.27), or 
marijuana (P = 0.29) use (Table 3-3). On average, participants were middle-aged, mostly male, 
and had generally low levels of depression/anxiety and drug/alcohol use. On the scan day, 
participants had low levels of exhaled CO (1.9 ± 0.8 ppm for the nonsmoker group and 3.3 ± 1.4 
ppm for smokers), and smokers had a mean of 17.9 ± 2.3 h abstinence at the time of radiotracer 
injection (due to overnight abstinence and availability of PET scanning for research at our 
institutions in the mid-to-late afternoon). 
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Variable Nonsmoker 
group 
(n = 18) 
Whole smoker 
group (n = 22) 
Nonmentho
l-smoker 
subgroup 
(n = 16) 
Menthol-
smoker 
subgroup 
(n = 6) 
Age 46.9 (± 13.4) 41.9 (± 13.2) 41.5 (± 12.6) 43.0 (± 16.7) 
Sex (% female) 22.2 27.3 25.0 33.3 
Race/ethnicity 
(%) 
 African 
American 
22.2 36.4 37.5 33.3 
 Asian 22.2 9.1 12.5 0 
 Hispanic 22.2 13.6 12.5 16.7 
 White 33.3 40.1 37.5 50.0 
TSPO 
genotype (% 
high affinity) 
83.3 77.2 87.5 50.0 
Height (in.) 69.7 (± 4.2) 68.0 (± 3.4) 68.5 (± 3.5) 66.6 (± 2.6) 
Weight (kg) 89.8 (± 23.8) 82.3 (± 16.5) 86.8 (± 15.8) 70.1 (± 12.1) 
Cigarettes/day 0 (± 0) 11.2 (± 6.7) 11.1 (± 6.7) 11.7 (± 7.3) 
Exhaled carbon 
monoxide 
(ppm) at 
screening visit 
1.7 (± 0.7) 12.7 (± 9.0) 11.6 (± 8.7) 15.7 (± 9.6) 
Fagerström 
Test for 
Nicotine 
Dependence 
(FTND) 
0 (± 0) 4.3 (± 2.9) 4.6 (± 3.0) 3.5 (± 2.6) 
Beck 
Depression 
Inventory 
1.1 (± 1.4) 2.1 (± 2.9) 2.3 (± 2.8) 1.8 (± 3.5) 
Trait Anxiety 
Inventory 
30.9 (± 9.1) 31.2 (± 11.6) 31.4 (± 12.0) 30.4 (± 11.8) 
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Variable Nonsmoker 
group 
(n = 18) 
Whole smoker 
group (n = 22) 
Nonmentho
l-smoker 
subgroup 
(n = 16) 
Menthol-
smoker 
subgroup 
(n = 6) 
Caffeine use 
(coffee cup 
equivalents/ 
day) 
0.9 (± 1.0) 1.3 (± 1.0) 1.2 (± 1.0) 1.6 (± 1.0) 
Alcohol 
drinks/week 
0.2 (± 0.5) 1.0 (± 1.7) 1.2 (± 1.9) 0.6 (± 0.8) 
Marijuana 
cigarettes/week 
0.1 (± 0.5) 0.5 (± 1.6) 0.7 (± 1.8) 0.2 (± 0.6) 
 
PET data analysis comparing overnight abstinent smokers and nonsmokers revealed a 
significant effect of group for whole brain SUVs (ANCOVA, P = 0.004), due to the overnight 
abstinent smokers having lower values than nonsmokers. Mean whole brain SUVs were 0.87 for 
nonsmokers and 0.73 for overnight abstinent smokers at UCSD and 1.00 for nonsmokers and 
0.83 for overnight abstinent smokers at VAGLAHS (15.5% lower at UCSD and 17.0% lower at 
VAGLAHS). Consistent with these global findings, a significant multivariate effect of group was 
found (MANCOVA, P = 0.002) for the smaller VOIs, with all VOIs having a significant between-
group effect on univariate analysis (range of P values < 0.0005 to 0.026), due to overnight-
abstinent smokers having lower SUV values than nonsmokers (range 6.8 to 29.5%) in all VOIs 
studied. 
 
Table 3-3. Baseline demographics and rating scale scores for the nonsmoker and 
overnight abstinent smoker groups. All values are presented as means (± standard 
deviation) or percentages. Using χ2 tests for categorical variables and Student t tests for 
continuous variables, no between-group (nonsmoker vs. smoker) tests were significant, 
other than differences in measures of smoking (cigarettes per day, exhaled carbon 
monoxide, and FTND scores; all P values < 0.0005) 
4.  
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For the three-group comparison (nonsmokers vs. nonmenthol-cigarette smokers vs. menthol-
cigarette smokers), the whole brain SUV comparison was significant (ANCOVA, P = 0.001), due 
to nonsmokers having the highest values, followed by nonmenthol-cigarette smokers, and then 
menthol-cigarette smokers. In the multivariate analysis of smaller VOIs, a significant effect of 
group was found (MANCOVA, P < 0.0005), with all VOIs having a significant between-group 
effect, due to the range (from high to low) of SUV values from smokers to nonmenthol smokers 
to menthol smokers. In comparing only the nonmenthol- with the menthol-cigarette smokers, the 
whole brain SUV comparison was significant (ANCOVA, P = 0.02), and similar results were 
found for the smaller VOIs (ANOVAs; P = 0.02 to 0.07), possibly less highly significant than the 
overall analysis due to the smaller samples used for comparing the nonmenthol- with the 
menthol-cigarette smoker subgroups. In comparing results from the two study sites, ratios of 
smoker to non-smoker SUVs were similar (Table 3-4). 
 
Region Ratio of mean 
SUVs between all 
overnight abstinent 
smokers and 
nonsmokers by 
site 
Ratio of mean 
SUVs between 
overnight abstinent 
nonmenthol 
smokers and 
nonsmokers by 
site 
Ratio of mean 
SUVs between 
overnight abstinent 
menthol smokers 
and nonsmokers 
by site 
UCSD VAGLAHS UCSD VAGLAHS UCSD VAGLAHS 
Whole brain 0.84 0.83 0.92 0.85 0.73 0.71 
Accumbens 0.73 0.80 0.80 0.83 0.63 0.69 
Amygdala 0.87 0.80 0.95 0.82 0.75 0.69 
Caudate 0.85 0.85 0.93 0.88 0.73 0.71 
Hippocampus 0.89 0.79 0.97 0.81 0.77 0.70 
Putamen 0.73 0.78 0.80 0.80 0.63 0.66 
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Region Ratio of mean 
SUVs between all 
overnight abstinent 
smokers and 
nonsmokers by 
site 
Ratio of mean 
SUVs between 
overnight abstinent 
nonmenthol 
smokers and 
nonsmokers by 
site 
Ratio of mean 
SUVs between 
overnight abstinent 
menthol smokers 
and nonsmokers 
by site 
UCSD VAGLAHS UCSD VAGLAHS UCSD VAGLAHS 
Thalamus 0.70 0.79 0.76 0.80 0.60 0.71 
 
In the exploratory analysis of smoking-related behavioral variables, a significant inverse 
relationship was found between depth of inhalation of cigarettes (as rated by participants on the 
smoker’s profile form) and whole brain SUV (correlation = −0.74, P = 0.02), suggesting that 
higher levels of cigarette smoke exposure were associated with lower levels of TSPO availability 
(Figure 3-3). No significant associations were found for cigarettes per day, FTND, SJWS scores, 
age, sex, or race/ethnicity. 
Table 3-4. Ratios of mean standardized uptake values (SUVs) between overnight 
abstinent smokers and nonsmokers for the two study sites. Ratios of mean 
standardized uptake values (SUVs) for whole brain and smaller volumes of interest (VOIs) 
between overnight abstinent smokers and nonsmokers for the two study sites, 
demonstrating that results from the two sites were consistent with one another. All values 
were less than 1, indicating lower [11C]DAA1106 binding on positron emission tomography 
scans for overnight abstinent smokers (and subgroups of smokers based on cigarette type) 
than nonsmokers for all VOIs and both study sites 
UCSD, University of California at San Diego; VAGLAHS, VA Greater Los Angeles 
Healthcare System 
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 DISCUSSION 
 
Cigarette smokers who underwent overnight abstinence had less [11C]DAA1106 binding than 
nonsmokers throughout the brain, indicating less TSPO availability (and less neuroinflammatory 
function). Furthermore, menthol-cigarette smokers had lower levels of [11C]DAA1106 binding 
than nonmenthol-cigarette smokers. These findings are remarkably similar to those of our 
previous study of smokers in the satiated state, and indicate that chronic cigarette smoking 
leads to reduced TSPO availability found in satiety and persisting into early (overnight) 
abstinence. In addition, the global (rather than localized) effect found here is consistent with 
prior research demonstrating global effects of smoking on other molecules (such as nAChRs) 
that are located throughout the brain.28, 163, 165-167, 189, 190 
 
Figure 3-3. Scatterplot showing inverse correlation (− 0.74, P = 0.02) between whole brain 
standardized uptake values and smokers’ ratings of depth of inhalation (for study smokers 
who filled out this questionnaire). The correlation value controlled for translocator protein 
genotype (high vs. medium affinity). 
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A straightforward explanation for the central study finding is that chronic cigarette smoking leads 
to global impairment of microglial activation in early abstinence. This explanation is consistent 
with much prior research demonstrating that smokers have impaired inflammatory functioning in 
other parts of the body, an effect that leads to compromised wound healing and lasts for 
weeks.126, 156-158 It is also consistent with basic science research demonstrating that microglial 
cells express nAChRs225  and that pre-treatment with nicotine (or acetylcholine) inhibits 
microglial activation. 225, 234, 235 Similarly, in an animal study of autoimmune encephalomyelitis, 
nicotine administration was found to decrease microglial activation,198 although other 
condensate of cigarette smoke was found to increase it. In addition, the inverse correlation in 
this study between [11C]DAA1106 binding and participant self-reports of depth of inhalation 
indicates that severity of impaired microglial activation may be related to the amount of 
exposure to cigarette smoke (since depth of inhalation is known to affect absorbed constituents 
of tobacco smoke).124 
 
Other explanations for study findings are possible. For example, cigarette smoking has been 
shown to reduce numbers of resident microglial cells,236 which would presumably lead to less 
radiotracer binding. Cigarette smokers are also known to have higher metabolism of some 
medications than nonsmokers,223 which (if applicable to [11C]DAA1106) would be expected to 
lessen radiotracer uptake and binding. In addition, cigarette smoking may result in inflammation 
in parts of the body other than brain,237 which could lead to sequestration of the radiotracer and 
less binding in brain. 
 
In addition to the overall difference between smokers and nonsmokers, the menthol cigarette 
smoker subgroup had less [11C]DAA1106 binding than the nonmenthol-cigarette smoker 
subgroup. This finding is consistent with prior research by our group showing greater up-
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regulation of nicotinic acetylcholine receptors throughout almost all brain regions in menthol- 
than nonmenthol-cigarette smokers, along with a similar finding for TSPO availability in our prior 
study with [11C]DAA1106 PET and smokers in satiety. Also, research by others demonstrates 
that menthol-cigarette smoking is associated with more severe biological abnormalities in 
some,171 but not all,172, 173 studies that have examined this issue. Therefore, as in prior research, 
the present finding may be due to greater brain exposure to cigarette smoke (leading to greater 
impairment of microglial activation) in menthol-cigarette smokers, a direct effect of menthol 
flavoring or some other mechanism. 
 
The primary limitation of this study is the absence of arterial blood sampling, precluding the 
determination of total distribution volume (Vt), which is the gold standard outcome measure for 
this type of research. Vt may control for the potential confounds of between-subject differences 
in radiotracer metabolism and binding to vascular endothelium and plasma protein149, 203, 204. 
While Vt is a common outcome measure in PET studies examining TSPO in conditions other 
than tobacco dependence,205-207 the SUV measure was used because it is less invasive than 
methods that include arterial blood sampling and arterial sampling was not feasible. Other 
similar studies have used pseudo-reference regions for PET data analysis146, 205, 210-213 to 
minimize potential confounds, but this method would not have been appropriate here due to the 
hypothesized and confirmed effect of smoking throughout the brain. Additional limitations 
included scanning at two sites with different model scanners (though results were similar at the 
two sites), a modest sample size, the absence of measurement of brain nAChR levels, and the 
fact that smokers were scanned in early abstinence, such that we did not determine whether 
TSPO availability normalizes with prolonged abstinence. Associations between TSPO 
availability and brain nAChR availability as determined with PET or single photon emission 
computed tomography imaging (as we and others have done in prior research) or evaluation of 
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normalization of TSPO availability with prolonged abstinence could be addressed in future 
research. 
 
In summary, cigarette smokers in the overnight abstinent state have lower TSPO availability 
than nonsmoking controls, similar to our recent finding in satiated smokers. The effect was 
global and greater for menthol- than nonmenthol-cigarette smokers. Future research could build 
upon this and our previous125 initial studies and directly compare TSPO availability in smokers in 
satiety with those undergoing short-term and prolonged abstinence. This approach could 
provide direct information about the time course of normalization of available TSPO levels in 
smokers who maintain abstinence. Additional future studies could focus on the interplay 
between smoking, neuroinflammation, and the progression of diseases thought to be mediated 
by neuroinflammation. 
 
 
Chapter 3 Wrap-Up 
 
The ability to identify clinically relevant biomarkers and quantify them in a meaningful manner is 
one of the most critical skills I have learned as a scientist in the last six years. The application 
for this field of pharmacodynamic research is endless, and can easily be combined with 
thorough pharmacokinetics, detailed pharmacogenetics, and eventually host and environmental 
interactions in order to paint an entire picture for a specific pharmaceutical candidate or 
treatment. When I had the chance to design my own research study later in my career, I 
proposed a biomarker forward hypothesis in hopes of solving an enigmatic drug side effect 
problem, which will be discussed in depth in chapter 6. Being exposed to neurobiology, 
genetics, imaging, and drugs of abuse over the course of the two salient case studies above 
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pushed me to learn more about fields that I was uncomfortable in calling my own, and I began to 
be able to implement a truly multidisciplinary approach to my own research.  
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Chapter 4  
Genomic Technology 
 
General Introduction to Genomic Technology in Precision Medicine 
 
Finally, there is the third piece of the pharmacology triforce: genetics. Because of the heavy 
presence of genomic technology (GT) in precision medicine, this branch of research is one of 
the most critical to understanding how we can impact clinical care for unique individuals as 
opposed to perpetuating a “one-size-fits-all” model. And while chapter 1 scratched the surface 
on a variety of these genetic or pharmacogenetic concepts, there are complex inner workings 
worth discussing and applying. 
 
By now, we understand the word pharmacogenetics has Greek roots, stemming from 
pharmakon (drug) and genesis, regarding origin, which was first adapted to the biological word 
for genetics in 1860. There are an estimated 30,000-40,000 genes in the human genome, both 
protein-coding and non-coding, representing a huge untapped market for medical and disease 
innovation.238 This is why a core component of personalized medicine is based on utilizing an 
individual’s genetic profile to curate the best therapeutic choices by facilitating predictions about 
whether that person will experience benefits or suffer serious side effects. There has been a 
distinct shift away from empirical and average-based medicine since the mid 2000’s as the 
technology and processing of genetic data continues to improve exponentially. In 
pharmacogenetics, human genomic information is used to study individual responses to 
pharmaceutical treatments, and connections are made between specific drugs, gene variants, 
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and physical response. When fabricating these ties, researchers utilize two main areas of 
genetic profiling: SNP genotyping for candidate genes or genome-wide association studies. 
 
SNP Genotyping Methods 
Single nucleotide polymorphisms, or SNPs for short, represent the bulk of our knowledge in 
common genetic variation among people. Each SNP is a difference in a single DNA building 
block, the nucleotide, for example, replacing cytosine (C) with a thymine (T) in a certain stretch 
of DNA sequence.239 These changes occur normally throughout a person’s DNA, and there are 
roughly 4-5 million SNPs in an individual’s genome. While the majority of SNPs tend to exist in 
non-coding regions, when they manifest within a gene or in a regulatory region, they may play a 
more direct role in disease by affecting the gene’s function. As just one SNP can have a direct 
biological effect, the process of selecting a “candidate” gene to study direct disease hierarchy is 
a popular method in pharmacogenetics.  Candidate gene studies rely on a set of determinates 
based on a priori hypothesis about the role of a selected gene, a group of pathway related 
genes, or a phenotype.240 However, overall the scientific community’s experience with these 
types of studies has been disappointing due to the large variance contribution to disease and 
genetic heterogeneity seen within and between populations. This is not to say this method of 
genotyping does not have merit; there are many functionally defined genetic loci that are used 
as biomarkers for direct pharmacokinetic and pharmacodynamic parameters as well as known 
genes encoding receptors and transcription factors directly involved in disease etiology. 
 
GWAS Technology 
The boom of genetic technology is allowing researchers to branch off from candidate gene 
studies. Rapid, affordable, and accurate genomic analyses such as next-generation sequencing 
and whole genome/exome sequencing harbor the potential to provide profound amounts of data 
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for millions of variants at a time. Stemming from these are genome-wide association studies 
(GWAS), which are a relatively new way for scientists to identify genes involved in human 
disease. Instead of only examining one or two SNPs in a candidate gene, this technique 
leverage millions of SNPs at a time. As most cate241gorical diseases are complex in nature, 
biostatistical methods can be employed to parse the significant associations and help pinpoint 
variations that occur more frequently in people with these ailments, indicating potential 
knowledge about genes that may contribute to a person’s risk of developing a certain disease. 
GWAS allows us to capture the cumulative effects of many variants with small penetrance, but 
that still change the manifestation of a disease.242 Multifactorial and grievous illnesses, such as 
Parkinson’s Disease,243 Type 2 Diabetes244 and Schizophrenia245 have all benefited in the last 
year from in-depth GWAS research. And while we still have much to uncover about how human 
disease works on the level of our macromolecules such as DNA and RNA, there has been 
incredibly progress that has allowed for new pharmacogenetic diagnostic tests to be 
implemented in clinical care and directly impact treatment outcomes. 
 
I was extremely lucky to be able to partake in pharmacogenetic and genomic pathway analysis 
research that leveraged both SNP genotyping as well as GWAS techniques. They were focused 
in an area of growing concern for psychiatry: addiction. Substance Use Disorder (SUD) is a 
highly prevalent and debilitating public health issue, both nationally and worldwide, affecting 
more than 600 million people.246 This can include alcohol, nicotine, cannabis, opioids, 
stimulants, and various recreational drugs. As the disorder persists, physical and mental 
sequelae are common and often result in profound functional impairment. Despite the clear 
importance to public and individual health, therapies are few and only partially effective, in part 
due to the rudimentary current understanding of the underlying genetic and biological 
underpinnings of addiction. The significant heritability of SUD suggests a moderate to strong 
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genetic basis, but the failure to identify specific risk alleles indicates that the underlying 
mechanisms are multifactorial and heterogeneous.247 The limited utility of traditional therapy has 
led the field of complex genetics to explore dimensional measures of functional neurocognitive 
phenotypes as more proximal to brain biology. Below, GT case study #1 is a candidate gene 
study of the influence of genetic variation in cholinergic receptors, nicotine’s direct target in the 
brain, on striatal dopamine release after smoking a nicotine containing cigarette and 
subsequently confer addiction risk. GT case study #2 applied advanced genetic techniques 
such as GWAS and polygenic risk scores to better understand the stark difference in the 
impulsivity trait as seen in addicts versus the general population and how it might be related to 
their susceptibility to developing a substance related disorder. Both are excellent examples of 
how pharmacogenetics can be an invaluable tool moving forward in psychiatric diagnoses and 
individualized treatments. 
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GT Case Study #1 : Cholinergic Genetic Variation Moderates Smoking-Induced Striatal 
Dopamine Release* 
*This work is currently unpublished. 
 
L.C. Seaman, K.S. Mallya, K. Ta, J.L. Chartie, J.T. McCracken, A.L. Brody, E.L. Nurmi 
 
Introduction 
 
Smoking is the leading preventable cause of mortality in the United States, formally established 
as the cause of 21 diseases encompassing cancer, cardiovascular diseases, and respiratory 
diseases.248 These smoking-related diseases account for an excess of 480,000 deaths each 
year in the United States alone. While there are currently several FDA-approved 
pharmacological treatments for smoking cessation, these approaches have limited efficacy, and 
even with the best treatments, nicotine abstinence rates at 1 year are only 23%.249 Given the 
high heritability (0.75)250 of nicotine dependence, genetic variability of nicotine receptors may 
explain the significant interindividual variability in clinically relevant smoking-related phenotypes 
including differences in the rewarding properties of smoking and response to smoking cessation 
treatments. 
 
The rewarding effects of nicotine, the addictive compound in tobacco smoke251, 252, are due to 
activation of the mesolimbic dopamine tract in the brain.253 Dopaminergic neurons within this 
tract project their axons from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) 
and release dopamine in response to nicotine binding to nicotinic acetylcholine receptors 
(nAChRs).254, 255 This well-known reward pathway has been implicated in nicotine dependence 
and many other drugs of abuse.256 Variations in smoking-induced dopamine release within this 
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pathway may underlie differences in individual sensitivity to the reinforcing properties of 
smoking257 and other clinically important smoking-related phenotypes.  
 
 
 
nAChRs are transmembrane homopentameric or heteropentameric non-selective cation 
channels composed of subunits encoded by nine α-subunits and three β-subunit genes.258 The 
various nAChR combinations differ in localization as well as their pharmacologic and kinetic 
properties.258 Within the brain, the two main types or nAChRs are the α7 homo-oligomer and the 
α4β2 hetero-oligomer.258 To date, the majority of research investigating the link between 
nicotine dependence and specific nAChR subunits has focused primarily on the α4β2 subunit 
based on its high affinity for nicotine, widespread distribution in the brain, and the success of 
varenicline, a partial α4β2 agonist, as a smoking cessation therapy.249 Another well-studied 
genetic risk region for heaviness of smoking, defined by cigarettes smoked per day (CPD), is 
the chromosome 15 cluster of CHRNA3, CHRNA5, and CHRNA4 which showed significant 
association with CPD in 3 genome-wide association studies.259 While these regions have 
yielded promising effects, recent research has shown the importance of other nACHR genes in 
nicotine-dependence phenotypes including CHRNB4, CHRNA7, CHRNA6, and CHRNB3 loci.260 
Of specific interest is CHRNA7, which has been implicated by a strong body of work to be 
Figure 4-1. The chemical 
structure of the neurotransmitter 
acetylcholine and the exogenous 
stimulant nicotine. Both activate 
the nicotinic acetylcholine 
receptors in the human brain. 
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involved in nicotine reward, dependence, and withdrawal phenotypes in both animals and 
humans.261-263 
 
 
α7 subunits may also play a role in short-term nicotine reward through a modulatory effect on β2 
activation.264 Within the VTA, single recordings of dopaminergic neurons demonstrate two types 
of neuronal firing rhythms in vivo which occur spontaneously and in response to nicotine: a 
slow, regular single-spike firing and bursting mode.265, 266 When α7 -/- mice were injected with IV 
nicotine there was a large and rapid increase in the firing rate of DA neurons that was short-
lasting and followed by a plateau at a slightly lower firing rate.264 These findings suggest that α7 
normally masks an inhibitory effect of GABAergic neurons in wild-type mice, and taken together, 
this data also suggests that β2 nAChRs may be responsible for switching neurons from a 
resting to excited state, with α7 nAChRs finely tuning this state after β2 nAChR activation. In 
this way, both α7 and β2 may be involved in the neurobiochemical events underlying nicotine 
reinforcement 
 
To briefly highlight the importance of human studies on CHRNA7, several groups have shown 
an association between CHRNA7 in nicotine dependence, smoking risk, and smoking cessation. 
In a sample of 710 African Americans, CHRNA7 and CHRNA10 both showed a modest 
Figure 4-2.  Structure of the most 
common nAChRs, (α7)5 and 
(α4)2(β2)3. nAChRs are 
homomeric or heteromeric 
pentamers of α and β subunits 
including α2-α10 and β2-β4. 
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association with nicotine dependence risk.267 Similarly, in a study of 501 female Israeli students 
(ages 20-30) a nominally significant (p<0.05) genotypic association was shown in SNPs in 
CHRNA7 (rs1909884), CHRNA9 (rs4861065), and CHRNB3 (rs9298629) with nicotine 
dependence.267 In yet another sample of 177 patients with schizophrenia an association was 
shown between the homozygous 113 bp allele in CHRNA7 and smoking risk (p=0.015).268 
CHRNA7 also appears to play a role in smoking cessation. In a randomized, double-blind, 
placebo-controlled study comparing the efficacy of varenicline and buproprion (n=1175), 
rs6494212 in CHRNA7 was associated with continuous abstinence from nicotine (p=0.0038) 
(weeks 9-12).269 
 
In our previous work we demonstrated a relationship between smoking-induced dopamine 
release in the VTA/NAc pathway and functional genetic variants within the dopamine system. In 
a study of 45 tobacco-dependent smokers, smoking-induced dopamine release was measured 
using positron emission tomography (PET) screening in patients who either smoked a cigarette 
or did not smoke a cigarette while screening. Smoking-induced dopamine release in the 
VTA/NAc was measured using the radiotracer raclopride, a competitive D2 dopamine receptor 
antagonist, labeled with radioactive carbon (11C), which revealed an association between gene 
variants in the dopamine transporter variable number tandem repeat (VNTR), D2 receptor Taq 
A1/A2, D4 receptor VNTR, and catechol-O-methyltransferase Val158Met polymorphisms and 
smoking-induced dopamine release.269 While these findings suggest that genetic variation in the 
DA system plays a salient role in smoking related behaviors, variation in DA dynamics in 
cigarette smokers remains only partially explained. 
 
Given recent evidence for the possible role of other nAChR genes in nicotine dependence, we 
tested common genetic variation in 6 nAChR genes (CHRNA3, CHRNA4, CHRNA5, CHRNA7, 
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CHRNB2, CHRNB4) as additional potential moderators of smoking-induced DA release. We 
hypothesized that more direct moderators of DA signaling in the striatum would include genetic 
polymorphisms in the nAChRs, as they are both the downstream targets of synaptic DA as well 
as the proximal site of nicotine action in the brain. Utilizing PET imaging with the same 11C 
raclopride radiotracer as described above, we were able to visualize in humans how smoking a 
tobacco cigarette directly impacts dopamine release in our pathways of interest and how this 
subsequently is related to, or affected by functional genetic variations in the corresponding 
nAChRs. Our research and findings are described here within.  
 
METHODS  
 
One hundred and two otherwise healthy adult smokers who met DSM-IV criteria for nicotine 
dependence completed the study. Subjects were adults (age 21-65 years) initially screened 
during a telephone interview in which medical, psychiatric, and substance abuse histories were 
obtained. Subjects who passed this screening were then assessed in person using screening 
questions from the Structured Clinical Interview for DSM IV. [First MB, JBW: Structured Clinical 
Interview for DSM-IV Axis I Disorders…] Subjects with a history of any axis I disorder other than 
nicotine dependence were excluded. Subjects were also excluded if they had a history of 
medications that might affect the central nervous system (e.g. current treatment with a beta-
blocker or analgesic medication, history of head trauma with loss of consciousness, history of 
epilepsy). Subjects who did not meet the criteria for abuse or dependence but were occasional 
users of alcohol, caffeine or other drugs were allowed to participate but were instructed to 
abstain from these substances for 24 hours before scanning. Subjects who experienced 
caffeine withdrawal symptoms or consumed more than two cups of coffee per day (200 to 300 
mg/day caffeine) were also excluded. Pregnant women were excluded due to potential risk to 
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the fetus of radiation exposure. After a complete description of the study, written informed 
consent was obtained.  
 
During the initial visit, additional screening data were obtained including smoking history data, 
current smoking   level, years smoked, brand of cigarette smoked, and quit periods. Fagerstrom 
Test for Nicotine Dependence (FTND)175, the Beck Depression Inventory176, the Spielberger 
State-Trait Anxiety Inventory270, and the Shiffman-Jarvik Withdrawal Scale were included in the 
psychological assessment battery. An exhaled carbon monoxide (CO) level was obtained using 
the MicroSmokerlyzer (Bedfont Scientific Ltd, Kent, England) at the initial visit to verify smoking 
status (subjects were considered to be active smokers if a CO level of >8 ppm was obtained). 
 
Study Overview 
On a single afternoon visit participants were interviewed with standardized questions; completed 
rating scales related to cigarette usage, mood, and personality; had blood drawn for genetic 
testing; and underwent [11C]raclopride PET scanning and either smoked a cigarette or did not 
smoke during the scan. On a separate morning, patients underwent structural MRI within 1 
week of PET scanning.  
 
PET Scanning 
Subjects underwent a pre- and post-cigarette smoking single [11C]raclopride bolus-plus-
continuous-infusion PET session190 and structural magnetic resonance imaging (MRI) to aid in 
interpretation of the PET scans. Subjects abstained from smoking for 3 hours prior to scanning 
and scanned <1 minute after smoking a cigarette. 
 
Genetic Testing 
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Whole blood samples were collected and genomic DNA was extracted using the Gentra 
Puregene Blood Kit according to the manufacturer’s protocol (Qiagen, Valencia, Calif.).  
 
Genotyping was performed using the Thermo Fisher TaqMan genotyping platform (Thermo 
Fisher Scientific, Waltham, MA, USA) with Qiagen Type-it Fast SNP Probe PCR Kit (Qiagen, 
USA) according to manufacturer’s protocols. Tag SNPs (tSNPs) were selected using Broad 
Tagger software, capturing all common variability >5% in most and >10% in all cases at an 
r2>0.8 in most and 0.6 in all cases. For quality control purposes, a subset of data was run in 
duplicate, demonstrating perfect concordance. All markers were in Hardy-Weinberg Equilibrium 
and minor allele frequencies (MAF) were similar to those previously published by the HapMap 
Consortium. 
 
Statistical Analysis 
 
Univariate analysis of variance (ANOVA) was performed with the percentage change in ventral 
caudate/nucleus accumbens binding potential as the dependent variable and the marker 
genotype as a between-subject factor with ethnicity and age as covariates. Because sex was 
not a significant predictor of binding potential, it was removed from the model. 
 
In post-hoc analysis, a combined risk measure of two significant variants (CHRNA7 rs12915695 
and CHRNA4 rs2236196) was constructed to determine whether each conferred independent, 
additive effects. Genotype at each locus was given a score of 0 or 1, with 1 denoting the 
presence of at least one allele associated with enhanced binding potential. Scores were 
summed across the two loci and each subject received an overall risk score from 0 to 2. A one-
way ANOVA was applied as above.  
102 
 
 
Genetic variants and imaging data were also tested for correlation with behavioral measures of 
craving, dependence (FTND), number of cigarettes per day, number of years smoking, and 
exhaled CO levels. 
 
RESULTS  
 
Table one displays the results that map the various nAChR subunit genetic variants and their 
role in nicotine-induced dopamine release. Two independent gene variants were associated 
with percentage change in VTA/NAc binding potential (Figure 18). Prominently, homozygotes 
for the common allele (GG) at an intro 2 polymorphism in CHRNA7 (rs12915695) demonstrated 
a greater than three times reduction in radiotracer binding potential (BP), corresponding to a 
significant increase in smoking-induced dopamine release, compared to minor A-allele carriers 
Table 4-1. Results mapping nAChR subunit polymorphisms and their published role in 
nicotine-induced dopamine release. 
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(-10.8% vs. -3.0% respectively, p=0.001, d=0.97). This finding survived multiple comparison 
corrections (p=0.009, Caucasian). PET brain images from this set of subjects confirm a larger 
reduction in raclopride binding in the striatum (resulting from greater dopamine release) after 
smoking a cigarette. (Figure 18) It is 
important to note that  
 
raclopride BP in both genotype 
groups was even at baseline. 
Additionally, a variant in the 3’ UTR 
Figure 4-3. NAChRs are Associated with Smoking-
Induced DA Release 
A. CHRNA7 Genotype Predicts Smoking-Induced 
Striatal DA Release. Homozygotes for the common 
allele (GG) at an intron 2 polymorphism (rs12915695) 
showed greater than 3X reduction in radiotracer 
binding potential after smoking a cigarette, indicating 
significantly greater DA release, compared to minor A-
allele carriers (-10.8% vs. -3.0% respectively, 
p=0.001, d=0.97), surviving multiple comparison 
correction (p=0.009 in caucasians). 
B. CHRNA7 Genotype Differences in Striatal 
Dopamine Release after Smoking.  PET brain images 
are shown with highest levels of raclopride binding in 
red and lowest in blue. A larger reduction in raclopride 
binding (resulting from greater dopamine release) 
after smoking a cigarette is evident in the striatum 
(red) of GG homozygotes (top) vs. A-allele carriers 
(bottom). 
C. CHRNA4 Genotype Predicts Smoking-Induced 
Striatal DA Release. A complex race by genotype 
interaction was observed at a variant in the 3’ UTR of 
the alpha 4 subunit (CHRNA4, rs2236196) where 
significant reduction in radiotracer binding was shown 
for Caucasian GG homozygotes, but African American 
carriers of the A-allele (interaction p=0.001, d=2.17). 
CHRNA7 rs12915695 
A. 
C. 
B. 
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of the CHRNA4 subunit (rs2236196) showed a complex race by genotype interaction. In 
Caucasians, a significant reduction in radiotracer binding was shown for common allele GG 
homozygotes whereas African American carriers of the minor A-allele showed a greater 
reduction in radiotracer binding (p=0.001, d=2.17).  
 
In order to test for independent or additive effects between these two variants we calculated a 
composite score for each subject by assigning one point for the presence of each allele 
associated with reduced BP. This  model and concurrent analysis demonstrated that each “risk” 
allele additively contributes to greater dopamine release in a dose-dependent manner; subjects 
with 0 alleles displayed little to no change in BP, subjects with one allele showed an 
intermediate reduction in BP, and subjects with two alleles showed close to double the reduction 
in BP as individuals with just one contributing allele, and therefore the greatest nicotine-induced 
dopamine release (p=0.007 ). (Figure 4-4) 
 
Auxillary cholinergic receptor variants 
were discovered to have significant 
effects in other smoking related endophenotypes. An individual’s genotype at a polymorphism 
just distal (3’) to the CHRNB2 gene (rs4845652) was able to predict a change in urge to smoke 
Figure 4-4. CHRNA7 and CHRNA4 Composite 
Score Predicts Dopamine Release in 
Caucasians. 
As shown previously in the Caucasian subset, 
homozygotes for the common allele (GG) at an 
CHRNA7 polymorphism (rs12915695) and carriers 
of the minor allele (G) at a CHRNA4 polymorphism 
(rs2236196) show significant reduction in 
radiotracer binding potential, corresponding to a 
much greater dopamine release than their 
counterparts. Composite analysis demonstrates 
that each risk allele additively contributes to 
greater dopamine release (p=0.007). Individuals 
with both variants display the greatest release, 
those with neither have almost no release, and 
those with only one are intermediate. 
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(UTS). Minor T-allele carriers of this polymorphism displayed close to twice a greater reduction 
in nicotine craving after smoking a tobacco cigarette than homozygotes for the common allele 
(CC) as measured by the change in UTS (p=0.003). (Figure 4-5) 
 
Craving, as measured by self-report, was found to be affected by two nAChR variants, one at 
the CHRNA7 gene locus as well as the same variant as above, located on CHRNB2 (rs8834373 
and rs4845652 respectively.) GG homozygotes at CHRNA7 rs8834373 and T-allele carriers at 
CHRNB2 rs4845652 have greater baseline nicotine craving before (p<0.01 & p<0.001) and 
greater reduction of craving after (p<0.05 & p<0.001) smoking a cigarette as compared to A-
allele carriers and CC homozygotes, respectively. (Figure 4-5) 
 
Finally, an individual’s genotype from a single variant located in the promoter region of the 
CHRNA4 gene (rs755203) showed correlations with both the number of years said individual 
had smoked cigarettes as well as their score on the Fagerstrom Test for Nicotine Dependence 
(FTND). Homozygotes for the common allele (CC) at this SNP has a significantly longer 
smoking history in years (22.3 ±1.6 vs. 17.6±1.69, p<0.05) and greater FTND scores, indicating 
a greater dependence for nicotine from cigarettes, (6.5 ±0.3 vs. 5.5 ±0.3) than T-carriers 
(p<0.01). (Figure 4-5) 
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Figure 4-5. NAChRs are 
Associated with Smoking 
Endophenotypes and Measures of 
Nicotine Dependence. 
A. CHRNB2 Genotype Predicts 
Change in Urge to Smoke 
(UTS). Minor T-allele carriers at a 
polymorphism (rs4845652) just 
distal (3’) to the CHRNB2 gene 
displayed close to 2X greater 
reduction in nicotine craving after 
smoking a cigarette than 
homozygotes for the common 
allele (CC), as measured by the 
change in urge to smoke, 
(p=0.003). Both Caucasians and 
African Americans show the 
same direction of effects. 
B. Variation in Subunits CHRNA7 
and CHRNA4 is Associated 
with Craving. GG homozygotes 
at CHRNA7 rs8834373 and T-
carriers at CHRNB2 rs4845652 
have greater baseline craving 
before (p<0.01 & p<0.001) and 
greater reduction after (p<0.05 & 
p<0.001) smoking a cigarette as 
compared to A-carriers and CC 
homozygotes, respectively.  
C. CHRNA4 Genotypes that 
Predict DA-Release are 
Associated with Measures of 
Nicotine Dependence. CC 
homozygotes at rs755203 show 
greater DA release and had a 
longer smoking history (22.3 ±1.6 
vs. 17.6±1.69, p<0.05) and 
greater Fagerstrom Test for 
Nicotine Dependence (FTND) 
scores, indicating a greater 
dependence for nicotine from 
ciagrettes, (6.5 ±0.3 vs. 5.5 ±0.3) 
than T-carriers (p<0.01). 
 
 
C. 
B. 
A. 
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DISCUSSION 
 
Overall, in a broad picture, these data suggest that structural and/or functional variation in 
midbrain nAChRs contributes to differential smoking-induced striatal dopamine release. Most 
notably, smokers with a homozygous common allele genotype (GG) at CHRNA7 locus 
rs12915695) consistently and significantly demonstrated close to triple the reduction in BP for 
11C raclopride, when measured with PET, than their A-allele carrying counterparts. As the 
radiotracer raclopride is a selective antagonist for dopaminergic D2 receptors in the striatum, 
DA will competitively bind in the same locations. When the brain is flooded with nicotine from 
cigarette smoke, and subsequent high dopamine release for GG individuals, the radiotracer will 
essentially be forced out of these receptor spots, causing large decreases in binding potential. 
On the other hand, it appears that individuals carrying an A allele (either homozygous AA or 
heterozygous AG) have a stunted reaction to nicotine in the same neurological regions, and less 
dopamine is released into the VTA/NAc. One can speculate, based on the salient role of 
dopamine in reward271, 272, that the majority of the population might be at risk for positive 
biological feedback from cigarette smoking. 
 
Interestingly, we observed a complex race by genotype interaction at CHRNA4 rs2236196 in 
regards to smoking-induced dopamine release. Caucasian smokers with a GG genotype and 
African Americans with either an AA or AG genotype experienced much greater striatal 
dopamine release after smoking a cigarette. While a finding such as this may be difficult to 
interpret accurately, it is critical to take note of. Pharmacotherapies for smoking cessation are 
commonly a “one size fits all” category of treatment. Interventions such as nicotine gum, the 
nicotine patch, bupropion, and more recently varenicline have wildly varying degrees of 
success, and perhaps this CHRNA4 finding can begin to help explain why this might occur. 
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Factors such as age, sex, race, and ethnicity may significantly alter the efficacy of treatment for 
an individual attempting to quit smoking in part because of their level of nicotine-induced 
dopamine release. Future work needs to be done to attempt to disentangle the many diversities 
of an individual, their genetic makeup, and their pharmacological responses to classic smoking 
cessation treatments. Additionally, it is our hope that findings such as this will engender the 
movement to more individualized treatments for nicotine dependence and perhaps inform small 
molecule drug targets in the specific nicotinic receptor subtypes. 
 
Our genetic findings at both nicotinic α4 and α7 cholinergic receptor subunits are consistent with 
animal and in vitro studies that have previously implicated these subunit types in DA-mediated 
reinforcement associated with cigarette smoking. However, it is worth discussing that past 
animal studies have revealed conflicting evidence for the role of CHRNA7 in nicotine 
dependence and withdrawal. A study by Laviolette and van der Kooy (2003) showed that 
following direct intra-VTA administration of methyllycaconitine (MLA), a nAChR antagonist 
considered to be relatively selective for α 7 pentameric nAChRs, a decrease was seen in the 
conditioned rewarding effects of nicotine in rats.263 In a similar investigation, Markou and 
Paterson (2001)273 demonstrated that MLA reduced intravenous nicotine self-administration, 
also in rats, suggesting that α7 nAChRs do in fact play a role in nicotine reinforcement. In 
contrast, a study by Walters, et. al274 found that treatment with the α4 α2 antagonist dihydro-
beta-erythroidine (DH, E) blocked nicotine conditioned place preference while the α7 antagonist 
MLA had no effect on this behavior, insinuating that the α2 subunit, but not the α7 subunit, is a 
critical component in nicotine reward systems. It will be vital to clearly define accepted nAChR 
subunit effects in smoking for future research before beginning to move studies of selective 
agonists and antagonists to a human population. 
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Putative effects on nicotine dependence and nicotine craving were observed in nAChR variants 
that did not correlate with smoking-induced striatal dopamine release, but were nonetheless 
consistent with previous research findings, indicating their relevance in future smoking-related 
investigations. Our data at CHRNA7 rs883473 implicating GG homozygotes as experiencing 
higher baseline cigarette craving and more robust satisfaction from consequently smoking a 
cigarette than A-allele carrying individuals are supported by minimal, but strong findings at this 
same locus related to smoking cessation275 as well as severity of nicotine dependence.276 
 
Of additional interest is the SNP located on the promoter region of CHRNA4 (rs755203) where 
we observed that smokers with a CC common allele genotype had spent significantly more 
years smoking as well as had displayed greater FTND test scores, indicating elevated nicotine 
dependence. A study in 2013 communicated that this SNP has a significant connection to the 
pathophysiology of nicotine dependence as well as the related phenotype being a critical 
component in the level of verbal memory and executive functioning in schizophrenia patients.277 
Taken together, we can surmise that this variant is not only consequential in identifying and 
addressing nicotine dependence, but also an important factor to examine in other psychiatric 
ailments, as many mood disorders include very high co-morbidities of smoking.  
 
As CHRNB2 is one of the most studied nicotinic receptor genes, it is reassuring that we also 
found significant results at a specific locus in this region (rs4845652). Individuals carrying the 
minor T-allele reported significantly elevated baseline nicotine craving and then subsequently 
less craving after smoking one cigarette of their choice. While this finding can be interpreted in a 
few different ways, a unique perspective is to consider the implications for the bulk of the 
smoker population – or the individuals with a common CC genotype. These people are still 
reporting high craving, but are in turn experiencing much less satisfaction from smoking their 
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cigarette than carriers of the T variation. We can look at this in two differing ways; one is that 
these individuals might be less at risk for developing nicotine dependence, as cigarettes are not 
as rewarding to them. However, it could manifest itself as these smokers engage in smoking 
even more tobacco cigarettes than their counterparts to achieve the same level of relief from 
craving. The latter, and more concerning view point, is supported by recent findings that 
CHRNB2 rs4845652 T-allele carriers may be associated with lower levels of nicotine 
dependence.278 We believe further examination of this locus is necessary to expand upon how 
this finding can be utilized for components such as early intervention and treating planning. 
 
An important limitation of the current study is the small sample size. We were only able to 
successfully image and genetically test 102 individual smokers for this work. Promisingly, 
Cohen’s D effect sizes at both variants are significant and large, and each variant confers 
unique, additive effects. We believe this warrants larger exploration in upcoming research 
studies of smoking populations that may include neuroimaging. 
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GT Case Study #2:  Polygenic Contributions to Decision-Making on a Laboratory Test of 
Reward-Based Risk-Taking* 
Nurmi EL, Laughlin CP, Seaman LC, Kohno M, Hellemann GS, Palmer A, DeWit H, London ED 
*This work is currently unpublished. 
 
INTRODUCTION 
 
The ability to make decisions in uncertain conditions that involve the balance between risk and 
reward is fundamental to personal development as well as survival. Heightened risk-taking 
behavior, however, has been linked to neuropsychiatric disorders, such as Attention Deficit-
Hyperactive Disorder (ADHD), addictions, and mood disorders279-284. For these reasons, the 
biological bases of risk-taking behavior, including their neural underpinnings285, 286 and genetic 
architecture287, 288 have been a subject of recent interest. A twin study that estimated the 
contributions of genes and environment across seven risk taking domains revealed additive 
genetic but individually unique environmental influences; heritability estimates from a meta-
analyses of twin studies ranged from 29% in financial risk taking to 55% in safety288. In a twin 
study using the Iowa Gambling Task, which evaluates reward-based decision-making in the 
presence of risk, a latent "decision-making'' factor was identified, explaining between 20%-46% 
of the variance across task administration timepoints289. A genome-wide association study 
(GWAS) on risk preferences, focusing on risk aversion, used a sample of 10,455 adults, and failed 
to identify single-nucleotide polymorphisms (SNPs) reaching genomewide significance290. The 
results suggested that risk aversion is a complex trait that is highly polygenic, likely to be driven 
by many genetic variants, each with a small effect size. 
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In this study, we evaluated the propensity for risk-taking, using the Balloon Analog Risk Task 
(BART), 284 a laboratory test of reward-based, risky decision-making, in two relatively large, 
independent samples. Using a youth-adapted variant of the BART, a candidate gene study of 223 
youths (average age 11.3 years) indicated that females, but not males, who are carriers of 
the COMT 158Met allele had higher risk-taking propensity compared to Val homozygotes. 287 A 
version of the BART adapted for administration to rats was used in a study of inbred strains, 
indicating a moderately heritable pattern of risk-taking behavior in rats, with about 55% of the 
variance in risk-taking behavior attributable to heritable factors, and data consistent with a 
polygenic model.291    
 
In summary, risky decision-making can profoundly influence well-being, and has been associated 
with several psychiatric disorders. Genetic factors appear to contribute to risk taking, but the 
underlying genetic architecture remains unknown. The goals of the present study were to develop 
and test a polygenic model to estimate the variability in risky decision-making that is explained by 
common genetic variation. Furthermore, we sought to apply our polygenic model to ADHD and 
bipolar samples available in the public domain, to estimate shared genetic risk for and risky 
decision making in psychiatric disorders characterized by risk-taking behavior. In our final 
analyses, we will similarly test shared genetic variation between risky decision making and 
substance use disorder and smoking cessation. 
 
METHODS 
Participants: 
Data for this study came from two projects. One was the Consortium for Neuropsychiatric 
Phenomics (the CNP project), a study performed at the Semel Institute of the University of 
California Los Angeles, to examine the underlying genetic and neural factors, such as memory, 
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and their link to three target neuropsychiatric illnesses, schizophrenia, bipolar disorder, and 
attention-deficit hyperactivity disorder. The other project was the Genetics of Impulsivity, 
performed at the University of Georgia and the University of Chicago, in Georgia and Illinois, 
respectively (the GIP project).   
 
CNP Sample292  
Subjects, ages 21-50, were recruited by community advertisements in the Los Angeles area and 
were only included if they identified as either “Caucasian, not of Hispanic or Latino descent,” or 
“Hispanic or Latino, of any race,” as per NIH racial and ethnic minority group guidelines. Exclusion 
criteria included neurological disease, history of head injury with loss of consciousness, use of 
psychoactive medications, substance dependence within the past six months, and a positive drug 
screen on the day of testing. Diagnoses for all individuals were verified using structured clinical 
interviews (SCID-IV;174). Included subjects underwent a neuropsychological battery and 
submitted blood samples for genotyping. All subjects gave written informed consent in line with 
the procedure approved by the Institutional Review Board at UCLA. In total, 1,600 healthy 
individuals, 58 patients with schizophrenia, patients with bipolar disorder, and participant-
hyperactivity disorder were evaluated for this study. However, due to substantial population 
stratification, only Caucasian healthy individuals were included in the polygenic score generation 
(N = 837;).   
 
GIP Sample293, 294  
934 Caucasian ancestry participants 18-30 years of age were recruited from Athens, GA and 
Chicago, IL. Subjects with recent psychiatric treatment for psychiatric illness or substance use 
were excluded. Participants completed assessments individually in a behavioral laboratory. DNA 
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was collected via a saliva sample for DNA collection in an Oragene DNA kit (DNA Genotek Inc., 
Kanata, ON, Canada). 
 
Balloon Analog Risk Task.  The BART is a computerized behavioral measure of risky decision-
making.284 Virtual balloons are presented on a computer screen, one balloon per trial, and the 
participant can “pump” the balloons up by pressing a response key, virtually inflating the balloons.  
Each pump produces a set increase in an amount of money (e.g., 5 cents per pump) or points 
earned on that trial. However, after a certain number of pumps, determined probabilistically, the 
balloon explodes and no money or points are earned on that trial. The participant must decide 
when to “cash out” of a given trial, by pressing a response key, to retain earnings in a cumulative 
bank. The objective is for the participant to earn as much money or points as possible across the 
task. Versions of the BART vary with respect to the number of trials/balloons used, as well as the 
probability of explosions [e.g., some tasks have used balloons with a single probability of 
explosion,282 while others have used different-colored balloons with different probabilities of 
explosion. 284, 295 The primary dependent variable of the task is the mean or total number of pumps 
on trials in which the balloon did not explode; these have been termed '''adjusted pumps'''. 
Adjusted pumps are preferred to absolute pumps because explosions artificially restrict the range 
of pumping behavior for evidence of the bias associated with absolute pumps see 296.  
Genetic Analyses. Genotyping was performed using the Omni Illumina 500,000 SNP chip. For all 
genotype data, markers were excluded for quality control if they had less than a 95% genotyping 
rate, a minor allele frequency less than 1%, deviated significantly from Hardy Weinberg 
equilibrium (p < 10-6), or were identified as having non-random genotyping failure (p < 10-10). 
Individuals were excluded for missing genotypic data (<2% genotypes), missing phenotypic data, 
or deviation from expected autosomal heterozygosity (Fhet < .2). GWAS was performed on each 
of the CNP (OMNI only) and GIP datasets as follows. Principal component analysis (PCA) was 
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performed within study as well as joint with the 1000 Genomes (1KG) ancestry informative 
markers for use in QC and modeling efforts. Partial correlations ere used to control for variability 
in population structure. Plink297 was used to perform two linear regressions with Mean Adjusted 
Pumps as the dependent variable of interest and Total Adjusted Pumps as (expected) negative 
control, supplying sex, age and the first five PCA dimensions as covariates (Mean Adjusted 
Pumps ~ sex + age + D1:5, Total Adjusted Pumps ~ sex + age + D1:5). Each set of summary 
statistics was clumped and, along with the paired genotypes from its complement study, used to 
create polygenic scores for each individual in the target sample.298 These scores were then 
compared using a partial correlation analysis that controlled for the same covariates in the target 
dataset as in the source's GWAS.  Outlier detection and removal was conducted on the polygenic 
scores via Cook’s distance to remove any egregiously anomalous scores. Imputation to 1KG 
Phase 3 was also performed on each dataset and the same methodology was applied. A MEGA 
analysis GWAS was performed on the merged raw genotypes of the CNP and GIP datasets. After 
stand QC measures (see methods above), PLINK, as used to perform a linear regression, was 
run using the following model (Mean Adjusted Pumps ~ gt + sex + age + dataset_code + D1:D5). 
A quantile-quantile (Q-Q) plot of observed vs. expected p-values and Manhattan plot of the linear 
regression results was performed in R. PRS where then derived and the best MEGA PRS was 
then tested against the public ADHD and bipolar disorder datasets using PRS methods above.  
 
RESULTS 
 
When a PRS for risky decision-making is constructed based on BART performance in the CNP 
sample, this PRS predicts BART performance in the GIP sample (r2=0.11, p=0.00094) and 
remains significant when corrected for multiple comparisons made in empirically determining the 
optimal p-value threshold for SNP inclusion in the model (FDRp=0.0057). Likewise, when the 
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PRS is derived from the GIP dataset and applied to the CNP sample, an identical correlation is 
observed at a similar level of significance (CNP   r2=0.11,  p=0.0012,   FDRp=0.011).  
 
When 135 Caucasian individuals with psychiatric disorders impacting risk-taking behavior, bipolar 
disorder, ADHD, and schizophrenia, are added to the CNP sample, significance is improved, 
suggested that risk-taking is a continuous trait across healthy individuals and those diagnosed 
with these disorders. An ANOVA of group membership (healthy, schizophrenia, bipolar, and 
ADHD) was significant (p<0.05) and followed an expected 
pattern where groups 
characterized by prominent impulsivity (ADHD and bipolar disorder) showed an increased mean 
adjusted pumps compared to healthy individuals, whereas mean adjusted pumps in the 
schizophrenia group were decreased (p=0.01).  
 
 
The MEGA analysis linear regression identified two variants rs12023073 and rs6891903 that were 
approaching genome-wide significance. Both SNPs (rs6891903 and rs12023073) are intronic and 
Figure 4-6. Risky 
Decision Making as 
Measured by BART 
Performance is a 
Heritable, Polygenic 
Trait.  
Top Panel: PRS for BART 
performance derived in 
the CNP sample predicts 
BART performance in GIP 
participants. Bottom 
Panel: PRS for BART 
performance derived in 
the GIP sample predicts 
BART performance in the 
CNP sample. 
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map within the catenin delta 2 (CTNND2) and immunoglobulin superfamily member 21 (IGSF21) 
genes. The Q-Q plot demonstrates that the principle components correct for any ancestry effects.  
 
An exploratory analysis applying the PRS derived from the MEGA analysis to large samples from 
the Psychiatric Genomics Consortium public datasets, we observed a significant association with 
the bipolar disorder phenotype (best p=0.00066, pFDR=0.018). but only a marginal association 
with the ADHD phenotype (best p=0.048, pFDR=0.28). 
GWAS Q-Q Plot
IGSF21 CTNND2 
Figure 4-7. Mega-analysis GWAS Results for BART Performance in the Combined 
CNP and GIP sample. Left Panel: Q-Q Plot show excellent correction for population effects 
and two SNPs with lower than expected p-value. Right Panel: Manhattan plot showing the 
location of two SNPs with suggestive lower than expected p-values. Blue line represents 
genome-wide significance. 
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DISCUSSION 
 
In line with the few previous rodent and human studies, our findings confirm a heritable, polygenic 
component to risky decision-making explaining 11% of the variance in BART performance. The 
bidirectionality of similar effect size and significance level is compelling. The PRS model performs 
best when additional individuals with psychiatric diagnoses impacting risk-taking behavior are 
included. These data are in line with prior studies demonstrating that both individuals with ADHD 
and bipolar disorder demonstrate increased impulsivity scores on behavioral tasks and more 
conservative BART performance is seen in individuals with schizophrenia.299 The improvement in 
PRS performance when psychiatric samples are included provides support for the 
conceptualization of a spectrum of risky decision-making throughout the population with more 
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Figure 4-8. An exploratory analysis applying the PRS derived from the MEGA analysis to 
large samples from the Psychiatric Genomics Consortium public datasets, we observed a 
significant association with the bipolar disorder phenotype (top panel) (best p=0.00066, 
pFDR=0.018). but only a marginal association with the ADHD phenotype (bottom panel) (best 
p=0.048, pFDR=0.28). 
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extreme phenotypes in individuals with mental illness.  
 
The MEGA analysis provided additional power and identified two intronic SNPs that approach 
genomewide significance, rs12023073 and rs6891903. The genes containing these SNPs are 
both good biological candidates for risk-taking and relevant phenotypic associations have been 
published. CTNND2 (Catenin delta 2) is known to be involved in neuronal development, 
specifically maintenance of dendritic spines and synapse.300 CTNND2 is among the genes 
affected by CNVs found in ADHD and, along with other cell adhesion genes, GWAS-associated 
SNPs in addiction. An intronic CTNND2 variant (rs11133644) was recently associated with social 
conformity.301 CTNND2 is often deleted in Cri-du-Chat syndrome, which commonly manifests in 
hyperactivity and impulsivity phenotypes. Associations with impulsivity and excitement seeking 
have been observed with SNPs in family member CTNNA2 in a Native American sample302 and 
a meta-analysis of GWAS respectively.303 A population level GWAS using the UK Biobank 
identified a sex-specific (males) genome-wide intronic SNP (rs140089781) in CTNNA2 to be 
associated with alcohol consumption.304 High drug use has been shown to associate with SNPs 
in family member CTNNA3. 
 
The second most significant association from the MEGA analysis was rs12023073, which is an 
intronic variant in IGSF21 (immunoglobulin superfamily member 21). This gene encodes a protein 
that is part of the immunoglobulin super family that multiple human tissue analysis has identified 
that it is most highly expressed in the brain and is believed to play an integral role in inhibitory 
synaptic development. Tanabe et al. (2017) through an unbiased expression screen and 
proteomics in mice identified postsynaptic IgSF21 to interact with presynaptic neurexin2α.305  
Igsf21 knockout mice from that safe study were found to have a number of phenotypic 
abnormalities including: impaired inhibitory presynaptic organization, diminished GABA-mediated 
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synaptic transmission in hippocampal CA1 neurons, and deficits in sensory gating.  
 
This study represents the first genome-wide assessment of heritability of risky decision-making 
based on BART performance. It benefits from comparing similar objective behavioral 
measurements in moderately sized, healthy, genetically homogenous samples. The ability to 
include a smaller number of subjects with psychiatric diagnoses assessed with the same protocol 
extends the implications of the results. The main limitation of this study is limited power. Given 
the highly complex phenotypes being evaluated, it is possible that a much larger sample could 
definitively identify genes associated with risky decision making at the genomewide significant 
level and that an association with ADHD diagnosis could be demonstrated. Additionally, a 
replication sample to confirm the MEGA PRS would be useful to further validate the findings. 
In conclusion, we demonstrate for the first time that polygenic scores derived from a genome-
wide association study of a risk-taking phenotype successfully predict the same phenotype in an 
independent sample. We found that 11% of the variance in performance on the BART was 
captured by common genetic variation, consistent with the idea that risk-taking behavior is a 
polygenic trait. A MEGA-analysis GWAS combining the two samples, while underpowered, 
produced suggestive association at two functionally relevant genes. A PRS derived from this 
MEGA-analysis successfully predicted categorical bipolar diagnosis in a large public sample. A 
marginal trend was seen when applied to an ADHD population. 
 
 
Chapter 4 Wrap-Up 
 
With the advent and continuous growth of the genomic revolution, it becomes possible to study 
individual genetic variation throughout the whole genome on an unprecedented scale. The study 
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of pharmacogenetics and genetics as a whole embody all of these new technologies, and while 
I have only been able to scratch the surface during my time in graduate school, I know both the 
wet-lab, such as various forms of genotyping, and biostatistical, such as high-throughput 
genomic data pruning, techniques I was able to acquire will be indispensable in my future; I will 
be able to understand how human diseases operates on the fundamental biological level and 
derive meaningful knowledge from human genetics. 
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Chapter 5  
Gene x Environment Interactions 
 
General Introduction to Gene-Environment Interactions 
 
After traversing the pertinent fields of pharmacology, the more subtle details of personalized 
medicine begin to take shape in the form of the applied combinations of these principles. While 
the underlying biochemistry of how our bodies function in response to pharmaceuticals is both 
fascinating and paramount, it is important to zoom out and examine how the world around us 
can both affect and change this delicate homeostasis. Because we just covered how critical 
human genetics is to keeping the machine that is precision medicine well-oiled in Chapter 4, I 
will first discuss how the environment can interact with our genes.  
 
Not surprisingly, we refer to this equilibrium as gene-environment interaction, and it is important 
for improving both accuracy and precision in the assessment of both influences, as one cannot 
usually exist without the other. Gene-environment interaction or GxE as I will refer to it 
throughout this work, is defined as “a different effect of an environmental exposure on disease 
risk in persons with different genotypes” or alternatively, “a different effect of a genotype on a 
disease risk in persons with different environmental exposures.”306 A simply way to approach 
this is to consider an environmental risk factor as a “high-risk genotype” and can be things such 
as physical exposure (e.g. radiation, extreme temperature), chemical (e.g. polycyclic aromatic 
hydrocarbons, free radicals), biological (e.g. viruses), a behavior pattern (e.g. late age at first 
pregnancy), or a life event (e.g. job loss, car accident, injury).307 Research assume the variables 
to be dichotomous in these scenarios in order to facilitate ease and clarity of measurement and 
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discussion. Subtle differences in genetic variation cause people to respond in distinct and 
differing ways when exposed to the same environmental agent. Using statistical methods and 
thorough phenotyping assessments, researchers can classify predictions about disease risk in 
individual patients, stratifying a large amount of unique health information.  
 
Testing Gene-Environment Interactions 
 
In order to test these associations, individuals must be classified by the presence or absence of 
both the exposure and the high-risk genotype. Exposures are relatively facile to uncover and 
quantify, while the genetic component can be more of an obstacle. The most common strategies 
to evaluate GxE involve identifying a susceptibility gene, implementing ecogenetic or candidate 
genes, measuring a linked genetic marker, or evaluating positive vs. negative family history.306 
Overall, the identification of subsets of populations with high disease risks due to particular 
combinations of environmental stressors and genetic mutations with allow development of more 
targeted screening, interventions, preventative strategies, as well as improved maintenance of 
everyday health.308 
 
There is a pocket in this field of research that focuses on the effects of early childhood 
development. Studies are indicating that gene-environment interactions during this period of 
development may have long lasting and penetrating effects on health that do not manifest until 
adulthood. One can imagine “risk” factors such as those encountered during the beginning of 
our lives would have resounding implications in psychological health and well-being. In fact, 
researchers have seen that the behaviors of rat moms towards their newborn pups changes the 
lifelong responses of those offspring to stress. The parental behavior patterns change the 
activity of genes in the pup’s brains, specifically genes that are involved in the response to 
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stress hormones such as cortisol.309 Considering there is a myriad of adult psychiatric disorders 
that operate through complex mechanisms that are not entirely understood, GxE interactions 
represent a valuable pathway for studying long term effects of childhood life events. 
 
Applying Gene-Environment Interactions to Psychiatric Research 
 
Through a long-standing collaboration with Dr. Jessica Borelli, I had a golden opportunity to 
incorporate my growing database of genomic science into her work with childhood attachment 
patterns and future psychiatric disorder risk and susceptibility. I present two case studies that 
revolved around GxE interactions in a diverse community of school-aged children. The first, 
GxE Case Study #1, we examined moderating effects of a SNP in the FKBP5 gene, which 
encodes for FK506 binding protein 5 and plays a role in immunoregulation and basic cellular 
processes310 on the links between parenting intensity (overcontrol) and child attachment. We 
assessed whether this genetic variation moderates the links between maternal and child 
attachment, and subsequently children’s emotional regulation. Detailed results can be seen 
below. Secondly, GxE Case Study #2, we expanded upon what is known about children’s 
genetic and environmental risk for anxiety by examining the unique and interactive effects of 
mother-child language style matching and a specific OPRM1 polymorphism on children’s 
separation anxiety disorder symptoms. OPRM1 is a µ-opioid receptor encoding gene, and these 
neuronal receptors can mediate acute changes in neuronal excitability via suppression of 
presynaptic release of GABA.311 Findings from this study provide support for a differential 
susceptibility model of childhood separation anxiety and are detailed below. 
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GxE Case Study #1: Interactive effects of attachment and FKBP5 genotype on school-
aged children's emotion regulation and depressive symptoms. * 
 
*This work is currently published in Behavioral Brain Research312 
 
Borelli JL, Smiley PA, Rasmussen HF, Gómez A, Seaman LC, Nurmi EL. 
 
1. Introduction 
A large body of research demonstrates that child attachment insecurity and genetic factors are 
each associated with elevated risk for emotion dysregulation and psychopathology.313, 314 
However, few studies have examined associations between these two factors [6] and even 
fewer have evaluated their interaction in predicting child outcomes. Using a developmental 
psychopathology framework,315 in a middle childhood community sample, we examine 
interactions of parenting and genes in predicting child attachment security, as well as 
attachment security (both children’s and mothers’) and genes in predicting children’s emotion 
regulation and depressive symptoms. 
 
1.1. Emotion regulation and depressive symptomatology 
Emotional reactions are multilayered experiences comprised of psychological, physiological, 
and behavioral components.316 Emotion regulation (ER) refers to the conscious or unconscious 
processes by which individuals modulate their emotions; some ER strategies result in worsened 
distress and poor psychological outcomes. Emotion suppression – a conscious process of 
pushing negative emotions away – is, ironically, associated with increases in negative 
emotion.317, 318 Rumination, another maladaptive ER strategy,319 involves a passive and 
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repetitive focus on the origins, meaning, or future implications of negative emotion;320 it is a well-
established risk factor for childhood depression.321 
 
Because multiple systems are involved in emotions and their regulation, multi-method 
assessment of ER is essential.322 Whereas traitlike ER strategies such as suppression and 
rumination are typically assessed via self-report, momentary emotional changes inaccessible 
through self-report can be measured physiologically.323 Respiratory sinus arrhythmia (RSA), 
which indexes parasympathetic vagal influences on the heart,324 is one such measure. Although 
the meaning of task-related RSA changes has been debated, generally speaking, greater 
decreases in RSA signify an adaptive response, namely, recruitment of additional resources to 
adequately cope with stress on ER capacity.324-327 Indeed, greater task-related decreases in 
children’s RSA are associated with fewer behavior problems, greater social competence, and 
more adaptive ER strategies,326, 328, 329 but see 330, for conflicting effects). 
 
1.2. Attachment insecurity, emotion dysregulation, and depressive symptoms 
One of the core tenets of Bowlby’s attachment theory is that attachment and ER are inextricably 
intertwined.331, 332 Attachment security develops through interactions with attachment figures 
(typically caregivers) who fulfill two central functions, serving as a secure base from which the 
child can explore (i.e., promoting the child’s autonomy) and serving as a safe haven to which 
the child can return in times of need (i.e., providing comfort); Caregivers who consistently fulfill 
these functions promote the child’s confidence that his/her emotional needs can be expressed 
and resolved within close relationships.333 In contrast, children exposed to caregiving that fails to 
provide comfort (e.g., rejecting the child for showing emotion) develop attachment avoidance,334 
which involves learning to deactivate their emotional responses and adopting a strategy of self-
reliance,335 responses that are phenotypically similar to emotion suppression.336 Similarly, 
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children whose parents are unable to promote children’s autonomy (e.g., by engaging in 
intrusive or overcontrolling parenting), or who respond inconsistently to children’s attachment 
needs, develop anxious attachment.337 Indeed, parental overinvolvement, a construct 
theoretically related to overcontrol, is associated with attachment insecurity in school-aged 
children.338 Like other forms of parental insensitivity,339 overcontrol may teach children that their 
environment is chaotic and unpredictable.340 Children parented this way adopt hyperactivating 
ER strategies336 such as rumination that prolong and intensify negative emotions in order to 
increase the likelihood of eliciting a caregiver response.341 
 
The theoretical claim that attachment insecurity is associated with suboptimal ER throughout the 
lifespan is now supported by a large body of research (see 342 for a review). Even in middle 
childhood, until recently a relatively understudied developmental phase in the attachment 
literature,343 links between attachment and ER abound: Attachment insecurity is associated with 
greater parent-reported child emotion dysregulation343  and with physiological indices of emotion 
dysregulation, including cortisol reactivity,344 startle magnitude,345 event-related potentials,346 
galvanic skin response,347 and cardiovascular reactivity.348 Although less research has 
examined links between parental attachment security and children’s ER (see 349), it is thought 
that attachment transmits across generations,350 and it follows that parental attachment 
insecurity should also be associated with impaired child ER. 
 
In theory, children’s insecure attachment also predisposes them to affective pathology such as 
depression because children’s lack of emotional security results in emotional (e.g., poor ER;351 
and cognitive (a sense of loss and uncontrollability) risk factors for depression.352 Consistent 
with these predictions, associations between attachment insecurity and depression have been 
documented at various stages of development, including middle childhood.353 Research 
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expanding our understanding of factors that contribute to the development of depression in 
middle childhood is particularly important given the dramatic rise in depression prevalence in 
adolescence.320 
 
1.3. FKBP5, emotion dysregulation, and depressive symptoms 
In addition to environmental risk factors, children’s ER and risk for depressive symptomatology 
may also be influenced by their genes. The hypothalamic-pituitary-adrenal (HPA) axis links the 
nervous and endocrine systems in the regulation of the human stress response. Hypothalamic 
corticotropin-releasing hormone, the main activator of the HPA axis, regulates the release of 
adrenocorticotropic hormone from the pituitary, in turn triggering adrenal secretion of cortisol, a 
glucocorticoid and key stress hormone.354 Cortisol, through its action at glucocorticoid receptors, 
has widespread effects throughout the body, diverting resources to cope with acute stressors. 
The stress response is limited by cortisol feedback on the hypothalamus. This negative 
feedback loop is regulated by the glucocorticoid receptor co-chaperone, FKBP5, which 
modulates glucocorticoid receptor sensitivity [30]. Functional polymorphisms in the FKBP5 
gene, however, alter FKBP5 expression and result in downstream glucocorticoid receptor 
resistance and dysregulation of the neuroendocrine stress-response. 
 
The two most studied polymorphisms, rs3800373 and rs1360780, map to the 3′ untranslated 
region and intron 2 respectively. Since they are in near-perfect linkage disequilibrium (r2 > 0.9), 
genetic effects cannot be independently differentiated; however, functional effects of the 
rs3800373-rs1360780 haplotype may be conferred by the rs1360780 variant, which maps to a 
glucocorticoid response element in intron 2 and results in a hyperactive allele,310.355 Minor 
alleles at these loci (rs3800373 C-allele, rs1360780 T-allele) present at a frequency of 20–40% 
across racial groups, result in poor regulation of the stress response system following exposure 
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to stress.310 Not surprisingly, these FKBP5 minor alleles have been associated with mental 
illnesses such as major depression, bipolar disorder and post-traumatic stress disorder.310, 356 
Additionally, environment by gene effects have been repeatedly observed, with FKBP5 minor 
alleles conferring risk for harmful psychological effects specifically in the context of childhood 
trauma exposure.357 During childhood, FKBP5 minor alleles also predispose individuals to 
stress-mediated epigenetic changes that further dysregulate the FKBP5 negative feedback loop, 
thus moderating the long-term impact of environmental stressors.358 Given that emotion 
dysregulation and depression have been associated with both attachment insecurity and genetic 
vulnerability as well as the fact that some research suggests an association between 
attachment insecurity itself and genetic variation,359 a comprehensive assessment must 
examine both factors simultaneously. Designs involving both predictors are able to determine if 
one is a more proximal correlate of the outcomes of interest than the other, and they are also 
able to explore the impact of their interaction. Two dominant theoretical perspectives regarding 
gene-environment interactions in predicting psychological outcomes are the diathesis-stress 
and the differential susceptibility models. The diathesis-stress model360 suggests that minor 
alleles will be associated with negative outcomes in the presence of negative parenting and/or 
attachment insecurity. In contrast, the differential susceptibility theory posits that genetic factors 
are markers of plasticity, or openness to environment inputs361, 362– children with genetic 
sensitivity may demonstrate worse outcomes in the context of negative environmental 
circumstances, but enjoy more optimal outcomes than expected in favorable environments. 
Evidence for the differential susceptibility theory continues to mount, as scholars reinterpret data 
from prior studies previously conceptualized as evidence for diathesis and conduct new studies 
to test the model.363 
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Studies show that interactions of parenting behaviors and monoaminergic gene variants predict 
attachment security, ER, and depressive symptoms.347, 359, 364-367 HPA axis candidate genes 
have also been studied for genetic influences on these phenotypes, including mineralocorticoid, 
glucocorticoid and oxytocin receptors.368, 369 The most replicated genetic findings occur at the 
FKBP5 locus. FKBP5 minor alleles interacted with chronic low family support in predicting child 
mental health status in 255 children with comorbid depression and disruptive behaviors.370 The 
interaction of FKBP5 gene variants and adverse life events predicted first episode depression 
onset in a large-scale 10-year prospective community study of adolescents and young adults371 
and symptoms of anxiety, depression, anger, and dissociation in adolescents.372 Similarly, 
FKBP5 variants demonstrated significant interactions with mild to moderate life events in 
predicting anxiety and depression in preschoolers.373 Finally, consistent with the differential 
susceptibility model, post-institutionalized girls with FKBP5 minor alleles exhibited more 
depressive symptoms at higher levels of peer victimization, but fewer depressive symptoms at 
lower levels of victimization,374 suggesting that gene variants confer openness to experience 
rather than simple risk for negative outcomes.375 Thus, based on the reliability of previous 
findings in independent samples, well-described impact of functional variation, and clearly 
demonstrated interaction with environmental stressors, we examine genetic influences of the 
FKBP5 risk haplotype (tagged by the rs3800373 variant) on attachment, ER, and depressive 
symptoms. 
 
1.4. Current investigation 
Using a diverse, community-based sample of school-aged children, we build upon prior work 
and examine interactive associations between attachment and genes to predict child ER 
outcomes. Using multimodal measurement of ER and incorporating assessments representing 
both mother and child perspectives, we evaluate four hypotheses. 
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First, we examine whether parenting behavior (operationalized as parental overcontrol), 
moderated by genes (FKBP5 genotype), predicts quality of children’s attachment (Hypothesis 
1). Consistent with the differential susceptibility hypothesis,361 we predict that the greatest 
variability in child attachment will occur among children with FKBP5 minor alleles; among these 
children, low parental overcontrol will be associated with the highest attachment security and 
high parental overcontrol with the lowest attachment security. 
 
Next, we examine whether children’s attachment security, which we propose represents the 
internalization of parenting behavior, moderated by children’s genes (FKBP5 genotype), 
predicts ER as measured by three indices – stressor-related RSA, emotion suppression, and 
rumination (Hypothesis 2) – and depressive symptoms (Hypothesis 3). We predict that in 
children with FKBP5 minor alleles, high attachment insecurity will be associated with the 
greatest degree of emotion dysregulation/depression and low attachment insecurity with the 
least. 
 
Finally, we investigate whether maternal attachment, moderated by child genes, predicts the 
same three indicators of emotion dysregulation and depression. We expect that among children 
with minor alleles only, maternal attachment insecurity will be associated with greater emotion 
dysregulation and depression (Hypothesis 4). 
 
2. Method 
2.1. Participants 
School-aged children (N = 106, 49% girls) and their mothers (see Table 5-1 for sample 
descriptors) were recruited from the community using various methods, including online 
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postings and flyers. In order to participate, mothers had to be proficient in English and have at 
least one child between the ages of 9 and 12. The sample was diverse socioeconomically (48% 
reported an annual income of less than $60,000), racially (63% Caucasian, 22% African 
American, 10% Asian, and 5% other racial category or mixed race), and ethnically (22% 
Hispanic, 78% non-Hispanic). 
 
2.2. Procedure 
The study was approved by the 
Institutional Review Board. Upon 
arriving at the laboratory, mothers 
and their children provided 
informed consent and assent. Then, in separate rooms, mothers and children completed self-
report measures of attachment. Children also reported on their emotion suppression, 
rumination, and depressive symptoms. Mothers self-reported their use of overcontrol. Finally, 
children participated in the performance challenge task (PCT) while their cardiovascular 
reactivity was monitored. 
 
2.3. Measures 
2.3.1. Maternal attachment style 
Table 5-1. T-tests between 
Key Study Variables. 
 
a - Values represent item-level 
mean scores. 
 
* - p < .05. 
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The Experiences in Close Relationships-Revised scale (ECR-R;376) is a self-report measure 
assessing individual differences with respect to attachment-related anxiety (e.g., I often worry 
my partner doesn’t really love me) and avoidance (e.g., I prefer not to show a partner how I feel 
deep down) as they occur in the context of adult romantic relationships. Each subscale consists 
of 18 items rated on 7-point scales, with higher values signifying greater insecurity. Item-level 
scores were averaged to yield attachment avoidance and anxiety scores. The ECR-R’s 
reliability and validity have been extensively demonstrated.373 In this study, αanxiety = 0.92 and 
αavoidance = 0.94. 
 
2.3.2. Maternal overcontrol 
Mothers completed the USC Parental Overcontrol Scale (USC-POS;), a 10-item questionnaire 
designed to measure parental overcontrol (e.g., I expect my child to tell me everything that 
happens when he/she is away from home) among parents of school-aged children. Parents rate 
each item on a 5-point scale (from 0, Not at all descriptive, to 4, Extremely descriptive); item 
scores were summed to create a total score. The USC-POS’s validity has been demonstrated in 
two prior studies (see 368, 377). Discriminant validity was shown in this sample by a nonsignificant 
association between USC-POS scores and social desirability as measured by the Balanced 
Inventory of Desirable Responding questionnaire, r = −0.13, ns. Cronbach’s alpha was 
comparable to reports in prior studies, α = 0.64. 
 
2.3.3. Child attachment security 
Children completed the Security Scale, a 15-item questionnaire presented in the form of self-
esteem questionnaire (e.g., Some kids find it easier to trust their mom but other kids are not 
sure if they can trust their mom). After selecting which group of children they are most like, 
respondents indicate how true that statement is for them (sort of true or really true). Responses 
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to the items are averaged to create a mean score, with higher scores suggesting higher security 
(range: 1–4). The measure has strong reliability and validity.378 In this study, Cronbach’s alpha 
was 0.88. Note that the Kerns Security Scale does not differentiate between anxiety and 
avoidance, two dimensions of insecurity. 
 
2.3.4. Child genetic plasticity 
Saliva was collected and DNA isolated using DNA Genotek’s (Ontario, Canada) Oragene Saliva 
Collection Kit (OG-500). FKBP5 variant rs3800373 was genotyped using Life Technologies’ 
(Carlsbad, CA) TaqMan platform according to the manufacturer’s protocol. To ensure quality 
control, a subset of the sample was genotyped in duplicate with perfect concordance. Minor 
allele frequencies were similar to expected published values and Hardy-Weinberg Equilibrium 
was satisfied. In line with existing literature, the minor C-allele was considered the risk/plasticity 
allele, with CC homozygotes at greatest risk/plasticity. Since the minor allele is present at 
similar frequencies across racial groups and race was not a significant predictor of the 
dependent variables, race was not expected to be a confound. There was insufficient saliva to 
allow for genotyping of n = 5 children and n = 2 children had undetermined genotypes; therefore 
we report findings on n = 99 children. 
 
2.3.5. Child emotion suppression 
The Emotion Regulation Questionnaire for Children and Adolescents (ERQ-CA;379 is a 10-item 
measure probing responses to happiness, sadness, and anger. The items are grouped into two 
subscales: emotion suppression and cognitive reappraisal. The current investigation utilized the 
emotion suppression subscale, comprised of 4 items that describe conscious forms of masking 
experienced emotion (e.g. When I am feeling happy, I am careful not to show it). Children 
respond using a 5-point scale (1 = strongly disagree, to 5 = strongly agree). Internal consistency 
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and convergent validity of the measure have been reported.379 Cronbach’s alpha for the emotion 
suppression subscale was 0.74 for this sample. 
 
2.3.6. Child rumination 
Children completed the Children’s Response Style Questionnaire (CRSQ;), comprised of 25 
items that assess rumination in response to feeling sad. There are three subscales: ruminative 
responses, distracting responses, and problem-solving. We utilized the total score of the 13-
item ruminative responses scale; items prompt children to describe how often they employ a 
passive, self-focused response to sad mood (e.g., think about how alone you feel). Children 
respond on a 0 (almost never) to 3 (almost always) scale, with higher scores indicating greater 
rumination. The ruminative responses subscale has good psychometric properties, including 
high internal consistency and test-retest reliability.380 Cronbach’s alpha for the ruminative 
response subscale was 0.84 in this sample. 
 
2.3.7. Child depression symptoms 
Children completed the Children’s Depression Inventory (CDI;381), a 27-item measure of 
depressive symptomatology. The CDI prompts children to choose the statement from a series of 
three statements that best describes how they felt over the past two weeks (e.g., “I am sad once 
in a while,” “I am sad many times,” or “I am sad all the time”). These responses are converted to 
a 0–2 scale; a mean score across 27 items was computed, with higher scores indicating more 
depressive symptoms. The CDI has good test-retest reliability, internal consistency, and 
validity.381 Cronbach’s alpha in this sample was 0.84. 
 
2.3.8. Performance challenge task 
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Children completed the Performance Challenge Task (PCT;382). Mothers, who were told their 
children should complete the task independently, sat in a chair placed a few feet behind the 
child and observed. The task consisted of solving six geometric puzzles adapted from the Block 
Design task in the Wechsler Intelligence Scale for Children, 3rd edition. For each puzzle, the 
screen displayed a reduced-size picture of the completed puzzle, and ten pieces that could be 
moved into an empty frame. Children were instructed to move the pieces to complete the 9-
piece puzzle. Puzzles were made impossible by only including eight of the nine correct pieces, 
along with two extraneous pieces. Each puzzle was displayed to the child for 50 s, after which a 
cartoon frown face appeared, indicating the child’s failure to solve the puzzle. For the next 10 s, 
a progress bar appeared, showing the child’s progress in comparison to other imaginary 
children, who supposedly got 5 out of 6 puzzles correct. 
 
Children sat approximately 20 inches in front of a computer monitor on which stimuli were 
presented and used a computer mouse to move the puzzle pieces. The screen was connected 
to an experimenter-controlled computer located in an adjacent room. Experimenters used the 
computer to present experimental stimuli using E-Prime 2.0 software (Psychology Software 
Tools, Pittsburgh, PA), which sent recording signals to the physiological data collection 
program, BioLab (Mindware Technologies, Gahanna, OH). 
 
2.3.9. Child cardiovascular reactivity 
Prior to the PCT, research assistants connected children to HRV equipment and tested the 
signals to make sure the electrodes were functioning well. Disposable Mindware 1.5-inch foam 
electrodes with 7% chloride wet gel and touchproof snap leads were connected to a BioNex 8-
slot chassis equipped with an impedance cardiograph (Mindware Technologies, Gahanna, OH). 
HRV data were collected using BioLab 2.5 acquisition software and later edited for peak errors 
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and noise due to movement using the BioLab HRV 2.0 application (Mindware Technologies, 
Gahanna, OH). 
 
Children were instructed to remain as still as possible. Children first completed a 5-min resting 
baseline during which they watched a nature video while their physiological activity was 
recorded. During the PCT, a 60-s segment of physiological data was recorded for each of the 
six unsolvable puzzles. For this study, we calculated mean scores across the five-minute 
baseline nature video (baseline RSA) and across the six unsolvable puzzles for each child 
(stressor-related RSA). RSA data from n = 7 children were lost due to equipment malfunction. 
To assess RSA reactivity, we created a standardized residual score (stressor-related RSA 
controlling for baseline RSA), which we used as the dependent variable in hypothesis testing. 
 
2.4. Data analytic plan 
Hypotheses were tested using hierarchical linear regressions, controlling for demographic 
variables that were significantly associated with dependent variables. Due to the strong 
association between rumination and depression,380 we initially included rumination in the 
regression predicting depressive symptoms; the pattern of effects was unchanged, therefore we 
present the results of the more parsimonious analyses not including rumination. Since the AA (N 
= 47) and AC (N = 38) genotype groups produced identical patterns across all analyses, we 
determined that the C-allele was acting in a recessive manner and therefore combined A-allele 
carriers (AA and AC) into a single group that was compared with CC homozygotes (N = 14). 
 
In order to adopt a conservative data analytic strategy that minimizes the number of analyses 
conducted to avoid type I error inflation, we tested all attachment × gene interaction effects 
simultaneously in each of the models, and subsequently performed post-hoc analyses of 
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interactions that emerged as statistically significant in these more complex omnibus models. 
Initial analyses revealed that attachment × gene interactions were not statistically significant for 
avoidance; therefore, in the models presented here, we included two interaction terms (child 
attachment security × FKBP5 and maternal attachment anxiety × FKBP5). As is customary in 
attachment research (e.g.,383), we controlled for maternal attachment avoidance when 
attachment anxiety was a predictor variable. 
 
We used the PROCESS macro for SPSS384 to test moderation by FKBP5 of associations 
between child and mother attachment and outcome variables. The PROCESS macro tests 
significance by creating 95% bias-corrected confidence intervals using 1000 bootstrapped 
samples. In the moderation models, the independent variable is the environmental factor 
(mother overcontrol, child attachment, mother attachment) and the moderator is the level of 
genetic risk/plasticity, treated as a dichotomous variable (AA and AC = lower risk/plasticity; CC 
= higher risk/plasticity). Dependent variables include child attachment security, measures of ER, 
and depression. For each individual hypothesis, a significance threshold of p < 0.05 was 
assumed. 
 
After conducting analyses, we followed the guidelines proposed by Roisman et al.385 for 
evaluating whether statistically significant moderation effects fit diathesis-stress or differential 
susceptibility models . Following their recommendations, we examined the simple slopes of the 
association between X and Y among children with low risk/plasticity (AA or AC) and high 
risk/plasticity (CC) alleles. For all significant moderation effects, we then determined the 
percentage of cases that fell past the crossover point, termed the proportion affected (PA) 
index. The crossover point in an interaction is the first value of X at which the regression lines 
cross. Roisman et al. recommend that when 16% or more cases fall beyond the crossover point, 
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the interaction can be interpreted as providing evidence of differential susceptibility, but when 
between 2 and 16% of cases fall beyond this point, the conclusion is less clear. 
 
3. Results 
Compared to girls, boys reported greater use of expressive suppression to regulate emotion, 
t(98) = −2.46, p = 0.016, but no other gender differences emerged (see Table 10). As shown in 
Table 5-2, child age was negatively associated with emotion suppression. Both maternal 
attachment anxiety and avoidance were positively associated with maternal overcontrol, and 
maternal attachment anxiety was positively correlated with child depressive symptoms. Maternal 
overcontrol was negatively associated with child attachment security and positively with child 
depressive symptoms. Child attachment security was inversely associated with children’s 
emotion suppression and children’s depressive symptoms. FKBP5 minor alleles were correlated 
with lower stressor RSA and positively associated with children’s depressive symptoms, but 
were not significantly associated with any of the environmental variables. A repeated-measures 
t-test suggested that for the 
sample as a whole, RSA 
decreased from baseline to PCT, 
t(90) = 4.79, p = 0.0001. 
 
 
Table 5-2. Zero-order 
Correlations between Key 
Study Variables. 
 
* - p < 0.05. 
 
** - p < 0.01 
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3.1. Predictors of child attachment security 
Beyond the variance explained by the covariates and the main effects of maternal overcontrol 
and FKBP5 genotype alone, R2 = 0.16, p = 0.009, the interaction between maternal overcontrol 
and FKBP5 genotype did not significantly add to the prediction of child attachment security, ΔR2 
= 0.01, p = 0.50 (i.e., the simple slopes were not significantly different from each other and a 
model with only one slope would be more parsimonious). However, we describe the simple 
slopes as descriptive statistics. The negative association between maternal overcontrol and 
child attachment security was statistically significant when children were heterozygous for the 
FKBP5 minor allele (AC), b = −0.04, p = 0.001, or homozygous for risk/plasticity (CC), b = 
−0.05, p = 0.01, but not when children had low genetic risk/plasticity (AA), b = −0.03, p = 0.05. 
 
3.2. Predictors of children’s emotion regulation and depressive symptoms 
Beyond the variance explained by the covariates and the main effects of child attachment 
security, maternal attachment avoidance, and FKBP5 genotype alone, R2 = 0.15, p = 0.03, the 
two interactions of child and maternal attachment with FKBP5 together yielded no significant 
improvement in the prediction of RSA reactivity, ΔR2 = 0.06, p = 0.07 (see Table 5-3). When 
decomposing this combined effect into the two separate interaction effects – the interaction 
between child attachment and FKBP5 by itself significantly improved prediction, ΔR2 = 0.04, p = 
0.048, whereas that between maternal attachment anxiety and FKBP5 did not, ΔR2 = 0.005, p = 
0.50. Fig. 5-1 depicts the 2-way interaction effect. For the significant interaction effect, child 
attachment security was inversely associated with RSA among children with high risk/plasticity 
(CC), b = −1.21, p = 0.01, but not among children with low risk/plasticity (AA or AC), b = −0.10, 
p = 0.64. According to the PA index, 100% of cases fell beyond the crossover point (2.22 on 
attachment security), providing evidence of minor alleles acting exclusively as a protective factor 
whose impact is enhanced when attachment security is high. 
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Beyond the variance explained by the covariates, including child gender, and the main effects, 
R2 = 0.17, p = 0.018, the two interactions between attachment and FKBP5 did not significantly 
contribute to the prediction of emotion suppression, ΔR2 = 0.06, p = 0.057 (see Table 5-3). 
When decomposing this combined effect into the separate interaction effects, the interaction 
Table 5-3. FKBP5 Genotype × Child Attachment Predicting Child RSA Reactivity, Emotion 
Suppression, and Child Rumination. Child gender was only significantly associated with 
emotion suppression; therefore we included it as a covariate only in the analysis in which 
emotion suppression was a dependent variable. PROCESS generates unstandardized b 
values, which are reported here. 
 
t - p < 0.10. 
 
* - p < 0.05. 
 
a - Standardized residual of mean RSA during insolvable puzzles controlling for baseline 
RSA. 
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between child attachment and FKBP5 significantly added to the prediction, ΔR2 = 0.06, p = 
0.018, whereas the interaction between maternal attachment anxiety and FKBP5 did not, ΔR2 = 
0.009, p = 0.75. For the significant interaction, child attachment security was inversely 
associated with emotion suppression among children with high risk/plasticity (CC), b = −1.19, p 
= 0.004, but not among children with low risk/plasticity (AA or AC), b = −0.22, p = 0.18 (see Fig. 
5-1). The PA index showed that 25.53% of cases fell beyond the crossover point (a value of 
3.14 on attachment security), providing strong evidence for differential susceptibility. 
 
Beyond the variance explained by the covariates and the main effects, R2 = 0.16, p = 0.015, the 
combined interactions between attachment and FKBP5 significantly added to the prediction of 
rumination, ΔR2 = 0.06, p = 0.041 (see Table 12). Decomposing this joint effect showed that the 
interaction between child attachment and FKBP5 was significant, ΔR2 = 0.04, p = 0.039, 
whereas that between maternal attachment anxiety 
and FKBP5 was not, ΔR2 = 0.008, p = 0.37. Child 
attachment security was inversely associated with 
rumination among children with high risk/plasticity 
(CC), b = −9.96, p = 0.004, but not among children 
with low risk/plasticity (AA or AC), b = 0.15, p = 
0.92, (see Fig. 5-2). The PA index revealed that 
22.34% of cases fell beyond the crossover point 
(3.14 on attachment security), providing evidence 
of differential susceptibility. 
 
 
Figure 5-1. Attachment × FKBP5 
rs3800373 predicting child RSA 
reactivity. The C-allele of FKBP5 
rs3800373 is believed to confer 
sensitivity to environmental stress. 
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Beyond the variance explained by the covariates 
and the main effects, R2 = 0.30, p =0.00001, the 
interactions between attachment and FKBP5 
genotype jointly added to the prediction of 
depressive symptoms, ΔR2 = 0.12, p = 0.001 (see 
Table 5-4). Decomposing this joint effect showed 
that the interaction between child attachment and 
FKBP5 added significantly to the prediction, ΔR2 = 
0.06, p = 0.005, whereas that between maternal 
attachment anxiety and FKBP5 did not, ΔR2 = 
0.03, p = 0.07. Attachment security was more 
strongly inversely associated with depressive 
symptoms among children with high risk/plasticity (CC), b = −0.43, p = 0.0001, as compared to 
those with low risk/plasticity (AA or AC), b = −0.09, p =0.03 (see Fig. 5-3). According to the PA 
index, 15.95% of cases fell beyond the crossover point (3.65 on child attachment security), 
providing tentative evidence for differential susceptibility. 
We interpret the trend-level effect for the interaction between maternal attachment anxiety and 
FKBP5 – of note is that when analyzed separately from the first interaction effect (i.e., without 
Figure 5-2. Attachment × FKBP5 
rs3800373 predicting children’s 
emotion suppression, controlling for 
child gender and maternal attachment 
avoidance. 
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controlling for the first interaction effect), the finding 
is statistically significant, p = 0.01. Maternal 
attachment anxiety was positively associated with 
depressive symptoms among children with high 
risk/plasticity (CC), b = 0.13, p = 0.01, but not 
among those with low risk/plasticity (AA or AC), b = 0.03, p = 0.25 (see Fig. 5-5). The PA index 
revealed that 7.21% of cases fell beyond the crossover point (1.64 on maternal attachment 
anxiety), providing weak evidence for differential 
susceptibility.   
 
It is 
important to note that in computing the PA indices, 
we examined single interactions in isolation (e.g., 
child attachment security × FKBP5). 
 
Table 5-4. FKBP5 Genotype × Maternal Attachment Anxiety Predicting Children’s 
Depressive Symptoms.  
t - p = 0.06. 
a - Pattern of effects remains the same when controlling for children’s rumination. 
PROCESS generates unstandardized b values, which are reported here. 
Figure 5-5. Attachment × FKBP5 
rs3800373 predicting children’s 
depressive symptoms, controlling for 
maternal attachment avoidance. The 
pattern remains unchanged when also 
controlling for rumination. 
Figure 5-4. Attachment × FKBP5 
rs3800373 predicting children’s 
rumination, controlling for maternal 
attachment avoidance. 
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We sought to advance the state of knowledge pertaining to the interactive associations of 
attachment and genetic risk with children’s ER and depressive symptoms. Our findings are 
supportive of the notion that relationship factors and children’s genotype interact in predicting 
child outcomes, and can be understood within a differential susceptibility framework. 
 
Importantly, in our sample, FKBP5 was not 
significantly associated with any of the variables 
representing environmental factors, suggesting the 
absence of gene-environment correlations. In 
combination with our other findings, these non-
significant associations suggest that while minor 
alleles may make children vulnerable to the effects 
of maternal attachment, children with these alleles 
do not have mothers with greater attachment 
insecurity. 
 
4.1. Predictors of child attachment security 
Although parental overcontrol was negatively associated with child attachment security, the 
FKBP5 genotype was not. Further, although the effect of the interaction between overcontrol 
and FKBP5 genotype on attachment security was not itself statistically significant, we noted that 
higher overcontrol predicted lower attachment security and lower overcontrol predicted higher 
attachment security among children with minor alleles. Prior work reports a link between 
parental over involvement and attachment insecurity,338 but here we found that this link only 
holds for children with minor alleles. We present this pattern of effects to facilitate future 
examination of these associations with larger samples. 
Figure 5-6. Attachment × FKBP5 
rs3800373 predicting children’s 
depressive symptoms, controlling for 
maternal attachment avoidance and 
child attachment security. The pattern 
remains unchanged when also 
controlling for rumination. M = maternal 
attachment. 
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4.2. Children’s attachment security as a predictor 
Although we identified few main effects between attachment or FKBP5 and children’s ER, the 
interaction between these two factors predicted all outcomes. With respect to state-like 
reactivity, we found that among children with the CC genotype, children’s attachment security 
was associated with a greater decrease from baseline RSA, suggesting readiness to respond to 
the stressor. In contrast, there was no association between attachment security and RSA 
reactivity in children with the AC or AA genotypes. This pattern, where genetic susceptibility is 
associated with more optimal functioning in positive environments, is consistent with a 
differential susceptibility framework. Importantly, however, the meaning of task-related 
decreases in RSA has been a topic of debate. Some scholars argue that decreases in RSA in 
response to a task, referred to as RSA withdrawal, represent readiness to engage the 
autonomic nervous system in mounting a response to a stressor.386 This may be true for 
community samples, for which decreases in RSA are more likely to suggest adaptive readiness. 
In support of this assertion, task-related decreases in RSA are associated with fewer 
externalizing problems, more prosocial behavior, and less sadness.328 Others argue that greater 
decreases in RSA in response to a stressful task indicate that the stimulus poses a greater 
regulatory challenge to the individual than can be easily handled. Indeed, associations between 
RSA decreases and rumination, internalizing and behavioral problems, and poorer executive 
functioning have been reported (e.g., 330). Given these competing perspectives, our 
interpretation of this finding – that attachment security is associated with greater adaptive 
decreases in RSA among CC children – is tentative. 
 
With respect to the traitlike measures of ER (suppression, rumination), children’s attachment 
was associated with ER for children homozygous for the minor C-allele, but not among children 
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with AA or AC alleles. Both rumination and suppression are considered maladaptive forms of 
ER – rumination can be conceptualized as a hyperactivating form of ER and suppression, a 
deactivating one. Our results show that children with CC genotypes had less optimal ER when 
security was low, but more optimal ER when security was high, as compared to children without 
minor alleles, providing evidence for differential susceptibility.385 
 
With respect to depressive symptoms, there was a negative association between children’s 
attachment security and depressive symptoms only for CC children, with modest evidence for 
differential susceptibility. However, because those with high child attachment security reported 
very low depressive symptoms regardless of genotype, trend-level protective effects seen for 
children with FKBP5 minor alleles and positive environments may be limited in significance by 
floor effects (i.e., pathology rating scales cannot capture improvement beyond the absence of 
symptoms). 
 
When considering these four interaction effects of child attachment security and child genotype 
on ER and depression, the findings provide strong support for differential susceptibility: Minor 
alleles predict more maladaptive ER/depression when children’s attachment security is low and 
more optimal ER/depression when attachment security is high. That is, minor alleles may confer 
sensitivity to the influence of the environment rather than exclusively conferring risk. 
 
4.3. Maternal relationship variables as predictors 
In comparison to the dependence of the associations between child attachment and children’s 
ER on genetic plasticity, associations between maternal attachment and ER did not depend on 
FKBP5 genotype, nor were there main effects of maternal attachment on children’s ER reactivity 
or strategies. Although contrary to theoretically-based predictions, the lack of significant effects 
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is unsurprising in that few studies have reported main effects between parent attachment and 
child ER (but see387, for an example of main effects of interview-based maternal attachment), 
and to our knowledge no studies have examined these links using parents’ self-reported 
attachment style. Further, in the present study, parents reported on attachment in the context of 
romantic relationships. Although emerging research shows that attachment security measured 
in the context of romantic relationships is associated with parenting behavior and emotion388, we 
would not expect parents’ romantic attachment security to be as strongly linked to children’s ER 
strategies as caregiving behavior. 
 
Maternal attachment anxiety interacted with children’s FKBP5 genotype in predicting children’s 
depressive symptoms; when maternal attachment anxiety is high, children with minor alleles 
report higher depressive symptoms, whereas when anxiety is low, children with minor alleles 
report lower depressive symptoms. Importantly, the nature of these associations varies as a 
function of children’s attachment security; children with CC genotypes and low security have the 
strongest positive association between maternal attachment anxiety and children’s depressive 
symptoms. Overall, with respect to depressive symptoms, minor alleles may confer openness to 
both the negative and positive influence of the caregiving environment (in this case, maternal 
attachment anxiety). 
 
Maternal avoidance did not interact with children’s genotype to predict outcomes. There are at 
least two possible explanations for this pattern, one conceptual and the other, methodological. 
Conceptually, parents higher in attachment anxiety may parent in a way that heightens the 
child’s attachment needs, for example, by catastrophizing when the child is afraid, which in turn, 
could intensify and prolong negative emotional experiences. Elevated reactivity may then 
enhance children’s risk for affective forms of pathology, such as depression and anxiety.389 If 
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parents do not heighten children’s attachment needs, children may be better at regulating their 
emotion in the face of ordinary stressors. High avoidance parents may treat children in a way 
that results in children suppressing emotion, which may more likely result in externalizing rather 
than internalizing problems.390 
 
From a methodological perspective, the absence of interactive associations between maternal 
attachment avoidance and child genotypes with child-reported reactivity and depression could 
also be explained by reporter biases.335 Self-reported attachment is only weakly associated with 
attachment representations as derived from interviews,391 and avoidance in particular may be 
the dimension least likely to correspond across measurement modalities. For these reasons, it 
is impossible to ascertain whether the absence of interaction effects with avoidance reflects a 
true lack of association, or whether interview-based, but not self-reported, assessments of 
avoidance would yield effects. 
 
4.4. Implications 
In the present study, multiple interactive associations between attachment and FKBP5 in the 
prediction of ER and depression provide evidence for differential susceptibility.361, 362 Children 
with this genotype had the most optimal psychological profiles (lower emotion suppression and 
rumination, greater RSA response) in positive caregiving contexts (i.e., when they reported high 
attachment security) and the most maladaptive outcomes (greater emotion suppression and 
rumination, higher depression) in negative caregiving contexts (i.e., low child attachment 
security or high maternal attachment anxiety). 
 
These effects lead us to wonder about the developmental period of plasticity of children with 
FKBP5 minor alleles – is their plasticity time-limited or are they open to the influence of their 
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environments throughout their lives? In future studies it will be interesting to examine parenting 
by gene interactions, measuring parenting constructs at different points in the child’s 
development. This would enable researchers to assess whether FKBP5 minor alleles confer 
plasticity during a sensitive or critical period, or whether children carrying minor alleles have 
greater plasticity throughout development. 
 
If replicated and extended using longitudinal designs, these findings could have implications for 
understanding which children are most at risk for emotion dysregulation and depressive 
symptomatology. One of the central predictions of attachment theory is that insecure attachment 
confers risk for emotion dysregulation351 and internalizing pathology,353 and these claims are 
supported in middle childhood for both dysregulation346 and internalizing pathology.353 Similarly, 
FKBP5 minor alleles have been linked to emotion dysregulation and depression in prior 
studies.310, 356 In contrast, our findings suggest that associations between attachment security in 
the mother-child dyad and self-reported and physiological emotion reactivity and with 
depressive symptoms, depend on FKBP5 genotype sensitivity. These findings imply that in 
future work researchers should evaluate the contributions of both attachment and FKBP5 
genotype, individually and interactively, to child outcomes. 
 
If replicated, these findings could have implications for intervention as well. If we assume that a 
causal mechanism underlies the findings, then it follows that for children with the CC genotype, 
attachment insecurity has the strongest impact on ER and depression. Translating these 
findings into the realm of prevention/intervention, then, it might make sense to identify CC 
children with histories of attachment-related adversity (e.g., youth in foster care) for treatment, 
or to target parents carrying minor alleles for engagement in parenting programs grounded in 
attachment theory during pregnancy. Alternatively, infants could be screened for FKBP5 
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genotype; the parents of infants with the CC genotype could then receive parenting 
interventions. Further, depending on the developmental specificity of plasticity, minor allele 
homozygotes may also be more receptive to the impact of interventions, making the potential 
gain from interventions targeted towards these populations greater. 
 
4.5. Limitations and strengths 
It is important to contextualize this study’s findings in light of its limitations. First, the 
interpretation of genetic findings is limited by the relatively small sample size (N = 106), which 
constrains our ability to draw conclusions regarding effects that were non-significant.369 In order 
to reduce the likelihood of inflation of Type I error due to multiple testing, we conducted joint 
analyses of both interaction effects with each outcome measure. However, this analytic 
approach may have resulted in inflated Type II errors. Many of the interactions involving 
maternal attachment anxiety and FKBP5 were statistically significant when examined in 
isolation, but were not significant after controlling for child attachment and its interaction with 
FKBP5. Accordingly, our findings warrant replication in larger independent samples with greater 
power to detect effects. Second, given the limited statistical power, we only considered one 
strong candidate gene variant in this study; however, many variants are likely to interact with 
one another and with environmental factors to contribute to stress phenotypes. Similarly, a 
larger study would allow researchers to include measures of potential confounding factors that 
cannot be ruled out here. 
 
In addition, this study was cross-sectional, limiting to some extent the conclusions we can draw. 
It is impossible to know if the measures of overcontrol and maternal and child attachment 
security solely reflect current conditions (i.e., current overcontrol), or instead reflect variability in 
these constructs that emerged when the child was younger. Answers to these questions would 
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provide information regarding the developmental timing of the influence of parent-child 
relationship quality and child genotypes on child outcomes. Further, the correlational nature of 
the study makes it challenging to infer the direction of effects among the environmental 
variables and outcome measures (e.g., does attachment insecurity cause depression or does 
depression cause attachment insecurity?) as well as to rule out the influence of unmeasured 
confounding factors. 
 
There are also limitations with respect to measurement. Our measure of children’s attachment 
security does not differentiate between attachment anxiety and avoidance, two dimensions of 
attachment insecurity. Therefore, we were unable to examine whether anxiety and avoidance 
were associated with our measures of emotion hyperactivation (rumination) and deactivation 
(suppression), respectively. In recent years, investigators have worked to develop the first self-
report attachment measures for school-aged children that differentiate between these 
dimensions;392 using this measure in future research may help generate and test more targeted 
hypotheses. Further, we used a self-report measure of child attachment security and three of 
the four dependent variables in the analyses with child attachment as a predictor were also 
measured with child self-report. Shared method variance may have contributed to these effects. 
On the other hand, these effects were entirely consistent with the findings using an objective, 
physiological measure as the outcome. 
 
Finally, in this study we assessed mothers’ self-reported attachment anxiety and avoidance in 
romantic relationships. Although to our knowledge no self-report measures of attachment-based 
caregiving systems exist, in future studies it would be interesting to examine children’s 
genotypes as moderators of the links between behavioral measures of parenting sensitivity or 
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parental reflective functioning, two constructs thought to promote secure attachment in children, 
in predicting child outcomes. 
 
This investigation also has significant strengths – our use of a multimethod approach to 
assessing ER-related constructs enhances confidence in our findings. Further, incorporating 
both parent- and child-reports of attachment and parenting provides a multilayered assessment 
of the parent-child relational context. Few studies examine the interrelations between factors 
across genetic, relational, subjective, physiological, and clinical levels of analysis − as such, our 
study has the potential to speak to the complexity of intersecting patterns of risk in the prediction 
of internalizing psychopathology. 
 
4.6. Conclusion 
In sum, using a cross-sectional design involving a community sample, we found that children 
with high attachment insecurity and homozygous FKBP5 minor alleles manifested the greatest 
signs of maladaptive ER and depressive symptoms, whereas children with high attachment 
security and minor alleles showed the most positive ER outcomes. These findings provide 
preliminary evidence for the genetic sensitivity or plasticity of children with FKBP5 minor alleles 
− when immersed in a positive caregiving environment, they show the best outcomes, whereas 
in a negative caregiving context, they manifest the greatest risk. 
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Disorder Symptoms. * 
*This work is currently published in Research in Development Disabilities  
 
Boparai S, Borelli JL, Partington L, Smiley P, Jarvik E, Rasmussen HF, Seaman LC, Nurmi EL.  
 
1. Introduction 
 
While experiencing distress in response to separation from caregivers is typical and adaptive for 
young children, separation distress normatively decreases between the ages of three and 
five.393 However, four to five percent of children take longer to outgrow these developmentally-
typical worries, developing separation anxiety disorder (SAD).393, 394 For children aged nine to 
twelve, SAD commonly manifests as excessive distress when separating from caregivers. Once 
apart, children with SAD experience sadness, withdrawal, and poor concentration. Adolescents 
with SAD report greater somatic complaints and school refusal.393 Importantly, SAD in children 
is a risk factor for future maladjustment; participants’ retrospective reports of childhood SAD 
predict both current and future adult psychopathology, including anxiety, panic, and depressive 
disorders.395, 396 Children with SAD who are treated for school refusal may return to school, but 
many continue to experience social and emotional difficulties in adulthood, suggesting that the 
psychological effects of the disorder extend far beyond presenting symptoms.397 Given the 
strong links between early SAD diagnosis and later pathology, identifying factors that confer risk 
for SAD is important for developing prevention and intervention efforts. Further, consistent with 
a developmental psychopathology framework, examining prospective predictors of SAD 
symptoms within community samples is necessary in the identification of risk factors. 
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2.2. Predictors of separation anxiety 
Various genetic and environmental factors have been suggested as candidate risk factors for 
the development of SAD symptoms, both individually and in interaction with one another. Two 
prevailing theories exist regarding interactions between genetic and environmental influences 
on development. According to the diathesis stress hypothesis, possession of certain “risky” 
alleles is thought to increase vulnerability to pathology when combined with life stress (e.g. 
MAOA gene polymorphism;398, 399 this hypothesis holds that in the absence of the risky alleles or 
the life stressor, individuals will not be as likely to exhibit pathology. Thus, negative 
environmental factors may serve as a catalyst for the development of psychopathology among 
individuals who possess the diathesis allele. 
 
An alternative theory of gene by environment interactions is the differential susceptibility 
hypothesis. It holds that some genes can affect individuals’ sensitivity to all environmental 
influences, both negative and positive.400 Belsky (2005) argues that it may be evolutionarily 
beneficial for siblings to differ in their degree of susceptibility to environmental influence.361 If 
children experience maladaptive parenting, those with lower plasticity will be less affected by it, 
but, if they experience supportive parenting, those with higher plasticity will maximally reap the 
benefits of parental support. In support of this theory, there is evidence for a number of genetic 
factors promoting differential susceptibility, rather that rendering individuals vulnerable to risk, 
such as the serotonin transporter polymorphism 5HTTLPR401, 402 and dopamine receptor gene 
D4 (DRD4;402). In the current study, we will examine the interaction between genetic and 
environmental influences on children’s SAD symptoms. We aim to distinguish whether the 
OPRM1 polymorphism A118G confers greater SAD symptoms in combination with an adverse 
environmental context (diathesis stress), or whether children with the allele have greater SAD 
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symptoms in a negative context, but fewer symptoms than those without the allele in a positive 
context (differential susceptibility). 
 
2.2.2. Environmental predictors of separation anxiety 
Due to the highly relational nature of SAD symptoms, interpersonal factors have been 
hypothesized to predict risk for SAD.332 For instance, both attachment insecurity and harsh 
parenting predict greater separation anxiety in school-aged children.403-406 
 
The manner in which individuals impact one another’s behaviors and emotions, referred to as 
co-regulation, may be another interpersonal factor involved in SAD development. Co-regulation 
between parents and infants is considered to be highly important for the emergence of 
children’s emotional self-regulation.407, 408 In co-regulated interactions, parents respond in a 
contingent and matched way to their infants’ emotional displays. Seeing their internal states 
mirrored by their parents provides infants with a visual representation of their internal states and 
conveys the powerful message that their caregivers understand their emotions and are available 
to help them regulate their emotions.409 Over time, a consistent pattern of co-regulated 
interactions teaches children how to regulate their emotions independently, while fostering a 
sense of security that their caregivers are there for them in times of distress.409, 410 
 
Co-regulation can be measured in terms of the patterning or matching of facial expressions 
(Fogel, 1994), language, vocal tonality, or physiology. Greater matching is linked with more 
optimal functioning, such as stronger parent-infant bonds,411 secure infant attachment,412 
increased vagal tone in response to an emotional stressor,413 lower externalizing symptoms,414 
increased emotion regulation in early childhood,415, 416 higher obedience to parental 
instructions,417 and lower negative emotionality.418 The majority of studies on co-regulation have 
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explored this construct during infancy, when co-regulation may predominantly occur through 
facial affect matching. However, in early and middle childhood, language becomes an 
increasingly important tool for communication and, thus, may be involved in the dyadic co-
regulation process. Like affect matching, higher linguistic matching within a parent-child dyad 
may reflect greater parental sensitivity and co-regulation.348, 419-421 
 
A novel method of assessing dyadic co-regulation that has emerged in the literature is language 
style matching (LSM;422, 423), a metric quantifying the similarity of function word use between 
individuals.422 Function words express grammatical relationships in a sentence and lack clear 
lexical meaning (e.g., the, and, of, have, could). Variability in the use of function words, which 
comprise more than half of colloquial speech,424 is not affected by the content of the speech,422 
and individuals tend to be unaware of their own and others’ function word use.425 Thus, 
comparing the use of function words allows us to examine matching that the participants 
themselves are unaware of and that is unrelated to the topic of their speech. 
 
The results of extant studies reveal that higher LSM is associated with more positive relational 
outcomes. In speed-dating conversations, LSM predicted mutual romantic interest, even when 
controlling for perceived similarity, and higher LSM in couples’ instant messages predicted 
greater relationship stability after three months.423 Additionally, bloggers with illnesses reported 
feeling more social support when LSM was greater between comments on their blog posts and 
the posts themselves.426 Thus, early evidence hints that LSM is a valuable indicator of 
relationship quality. 
 
Prior work also suggests that LSM is a noninvasive measure of the dyadic matching involved in 
parent-child co-regulation; scholars argue that dyads who have a history of behavioral matching 
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may also have more closely aligned speech patterns.427 Although research on LSM is in its 
infancy, preliminary work suggests that higher LSM between parents and children is associated 
with greater child attachment security, lower children’s galvanic skin response in anticipation of 
a reunion with their parents, and less self-reported negative emotion in response to a stressful 
task.348, 427 These findings have lead scholars to contend that LSM may tap into a history of 
parent-child co-regulation that has become ingrained linguistically. 
 
Given the influence of co-regulation on parent-child relationship quality and emotional 
development, it seems plausible that the absence of co-regulation could elicit the emergence of 
separation anxiety. Indeed, LSM is associated with factors that have been found to influence 
separation anxiety, such as attachment quality and physiological dysregulation,348, 427 but has 
never been directly examined for its association with separation anxiety. Prior research on SAD 
etiology has focused on individual-level variables (e.g., attachment security, parenting 
behavior), rather than on measures of dyadic-level processes. Since LSM reflects the level of 
matching between parent and child, it may constitute a more robust predictor of risk for 
relationship-focused psychopathology, allowing us to explore the influence of parent-child 
interaction on separation anxiety in a novel manner. 
 
The links between LSM and SAD symptoms may be especially important to investigate in 
middle childhood, an understudied developmental stage.343 As it is developmentally appropriate 
for children in this age range to experience separations from their parents and engage in greater 
autonomy-seeking, symptoms of SAD may indicate a lack of security in the parent-child 
relationship and a failure to express developmentally-expected autonomy striving. Children 
exhibiting maladaptive responses to hypothetical separation from parents have been found to 
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have poorer academic performance and lower self-esteem, indicating that symptoms of SAD in 
this age range may be cause for clinical concern.428 
 
1.1.2. Genetic predictors of separation anxiety 
Genetic factors may also increase risk for SAD symptoms. Forty-seven percent of children with 
SAD in one sample had mothers with an anxiety disorder and a meta-analysis of twin studies on 
SAD estimated moderate heritability (43%), suggesting the important role of shared genetic 
risk.429-431 
 
Research regarding the impact of specific genes on SAD is limited,432 although one study found 
an association between the duplication of gene GTF2I and increased SAD symptoms, possibly 
through its role in downregulating calcium entry into cells, which could affect downstream 
signaling pathways.433 Other genes have been associated with generalized anxiety in human 
and animal studies, such as the rs2254298 polymorphism in the oxytocin receptor gene 
(OXTR;)434 and the 5HTTLPR polymorphism in the serotonin transporter gene (SLC6A4435). 
 
One genetic factor that has not been previously examined for its association with children’s 
separation anxiety is the gene encoding the μ opioid receptor (OPRM1), which is involved in the 
HPA axis, the brain’s reward and stress response systems, as well as in physical and social 
pain processing via the anterior insula and dorsal anterior cingulate cortex.436-439 OPRM1 has 
been extensively researched,439 and a functional, nonsynonymous single nucleotide 
polymorphism in the first exon of this gene, called A118G or rs1799971, has been linked to 
psychological outcomes.440-443 
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The presence of the minor G-allele, in about 15–30% of those with European ancestry, 40–50% 
of those with Asian ancestry, and 1–3% of Latinos and African Americans,444-446 results in a non-
conservative amino acid substitution from asparagine to aspartic acid,447 altering gene 
expression, ligand sensitivity and signal transduction.439, 448 Because the μ opioid receptor 
system inhibits the HPA axis, individuals with the minor allele may have altered HPA axis 
functioning, impacting their stress response.437, 439, 449 G-allele carriers were found to have 
higher resting cortisol and a blunted cortisol response to a psychosocial stressor.439, 450 A recent 
study also showed an association between G-allele possession and neuroticism, the tendency 
to experience negative emotions in stressful situations.451 
 
Further, gene by environment interactions have been observed for OPRM1 in both human and 
rodent models. Genetically altered mice lacking the Oprm1 gene show abnormal maternal 
separation and attachment,452 an effect reversed by enhanced maternal care.453 Although 
candidate gene studies in humans suggest that the A118G polymorphism interacts with 
environmental factors to affect stress reactivity, there are varied findings on the nature of this 
interaction. Among psychiatric patients, A-allele homozygotes had greater susceptibility to the 
effects of maternal caregiving on their levels of fearful attachment, while those with the minor 
allele had similarly high levels of fearful attachment regardless of caregiving.443 However, 
studies involving other populations have found that G-allele carriers were more sensitive to 
stress.440 For example, one study conducted with African American adolescents found that 
individuals with the minor allele and high life stress had greater depression symptoms than A-
allele homozygotes.442 While these studies are limited in scope and complexity, they 
preliminarily suggest that children’s susceptibility to environmental risk factors may be 
influenced by their OPRM1 genotype, but are varied in terms of their support for the differential 
susceptibility or diathesis stress hypothesis. The majority of evidence among community 
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samples indicates that the OPRM1 minor allele is associated with increased stress sensitivity, 
so it may be particularly difficult for children with this genotype to regulate distress. When 
combined with maladaptive parent-child relationship quality, minor allele carriers may be at 
greater risk for relationship-focused psychopathology, such as SAD; however, it is unclear if 
possession of the minor allele may be associated with lower SAD symptoms among dyads with 
high co-regulation. 
 
1.2. Current study 
Here we provide the first exploration of the interaction between parent-child LSM and OPRM1 to 
predict children’s concurrent and future SAD symptoms. We test the following four hypotheses: 
First, based on findings on the link between parent-child relationship quality and SAD, we 
predict that LSM will be negatively associated with concurrent and future SAD symptoms.403-406 
 
Second, we hypothesize that the OPRM1 118G allele will be associated with greater concurrent 
and future SAD symptoms, in line with previous findings linking the allele with greater stress 
reactivity.439-441, 450, 451 
 
Third, we predict that these two factors will interact such that low LSM will have a stronger 
association with SAD symptoms among children who possess the 118G allele. This reflects 
previous findings on interactions between the A118G polymorphism and environmental 
factors.440-443, 453 Importantly, current research does indicate whether the role of the 
polymorphism follows the diathesis stress or differential susceptibility hypothesis for 
psychopathology, so we are unable to make any predictions in that respect. 
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Our fourth hypothesis concerns the potentially unique and important role of LSM as a measure 
of parent-child interaction quality. While previous research has examined the effects of intra-
individual level variables on separation anxiety, our study aims to utilize LSM to capture the 
influence of dyadic matching above and beyond the contribution of individual-level 
characteristics of the members of the dyad. We expect that this measure will provide additional 
nuance in our understanding of the development of SAD and the importance of dyadic factors. 
Specifically, since LSM has previously been associated with attachment security (Borelli et al., 
2016), we will control for mothers’ and children’s self-reported attachment in our analyses to 
study the role of their interactions independently of each dyad member’s perception of their 
relationship. We predict that the effects of LSM, both separately and in conjunction with genetic 
risk, will remain after controlling for the attachment styles of the mother and child. 
 
2. Method 
 
2.1. Participants 
Participants were recruited from Southern California via online postings, flyers displayed in 
community gathering sites (e.g., coffee shops), and word-of-mouth to participate in a study of 
child development. Forty-five children aged between nine and twelve (49% females, 
Mage = 10.37 years, SDage = 1.09) and their mothers (Mage = 40.24, SDage = 6.70) took part in 
this longitudinal study, which was an extension of a larger study. The sample was diverse in 
terms of race (53.3% Caucasian, 17.8% African American, 8.9% Asian American), ethnicity 
(17.8% Hispanic), and family income (median: $61,000–$80,000 annually, with 17.8% reporting 
under $40,000). Mothers needed to be proficient in English to be eligible for participation and all 
children were fluent in English. 
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2.2. Procedure 
Prior to data collection, the study was approved by the Institutional Review Board. The Time 1 
assessment (T1) was conducted in a laboratory. After providing consent (mothers) and assent 
(children), children reported their symptoms of SAD and provided a saliva sample to a trained 
research assistant, later used to determine OPRM1 genotype. The children then completed a 
standardized Performance Challenge Task (PCT) in which they attempted to complete a series 
of six unsolvable puzzles on a computer while their mothers observed. The puzzles in this 
standardized task were adapted from the Block Design task in the Wechsler Intelligence Scale 
for Children-III 454 and were a slightly modified version of a task used in a previous study.348 In 
each puzzle, children had 50 s to recreate an image of a completed puzzle by dragging red and 
white square tiles into an empty nine-piece puzzle frame. Unbeknownst to the participants, 
some of the tiles needed to solve the puzzle were missing (children are given ten tiles, of which 
two are incorrect). For ten seconds after each of the six puzzles, children were presented with a 
progress bar indicating that other children who had taken part in the study got five of the six 
puzzles correct, while the child had not completed any correctly. During this task, the mother’s 
chair was placed six feet behind the child and the mother was asked not to help her child unless 
necessary. Following this task, mothers and children were taken into separate rooms and 
interviewed about their own and the other’s experiences during the PCT. These interviews, 
described below, were used to compute the LSM score of the dyad. 
 
At the outset of the data collection, we only anticipated collecting data from families at a single 
time point. However, two years later (Time 2 [T2] assessment; range: 2 years, 3 months to 3 
years, 5 months), we obtained additional funding to conduct an online assessment of the youth 
in the study. At this time, we re-contacted T1 participants via phone and email. Due to the fact 
that we had not planned for a longitudinal follow-up, we had not made any attempts to maintain 
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relationships with the participants in the study, and therefore were only able to successfully 
reenroll 42% of the original T1 sample. Importantly, the participants who did and did not 
participate in the T2 data collection did not significantly differ in T1 measures of SAD symptoms, 
LSM, OPRM1, age, gender, or attachment security (child or mother). However, those who 
completed the follow-up T2 data collection reported significantly higher household income at T1 
than those who did not, t(45) = −2.56, p = 0.01. Consequently, we controlled for income in further 
analyses. In the T2 data collection, youth again reported on their SAD symptoms though an at-
home online survey. 
 
2.3. Measures 
 
2.3.1. Language style matching 
Following the PCT, the child and mother independently completed semi-structured interviews 
about their experiences during the stressor task. At the start of the interview, mother and child 
were shown the same two-minute video clip of the child working on the fifth and sixth impossible 
puzzles. This visual prompt was designed to reinstate their emotions at the end of the puzzle 
task. The mother and child were asked four parallel questions regarding their own and the other 
person’s thoughts and feelings during the puzzle task. Participants’ responses to the questions 
in the interview formed the corpus for the LSM calculation (mean child word count = 365, 
SD = 245; mean mother word count = 894, SD = 458). 
 
The interviews were transcribed verbatim, and research assistants were trained to manually 
review and edit transcripts according to the procedures outlined by Pennebaker, Francis, and 
Booth (2001). The edits allowed the participants’ speech to be analyzed by the Linguistic Inquiry 
and Word Count system (LIWC455). For example, editors removed interviewer speech from 
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transcripts so that it was not included in measures of participant speech and flagged “filler” 
words and “nonfluencies” (e.g., “um,” “like”) to ensure that the program would not mistake those 
words for meaningful word production. The LIWC program calculates the percentages of words 
in the text sample that fall within certain categories. Nine function-word categories are used in 
calculating LSM: auxiliary verbs (e.g., might), articles (e.g., the), common adverbs (e.g., 
naturally), personal pronouns (e.g., you), indefinite pronouns (e.g., someone), prepositions and 
relative pronouns (e.g., of, which), negations (e.g., not), conjunctions (e.g., and), and quantifiers 
(e.g., most).422 
 
To produce the LSM metric, we followed the procedures of Gonzales et al. (2010), a method 
used in a number of other studies.423, 426, 427, 456, 457 We first calculated the proportions of words in 
each function word category out of the total number of words in the responses and took the 
absolute difference of the proportions within each dyad (i.e., |Mother − Child|). Next, we divided 
this value by the sum of the dyad’s proportions of that function word category (i.e., 
(|Mother − Child|)/(Mother + Child)). This provides the difference between mother and child word 
usage adjusted for combined word usage in that category. Finally, we subtracted this value from 
1 in order to determine the level of similarity in the frequency of certain types of words in the 
dyad’s speech. The equation is shown below: 
LSMwordcategory = 1 − [(|Mother − Child|)/(Mother + Child)] 
 
To illustrate the computation of this metric, we provide an example for one function word 
category: The auxiliary verb category generated by LIWC provides the proportion of auxiliary 
verbs used by a speaker out of the total number of words uttered by the speaker (e.g., 457 
auxiliary verbs/10,000 words = 0.0457 for mother; 80 auxiliary verbs/6000 words = 0.0133 for 
her child). Using the proportional values generated by LIWC (Maux = 0.0457; Caux = 0.0133), 
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we computed the absolute value of the difference between mother and child auxiliary word 
usage as a proportion of the total auxiliary word usage: 
(|Maux − Caux|)/(Maux + Caux) = (|0.0457 − 0.0133|)/(0.0457 + 0.0133) = 0.5520. We then 
subtracted this value from 1, yielding LSMaux = 0.4480 for this particular dyad. 
 
We performed the same calculation for each of the nine function word categories for each dyad. 
Then, we averaged the nine individual word category LSM calculations to look at matching 
across all function words, as validated by of Gonzales et al. (2010). This creates an overall LSM 
score for each mother-child dyad. 
LSMTotal = (LSMwordcategory1 + LSMwordcategory2 + … + LSMwordcategory)/(9) 
 
Overall, the algorithm used to compute LSM is thought to measure the degree of linguistic 
matching within a dyad independently from the content of their speech. LSM scores range 
between 0 and 1, with higher scores signifying greater verbal matching (Gonzales et al., 2010). 
We provide narrative responses from dyads with high and low LSM scores in Table 5-5i98. 
 
High LSM Low LSM 
Child Mother Child Mother 
Questions 
about 
child’s 
thoughts 
I was thinking about 
um, like, like how I 
was supposed to do 
the puzzles, 
because once, once 
I got it right, well not, 
well I ha-had a 
triangle, but I was 
flipping it inside the 
thing 
Um initially he was 
probably excited and 
happy. After he got 
the first one wrong 
he’s like, “What oh 
okay okay I did 
something wrong I 
gotta refocus.” 
I was thinking 
that I was really 
gonna 
accomplish it. I 
was thinking I did 
really well and 
that I almost had 
it and I almost 
finished the 
whole thing. 
He probably was 
thinking about 
finishing in the 
allotted time also. 
I'm sure he 
probably figured by 
looking at it he 
knew exactly what 
to do, but once he 
started, you know, 
and then having to 
turn the pieces 
around it changed 
his outlook. 
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Questions 
about 
child’s 
feelings 
I was curious about 
how to do it. I was 
wondering if when I 
put the block – put it 
down to see if it that 
actually was right. 
Um he probably felt 
um excited in the 
beginningand then 
after probably 
frustrated. Yeah. 
I felt really good 
and I enjoyed 
that. I did pretty 
good and I’m 
proud of myself. 
Um I think he knew 
that he didn’t do 
good, you know, 
because he didn’t 
get any of them 
right. But it wasn’t 
like a devastating 
thing. It was more of 
an excitement to try 
to get the next one 
finished. 
Questions 
about 
mother’s 
thoughts 
She might have 
been thinking that − 
she might have 
been thinking about 
the correct answer 
in her head, but she 
couldn’t really just 
say it out loud. I 
think she was 
thinking uh— 
thinking about how I 
did. 
Um, initially I was 
thinking um that he 
would get them all 
right because I know 
that he’s really good 
at kind of stuff. Um 
and then after a 
while I just figured 
um … the point was 
for him to get them 
wrong. 
Maybe she was 
thinking about 
how good I was 
doing it and how 
she was helping 
me. She might 
have thought I 
was doing pretty 
good and she 
might have been 
proud of me. 
That I hoped he 
would make it in the 
allotted time um and 
that it wasn’t too 
hard for him. He did 
good for his first 
time seeing those 
types of puzzles. So 
now I think he will 
probably want to do 
more puzzles like 
that. 
Questions 
about 
mother’s 
feelings 
I mean, a little 
disappointed. I kept 
on getting them 
wrong. Maybe, is 
this really how he’s 
– is this really how 
my son is doing? 
‘Cause I was getting 
them wrong. 
Um…I felt…I don’t 
know I guess 
content or happy or 
yeah. I like watching 
him do you know 
things you know that 
may be a challenge 
so. 
She might have 
thought that I was 
doing really good 
and she tried to 
help me really 
hard. I think she 
felt really good 
that I almost had 
it and I had one 
more puzzle 
piece to 
complete. 
It felt good. He was 
interested in doing 
it, you know, so I 
always like just to 
watch him do 
things. I love it, I 
love it. I mean that it 
was nice, it went by 
well, and it was 
great. 
 
2.3.2. OPRM1 
Trained research assistants collected saliva samples immediately following consent procedures. 
We isolated DNA using DNA Genotek’s (Ontario, Canada) Oragene Saliva Collection Kit (OG-
500). The OPRM1 genotype was then determined using Life Technologies’ (Carlsbad, CA) 
TaqMan platform, following the manufacturer’s protocol. To ensure quality, we genotyped a 
subset of the sample a second time, which yielded perfect concordance with the original results. 
The minor allele frequency in our sample was similar to that reported in previous studies and 
Table 5-5. Narrative Examples of High and Low LSM Interviews. 
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satisfied Hardy-Weinberg Equilibrium. There was insufficient saliva to allow for the genotyping 
of one sample out of the 45 who participated in the T2 data collection, so we report on 44 
children. 
 
2.3.3. Separation anxiety 
Children reported their anxiety symptoms in the Multidimensional Anxiety Scale for Children at 
both time points (MASC458). The scale has 39 items that are divided into four subscales: 
Physical Symptoms, Social Anxiety, Harm Avoidance, and Separation/Panic. Children rated 
how much each item applied to them (e.g., from the Separation/Panic subscale: “I try to stay 
near my mom and dad”) on a 4-point Likert-type scale from 0 (“never true about me”) to 3 
(“often true about me”). The MASC is a reliable and valid measure of anxiety symptoms in 
community samples.459 The 9-item Separation/Panic subscale was used to assess SAD 
symptoms. It has been found to significantly predict the presence and severity of SAD among 
children aged 7–17.460, 461 Internal consistency for the Separation/Panic scale in this sample was 
0.78 at T1 and 0.80 at T2. 
 
2.3.4. Dyad-level covariates 
To assess attachment, mothers completed the Experiences in Close Relationships Scale 
Revised at T1 (ECR-R376), a 36-item measure consisting of an attachment anxiety scale (e.g., I 
often worry my partner doesn’t really love me; α = 0.92) and an avoidance scale (e.g., I prefer 
not to show a partner how I feel deep down; α = 0.94). Children completed the 15-item Kerns 
Security Scale at T1378; e.g., Some kids find it easy to trust their mom but other kids are not sure 
if they can trust their mom; α = 0.88). We included these variables as controls in our analyses. In 
this way, we were able to test whether our dyadic-level matching variable (LSM) predicted SAD 
symptoms above and beyond the contributions of mother and child attachment. 
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2.4. Data analytic plan 
After examining the distributions of our key variables, we determined whether demographic 
factors (age, race/ethnicity, gender, income) should be included as covariates in subsequent 
hypothesis testing through t-tests and zero order correlations. To aid the interpretation of our 
data, we also performed a t-test to examine differences in separation anxiety levels at the two 
time points. 
 
To test our hypotheses, we first conducted four linear regressions to examine the main effects 
of LSM and OPRM1 genotype on T1 and T2 SAD symptoms. OPRM1 was analyzed as a 
dichotomous variable, with 1 indicating that the child possessed at least one G allele. We 
controlled for T1 separation anxiety when examining T2 separation anxiety scores. In all four 
regressions, we controlled for child age, gender, and family income. 
 
We next analyzed the effectiveness of the interaction between LSM, and OPRM1 genotype, 
measured at T1, in predicting T1 and T2 SAD symptoms, using Hayes’ publicly available, free 
statistical PROCESS macro software.462 PROCESS operates by using 1000 bootstrapped 
samples to estimate 95% bias-corrected confidence intervals for the interaction coefficient and, 
in moderation analysis, provides estimates of simple slopes for the conditional effects. We 
performed four moderation analyses, testing both LSM and OPRM1 as moderators of the 
relation between the other independent variable and T1 and T2 separation anxiety. We 
controlled for child age and gender, family income, and the main effects of LSM and OPRM1 in 
all four moderations. When predicting T2 separation anxiety, we controlled for T1 symptoms. 
We also controlled for maternal and child attachment to isolate the effects of dyadic linguistic 
matching on SAD symptoms from individual-level factors. 
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After conducting analyses, we followed guidelines proposed by Roisman et al. for evaluating 
whether significant moderation effects fit diathesis-stress or differential susceptibility models.385 
This entails examining the simple slopes of the association between X and Y among children 
with low risk/plasticity (AA) and high risk/plasticity (AG and GG) alleles. For significant 
moderation effects, we determined the percentage of cases that fell past the crossover point, 
termed the proportion affected (PA) index. The crossover point in an interaction is the first value 
of X at which the regression lines cross. According to Roisman et al. (2012), when 16% or more 
cases fall beyond the crossover point, the interaction can be interpreted as providing evidence 
of differential susceptibility, but when between 2 and 16% of cases fall beyond this point, the 
conclusion is less clear. 
 
3. Results 
 
Prior to hypothesis testing, we examined the distributions of our study variables and their 
associations with demographic factors. The results of initial analyses revealed that all study 
variables were normally distributed. Twenty-four percent of the children possessed at least one 
G-allele. An independent samples t-test indicated that girls endorsed significantly more 
symptoms of SAD than boys at T1, t(44) = 2.36, p = 0.02, but no other gender differences were 
observed. Zero-order correlations revealed that younger children had greater SAD symptom 
severity at both time points (Table 5-6). On average, children reported significantly greater SAD 
symptoms at T2, t(44) = −9.55, p = 0.001. 
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3.1. Hypothesis testing 
Through regression analyses, we explored the main and interactive effects of LSM and OPRM1 
genotype in the prediction of T1 and T2 SAD, including simple slopes analyses to gain further 
information on significant interactions. As shown in Table 5-6, the LSM x OPRM1 interaction 
was not a significant contributor to the model predicting T1 SAD symptoms after controlling for 
child age child gender, income, mother and child attachment, and the main effects of LSM and 
OPRM1 on T1 SAD symptoms. 
 
However, a parallel regression analysis (see Table 5-7) revealed that the LSM x OPRM1 
interaction was a significant contributor to the model predicting T2 SAD symptoms with a large 
Table 5-6. Zero-Order Correlations Between Key Study Variables. 
Note: Ma= Maternal, Anx = Anxiety, Avoid = Avoidance, C = Child, Sep = Separation. 
*p < 0.05, ***p < 0.0001. 
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effect size after controlling for T1 SAD symptoms, child age, child gender, income, mother and 
child attachment, and the main effects of LSM on T2 SAD symptoms. 
 
A simple slopes analysis revealed that among homozygous AA allele children, LSM was 
positively associated with T2 SAD symptoms after controlling for T1 SAD symptoms, b = 6.73, 
p = 0.03. However, among children who possessed at least one G allele, LSM was negatively 
associated with T2 SAD symptoms, controlling for T1 SAD symptoms, b = −52.38, p = 0.004 
(see Fig. 5-7). The PA index revealed that 18.18% of the cases fell beyond the crossover point 
(.90 on LSM), providing evidence for differential susceptibility. 
 
 
 
 
Table 5-7. Results of 
Regression Analyses 
Examining OPRM1 as 
a Moderator of the 
Relationship Between 
LSM and Child SAD 
Symptoms. 
Note: C = child 
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Reversing the independent and 
moderator variables revealed that among 
children in dyads with high LSM, 
b = −3.94, p = 0.05, and mean level LSM, b = 2.50, p = 0.06, OPRM1 minor allele possession 
was not associated with T2 SAD symptoms, although the slopes approached significance. 
Among children with low LSM, those with minor alleles had significantly higher T2 SAD 
symptoms than A-allele homozygotes, b = 0.63 p = 0.002. 
 
4. Discussion 
This study examined the independent and interactive roles of OPRM1 genotype and mother-
child LSM, a form of behavioral matching measured at T1, in the prediction of children’s self-
reported T1 and T2 SAD symptoms. Both LSM and OPRM1 had significant main effects on T2, 
but not T1 SAD symptoms. In addition, as hypothesized, the interaction between LSM and 
OPRM1 genotype predicted T2 SAD symptoms, controlling for T1 SAD symptoms. Specifically, 
the G-allele was significantly associated with greater T2 SAD symptoms among low LSM dyads 
only. Approaching significance, the G-allele was also associated with higher separation anxiety 
in dyads with medium levels of LSM, but with reduced SAD symptoms among high LSM dyads. 
Our findings are consistent with previous research linking the OPRM1 minor allele with greater 
sensitivity to environmental effects.440-442 They are also consistent with findings on the negative 
association between LSM and factors that play a role in separation anxiety, including 
physiological stress reactivity and attachment insecurity.348, 403-406, 427 
Figure 5-7. OPRM1 genotype 
moderates the association between 
mother-child LSM and T2 separation 
anxiety symptoms, controlling for T1 
separation anxiety symptoms. 
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Moreover, our findings support a differential susceptibility model of the relation between OPRM1 
genotype and T2 SAD symptoms. Possession of the OPRM1 minor G allele is non-significantly 
associated with fewer SAD symptoms when LSM is high and significantly associated with 
greater SAD symptoms when LSM is low; for AA homozygotes, LSM and SAD symptoms are 
significantly positively related with a much smaller coefficient. The lack of a significant difference 
between the genotypes for the high LSM group may be due to the limited statistical power from 
our small sample size. It is possible that, with more power, we would have found significant 
evidence that the G-allele is associated with reduced SAD symptoms among children who 
experience greater behavioral matching. The PA analysis confirms the differential susceptibility 
interpretation, suggesting that possession of the minor allele confers greater plasticity or 
openness to environmental influence. This is a novel finding, as the roles of the A118G 
polymorphism and LSM in human SAD have not yet been examined. However, our conclusions 
are tentative given the small sample size, resulting in limited statistical and external validity. In a 
study among psychiatric patients, the AA homozygous allele conferred greater plasticity to the 
effect of maternal caregiving on levels of fearful attachment, suggesting that the role of the 
polymorphism may differ in clinical populations.443 Further research with larger samples is 
required to reach more definite conclusions. 
 
Given that the gene by environment effect held after controlling for maternal and child 
attachment, we propose that LSM is linked to T2 SAD symptoms beyond the effects of 
individual attachment style because it is an indicator of ongoing co-regulation between dyad 
members. Increased co-regulation among dyads with higher LSM may be related to children’s 
greater emotion regulation and security in their relationships. For children who are particularly 
sensitive to stress, which the minor genotype seems to engender, co-regulation may be 
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especially crucial for them to learn how to deal with their negative emotions. When the parent-
child relationship is characterized by low LSM, indicating low co-regulation, the child may not 
develop the coping skills needed to independently handle separation from parents or other daily 
stressors. 
 
On the other hand, some of our findings did not support our hypotheses. Although the 
interaction between OPRM1 genotype and LSM predicted future SAD symptoms, the variables 
were not associated with concurrent symptoms. Given that LSM is theorized to reflect a dyad’s 
long-term history of co-regulation, we would expect LSM to be associated with both concurrent 
and future SAD symptoms. Similarly, we would expect the role of OPRM1 to remain stable with 
time. Future study could investigate whether the factors affecting SAD development vary with 
age. Secondly, among AA homozygotes, LSM was positively associated with T2 SAD 
symptoms. However, the slope for this effect is substantially smaller than that for G allele 
carriers and the SAD scores fall within a lower range. Thus, homozygous children with higher 
LSM may be more willing to be open about their fears, resulting in higher, but still relatively low 
SAD symptoms. 
 
A further unexpected finding was that, contrary to previous research indicating that separation 
anxiety decreases with age,393 the mean level of SAD symptoms was higher at T2, when the 
children were aged twelve to fifteen, than at T1, when the children were aged nine to twelve. 
One possible explanation is that the T2 data collection period occurred around the time that 
most children start middle school, a transitional period has been associated with greater 
psychological distress.463, 464 Increased independence and academic and social demands may 
act as additional stressors that heighten children’s levels of separation anxiety. Additionally, the 
T2 data collection occurred during the six months following the 2016 U.S. Presidential election, 
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which spurred increases in anxiety particularly among Latino/a populations.465 The increase in 
T2 SAD symptoms could reflect a general increase in anxiety among vulnerable populations 
within the United States (about half of our sample was non-White). Children with the OPRM1 
minor allele may be especially sensitive to these stressors (transition to middle school or the 
election), particularly if they have not developed effective emotion coping skills through co-
regulation. Further research could investigate this possibility by examining how children’s 
current stressors interact with genetic and relational factors. 
 
4.1. Strengths and limitations 
This study is characterized by a number of strengths. The longitudinal design allowed us to 
examine the prospective predictive effects of LSM and OPRM1 in a racially and ethnically 
diverse sample. Further, LSM is an unobtrusive metric of behavioral matching that allows us to 
examine subtle variation in the synchrony of dyadic relationships. It is worth noting that this 
matching occurred even though we interviewed mothers and children separately, suggesting 
that they were carrying a co-regulatory mental representation of their relationship. Additionally, 
the fact that the gene by environment effect occurred independently of mother and child self-
reported attachment highlights the importance of investigating dyadic interactions beyond each 
individual’s perception of the relationship. 
 
There are also important limitations to the current design. Participants elected to take part in the 
study in response to our recruitment methods, introducing possible sampling bias. Those willing 
to participate in a study on parent-child relationships may systematically differ from the general 
population, such as by having greater interest in the topic, and our study did not include fathers. 
Additionally, there was variability in the time interval between T1 and T2 for participants 
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because the T1 data collection took several months to complete, affecting the amount of time 
between data collections for different participants. 
 
This is a small candidate gene by environment study that requires replication in larger samples 
to provide definitive results. Our hypotheses test only one genetic and one environmental factor 
in a complex system that leads to anxiety symptoms. Although we have proposed some 
possible explanations, the mechanism through which LSM and the OPRM1 minor allele affect 
separation anxiety remains unclear. Additionally, even though we employed a longitudinal 
design, we cannot test for causal relations between our variables. In particular, because the 
environmental factor that we are measuring cannot be separated from the genetic contributions 
of the participants, we are not examining a true gene by environment interaction. That is, 
variability in LSM may itself be related in part to other genetic factors of the dyad, rather than 
representing a purely environmental influence. Further, since we only assessed SAD symptoms 
in this study, it is also possible that children with the minor OPRM1 allele and high LSM are at 
heightened risk for less relational forms of anxiety-related problems. In future studies, it will be 
important to explore whether the proposed protective effects of LSM apply to multiple forms of 
anxiety or just to separation anxiety. Finally, with respect to our sample, although the first step in 
a developmental psychopathology study involves exploring correlates of risk in community 
samples, it would be advantageous to study these constructs within a clinical sample. 
 
5. Conclusion 
 
Children who carry the minor 118G allele of the OPRM1 gene experience more symptoms of 
SAD than those who are AA homozygous in the context of low parent-child dyadic behavioral 
matching (LSM), but they experience fewer SAD symptoms in high LSM contexts. Since SAD is 
178 
 
most common in children from low-income backgrounds393 who face multiple forms of adversity, 
future studies should assess the relative roles of LSM and OPRM1 in the context of additional 
risks. Greater knowledge of the factors that contribute to the development of SAD can inform 
both treatment and preventative measures. If the effects identified in the current study are 
replicated, this could point toward the importance of testing whether interventions designed to 
strengthen the parent-child relationship reduce the risk of developing SAD symptoms in children 
who carry the minor OPRM1 allele. 
 
Chapter 5 Wrap-Up 
Obtaining a deeper understanding of how the environment affects the lives of people every day 
has extreme value in personalized medicine. In the above studies I specifically contributed the 
genetic component of the gene-environment interactions, but through this process I was able to 
learn a significant amount about a large portion of environmental effects and their implications in 
human health and disease. It is often overlooked that the world around us can have such a 
profound impact on our daily lives, our physical health, and even more importantly, our mental 
health. By leveraging this knowledge, we can integrate it and develop and apply genome-based 
strategies for the early detection, diagnosis, and treatment of psychiatric disease. It aids us in 
predicating disease rates and provides a formidable foundation for well-information 
recommendations of therapeutic strategies as the medical community shifts their focus to more 
stratified approaches. Additionally, public health can be significantly impacted as we uncover 
more about these unique GxE interactions, as policy-makers could design more “user-friendly” 
living conditions, allowing for a delay or even prevention of many diseases. 
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Chapter 6  
Microbiota and Host Interactions 
 
General Introduction  
We have slowly inched our way through the trenches of the multitude of personalized medicine 
tools and techniques to finally reach this point. My final 2 chapters will not only attempt to 
leverage the most salient components I’ve covered but will also present a unique and novel 
research project that I was able to develop utilizing the in-depth knowledge I have acquired 
through a diverse graduate school career. First, let’s get started by discussing the general basis 
for this area of research – host biological interactions. 
 
The term host might spur a small amount of negative connotation, sometimes associated with a 
parasitic relationship, but in biology it simply means an organism that harbors a guest, whether 
it is parasitic, mutualistic, or symbiotic.466  A biological interaction is the effect that a pair of 
organisms have on each other. And although it is typically forgotten, humans play host to the 
large collective bacterial population in our bodies, and I will be specifically focusing on those 
found in the gut, appropriately named the gut microbiome. These human-bacterium interactions 
are long-term in nature, strongly influencing the evolution of our species as a whole and are 
therefore considered symbiotic and mutualistic. 
 
Understanding the Gut Microbiome 
In humans, the gut microbiota has the largest number of bacteria and the highest number of 
unique species compared to other areas of the body; a complex and dynamic ecosystem of 
approximately 200 bacterial species exists in the gastrointestinal tract.467 It is important to 
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differentiate between the gut microbiota and the gut microbiome, even though these terms are 
typically interchangeable. The microbiota / flora are the actual organisms while the microbiome 
is their collective of genes, which number roughly over 2 million, and is vastly greater than the 
human genome itself.468 Due largely to rapid advancements in analytical techniques in 
microbiology, molecular genetics, and bioinformatics, the true diversity of these microorganisms 
is quickly being revealed and its contributions to homeostasis in both health and pathogenesis 
are continuously emerging. This field of study is one of the most active and exciting in both 
biology and medicine and stands to be one of the greatest contributors to precision health care 
to date. 
 
The gut microbiota have four general roles in the human body that are imperative to regular 
biological function. First, there is the clear metabolic role; bacteria aid in salvaging calories,469 
producing short-chain fatty acids,470 synthesize vitamin K and folic acid,471 as well as participate 
in certain drug metabolic pathways. Next, the gut bacterium have the exclusive ability to 
deconjugate bile acids through the production of an enzyme known as bile salt 
hydrolase.472Third, interestingly, these bacteria play a major role in the prevention of host 
colonization by foreign pathogens. (28856738) And lastly, the gut microbiome stimulates 
immunologic effects through avenues such as immonuglobulin A production, promotion of anti-
inflammatory cytokines, and induction of regulatory T cells.473 We can see that this diverse 
microbial community has an extensive repertoire and is a key factor in shaping the human 
biochemical profile, and therefore has a direct impact on our health. This has stimulated an 
exciting amount of research in the past 5-10 years, and scientists are striving to identify the 
functionality of many microorganisms and their relationship with implicit human biology, 
signaling, and pathways and how the composition of this unique body can influence disease 
pathology. 
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With over 1000 identified species of bacteria, it can be difficult to classify distinct enterotypes of 
the human gut microbiota, however the improvement of genomic technologies such as 16S 
ribosomal RNA sequencing and shotgun metagenomics has allowed for a detailed look at the 
composition of diversity between individuals.474 A general consensus of the phylum level 
composition in the human gut is emerging and is focused around the Firmicutes and 
Bacteroidetes classifications to represent the dominant bulk of variable bacteria.475 A variety of 
populations, whether it be children vs. adults, healthy individuals vs. disease states, or obese 
vs. lean persons, have quantifiable and distinct differences in gut microbiota compositions, 
pointing to a more direct biological link to certain human archetypes. But in order to elucidate 
these connections to disease we must also understand how the bacteria communicate to the 
host directly. 
 
Microbiota and Bile Acid Crosstalk 
As mentioned above, one of the primary functions of the gut microbiota is to influence the 
chemical structure of a major class of endogenous signaling molecules, the bile acids. These 
species are examples of trans-genomic metabolites arising from the interactive metabolism 
between the host genome and the gut microbiome.476 Outlined in Figure 30, bile acids (BA) are 
synthesized in the liver from the nutrient cholesterol. The two primary BAs, cholic acid (CA) and 
chenodeoxycholic acid (CDCA) undergo amidation and subsequent conjugation by either 
glycine or taurine, and therefore present downstream as molecules that are fully ionized at 
physiological pH.477 This enhances the amphipathic and detergent properties which facilities 
lipid digestion and absorption. Only a small fraction (1-5%) of all BAs escape reabsorption into 
the distal ileum and enterohepatic circulation, however these are the few that enter the colon 
and are subjected to the transformative powers of the gut microbiota. It is here that a 
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bidirectional relationship exists, whereas unique bacterial enzymes can structurally and 
functionally modify the BAs, but the bile acids can also exert antimicrobial selection pressures 
on the community of bacteria. It is this host-based relationship that builds the blocks for a 
potential feedback mechanism that can control bacterial populations while also influencing 
hormonal signaling, lipid and glucose homeostasis, and disease perturbations and warrants 
further explanation in a multitude of fields, but specifically in those revolving around weight-gain 
and metabolic syndrome. 
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The Gut Microbiota, Bile Acids, and Psychotropic-Induced Weight Gain 
 
After extensive research into both the fields of the gut microbiome and bile acids, I took the ball 
and ran with it. I had spent many years deep in the thralls of psychiatric medicine and 
therapeutics, however one question always lingered; why do a large percentage of individuals 
experience such adverse and weight related side effects on a variety of psychotropic 
medicines? In my third year, I had a serendipitous opportunity to delve into the world of bariatric 
surgery in the same sense, and I learned a large amount about how both salient biological 
Figure 6-1. Bile acid metabolism 
(Modeled after a previously 
published figure REF 478). 
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components can play a significant role in weight-loss. I became fervent in my quest to better 
understand how human metabolism is controlled on a biochemical level, and because of Dr. 
Nurmi’s previous work in the genetics of antipsychotic-induced weight gain, we were able to sit 
down and brainstorm a completely novel idea – elucidating a more direct, biological mechanism 
of this deleterious side effect. You can read more about how antipsychotic induced-weight gain 
(AIWG) works in the case study presented in this chapter below. I had to work from the ground 
up, and I spent a large amount of time developing a novel method for detecting human bile 
acids in plasma utilizing high performance liquid chromatograph tandem mass spectrometry. I 
truly felt that this was one of the crowning chemistry jewels of my chemistry PhD, and the entire 
method is presented here. Being cognizant of the backbones of precision medicine is rewarding 
as a scientist but being able to implement them in a way that has the potential to change 
people’s lives is rewarding to my soul. In both this chapter and the next, chapter 7, I would like 
to share the preliminary results and continuing project I have developed during the last 2 years 
of my graduate career that brings a new viewpoint to the enigma that is weight gain following 
pharmaceutical treatment. 
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Original Method: Fit-For-Purpose HPLC-MS/MS Targeted Detection and quantitation of 11 
Bile Acids and Their Biological Precursor, 7-alpha-hydroxycholest-4-en-3-one* 
* This work is currently unpublished 
 
Lauren C Seaman, Hüseyin Kayadiḃi, Kym F Faull, Erika L Nurmi 
 
Introduction 
 
Classically viewed as the simple “dish-detergent” molecules of the digestive system, bile acids 
(BAs) are quickly gaining recognition as critical metabolic signaling compounds, hormone 
regulators, and disease state clinical biomarkers. BAs are the major component of bile, and are 
synthesized from cholesterol through a hepatic cytochrome p450 7A1-mediated enzymatic 
pathway479. They are powerful dietary lipid emulsifiers, allowing for solubilization and 
subsequent digestion of fats and oils through a mixed-micellular surfactant process.480 Bile acids 
regulate their own synthesis, utilizing a negative feed-back loop that spans  across the liver and 
the gut481, where they can additionally act as antimicrobial agents.482 Interestingly, recent 
research has begun to uncover the role of BAs as salient biological signaling molecules, acting 
as hormonal ligands for nuclear receptors such as the farnesoid X receptor (FXR), pregnane X 
receptor (PXR), and cell-surface G-protein coupled receptors (GPCRs),483 which have all been 
implicated in glucose and lipid homeostasis in humans484-486 . Stemming from this, BAs are now 
increasingly being identified as markers for hepatic disease states487, chronic inflammation488, 
and cancer489, 490, making them a desirable, measurable target for many fields of work. 
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Bile acids obtain their robust structural diversity from cholesterol catabolism and amino acid 
conjugation in the liver, as well as enzymatic transformations by bacteria found in the gut491. 
Additionally, bile acids can become charged and associate with alkali metal cations such as Na+ 
or K+ to form bile salts, which can act as electron acceptors in intestinal homeostasis.492 
Importantly, they lend themselves to cross-talk between the human (or host) and gut microbial 
metabolism493. While the overall bile acid pool may contain close to 150 unique species494, 
generally speaking this collection is composed of two primary BAs (cholic acid [CA] and 
chenodeoxycholic acid [CDCA] in humans, and CA and β-muricholic acid [BMCA] in rodents 
which are synthesized in hepatocytes, as well as 4 major secondary BAs (deoxycholic acid 
[DCA], lithocholic acid [LCA], ursodeoxycholic acid [UDCA], and hyocholic acid [HCA])495. These 
secondary bile acid species are produced through structural modifications of primary BAs in the 
small intestines and colon following interaction with present microbial populations. Various 
enzymes produced by these bacterial species have the capabilities to deconjugate, hydroxylate, 
dehydroxylate, and epimerize491, 496-498 both primary and secondary BAs altering their chemical 
properties and binding affinities, indicating microbial importance in host enterohepatic 
circulation. Moreover, each of the individual BAs has the potential to further become conjugated 
at their terminal acetyl junction with either glycine or taurine499, yielding an overall wide range of 
molecular variants. This provides an interesting analytical challenge for both sensitive and 
selective measurement of BAs.  
 
While this challenge has been attempted by numerous researchers over the past decade, many 
of the published analytical methods suffer various shortcomings based on specific measurement 
needs. Liquid chromatography tandem mass spectrometry (LC-MS) has been frequently utilized 
for the separation and concurrent detection of BAs in both human and animal biological 
samples. However, successful methods often contain a plethora of pitfalls – making application 
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of these techniques to broad research studies, both clinical and laboratory based, an arduous 
task. Involved and tedious sample preparation500, long analytical cycles500, 501, lack of complete 
chromatographic separation502, a requirement for expensive equipment or reagents494, 503-505, 
and negative ion selectivity494, 506, 507 seem to permeate the bulk of currently available BA 
measurement methods. It can be frustrating to attempt to successfully reproduce an analytical 
method with very narrow parameters. In fact, many clinical measurements of bile acids are 
accomplished through a blanket enzymatic assay that can only measure relative bile acid pool 
size508, 509 completely circumventing the potential for these compounds as biomarkers in many 
metabolic and non-metabolic studies alike. This was the driving motivation for the method 
development described herein.  
 
High performance liquid chromatography coupled with mass spectrometry (HPLC-MS) is the 
analytical foundation of this method, allowing for coverage of the diverse range of bile acid 
hydrophobicity510 as well as a multitude of isobaric species. Given the range in chemical 
structures, a one-size-fits all approach is not the optimal way to present a method, which is why 
various MS parameters, sample preparations and chromatographic options were tested and 
presented as viable and reproducible options. Facile biological sample preparation for both 
human and rodent plasma was combined with a medium throughput analytical cycle (45 min) 
with both positive and negative ion ESI mode detectability options. Utilization of reversed-
phased C18 separation via column chromatography provided excellent coverage of the main bile 
acid pool constituents, as well as 7-alpha-hydroxy-4-cholesten-3-one (C4) (a predictive and rate 
limiting marker for bile acid synthesis),511 while still  effectively separating isobaric conjugates 
and species. Multiple reaction monitoring mode was implemented to identify and track unique 
fragments of the BAs of interest, validating accurate measurement of 11 unique compounds in a 
lipid-rich biological matrix. Additionally, classically troublesome samples, such as pediatric, 
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disease state, and older (>10 years’ storage) plasma collections were successfully measured. 
We feel the HPLC-MS parameters and options presented within provide an excellent starting 
point for a wide array of research goals involving BAs, and hopefully present others with the 
ability to incorporate these important molecules in more and growing studies. 
 
Materials and Methods 
 
Chemical Materials 
All organic solvents used in biological sample preparation and mobile phases were prepared 
with LC-MS grade solvents and chemicals obtained from Sigma-Aldrich (St. Louis, MO). This 
included methanol, acetonitrile, formic acid, triethylamine, and ammonium acetate. Nine bile 
acid standards (cholic acid, taurocholic acid, glycocholic acid, chenodeoxycholic acid, 
taurochenodeoxycholic acid, deoxycholic acid, taurodeoxycholic acid, ursodeoxycholic acid, and 
lithocholic acid) were also purchased from Sigma-Aldrich (St. Louis, MO). One rodent-dominant 
bile acid (β-muricholic acid) was purchased from Cayman Chemical (Ann Arbor, MI). 
Additionally, one deuterated internal standard (chenodeoxycholic acid-2,2,4,4-d4 [CDCA-D4]), 
which was chosen due to its predominance in the human bile acid pool512 and shared molecular 
weight with two other unique BAs, and 7-alpha-hydroxy-4-cholesten-3-one, were also procured 
from Sigma-Aldrich (St. Louis, MO). The structures of all the BA species measured can be seen 
in Figure 6-2. 
 
Collection of Human Plasma 
Samples were collected from pediatric patients with autism spectrum disorder, pediatric and 
adult healthy controls for use in the bile acid profiling method application.  Blood was initially 
taken into Vacutainer blood collection tubes (Becton, Dickinson and Company, Franklin Lakes, 
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NJ) which were treated with 7-10 mg of K2EDTA to prevent erythrocyte clotting. Venous blood 
samples were stored immediately at 4oC until further processing could occur – within 1 week. All 
specimens were centrifuged at 2000xg, 4oC for 10 minutes in a Beckman Coulter Allegra 6R 
(Beckman Coulter, Indianapolis, IN) to separate red blood cells from what is deemed “blood 
plasma”. This resulting plasma sample was aliquoted into 500 µL fractions for long term storage 
at -80oC. The oldest of the plasma samples used in the following measurements dated back to 
1999, representing 18 years of -80oC storage with viable detection of bile acids, while the 
newest plasma sample was collected 1 week before LC-MS analysis, indicating a robust 
method application timeframe.  
 
Plasma Sample Preparation 
Prior to profiling analysis, samples were thawed at 4oC, and 100 µL aliquots were transferred 
to 1.5 mL Eppendorf microcentrifuge tubes (Eppendorf, Hauppauge, NY), spiked with the 
internal standard (CDCA-D4, in a final concentration of 5 pmol/µL [5 uM] (5 µL addition of 20 
pmol/µL in methanol). For a liquid-liquid based extraction, 300 µL of 100% methanol was 
added (1:3 v/v), before 1 min of high speed vortexting, followed by a 15-minute incubation at 
room temperature (RT). Following centrifugation (16,000xg, 5 min, RT) the resulting 
supernatant was transferred to a clean microcentrifuge tube. This supernatant was dried  
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down in a vacuum centrifuge (Savant 
SpeedVac Concentrator, ThermoFisher, 
Waltham, MA) for 2 hours, and the 
pellet was re-dissolved in 20 µL of 
60/40% MeOH/H2O. A final round of high speed vortexing for 30 seconds, accompanied by 
centrifugation (16,000xg, 5 min, RT), provided a clear supernatant which was transferred to 
300 µL polypropylene HPLC vials (American Chromatography Supplies, Vineland, NJ) for 
subsequent analytical examination. 
 
Compound R1 (α) 
R2 
(α) 
R3 
(β) 
R4 
(α) 
R5 
Figure 6-2. Structure variations and substitutions of the 11 bile acid species measured with 
their corresponding abbreviations. Tauro-conjugates have the amino acid taurine connected 
by the N terminus at the R5 position. Glyco-conjugates have glycine connected by the N 
terminus at the R5 position. Underneath the table is the structure of the 12th species 
evaluated, the bile acid synthesis precursor: 7-alpha-hydroxy-4-cholesten-3one. 
190 
 
 
HPLC-MS Analysis – Positive & Negative ESI Conditions 
Analysis was performed by an Agilent 1260 Infinity high performance liquid chromatograph 
(HPLC) (Agilent, Santa Clara, CA) coupled to an Agilent 6460 triple quadrupole mass 
spectrometer equipped with an electrospray ionization source operating in either the negative 
ion mode (ESI-) or the positive ion mode (ESI+) for targeted detection options. While the  
conditions described below produced the most sensitive and reliable BA detection results, 
additional chromatographic conditions were tested, and they are summarized in the Table 6- 
Cholic acid (CA) H OH H OH OH 
Chenodeoxycholic acid (CDCA) H OH H H OH 
Deoxycholic acid (DCA) H H H OH OH 
Lithocholic acid (LCA) H H H H OH 
Ursodeoxycholic acid (UDCA) H H OH H OH 
Taurocholic acid (TCA) H OH H OH NHCH2CH2SO3H 
Taurochenodeoxycholc acid 
(TCDCA) 
H OH H H NHCH2CH2SO3H 
Taurodeoxycholic acid (TDCA) H H H OH NHCH2CH2SO3H 
Glycocholic acid (GCA) H OH H OH NHCH2COOH 
Glycochenodeoxycholic acid 
(GCDCA) 
H OH H H NHCH2COOH 
β-Muricholic acid (BMCA) OH 
(R1β) 
H OH H OH 
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1. 
 
 
 
The chromatographic methods were reverse-phase in nature, utilizing a long alkyl chain 
stationary phase (C18) paired with differing mobile phase systems for each positive and 
negative ion modes to facilitate both dampening of adduct effects, elution of widely varying 
hydrophobicity levels, as well as separation of isobaric  
Ion Mode Column 
Mobile Phase 
A 
Mobile Phase 
B 
Gradient 
Length 
Separation 
of BAs 
Positive Kinetex C18 
1.7 uM, 150 
x 2.1 mm 
10 mM 
Ammonium 
Acetate in 
H2O 
100% MeOH 70 mins 9 out of 11 
Positive Luna Omega 
polar C18 
1.6 uM 100 x 
2.1 mm 
0.1% Formic 
Acid in H2O 
100% MeOH 60 mins 7 out of 11 
 Negative Kinetex C18 
2.6 uM, 150 
x 2.1 mm 
10 mM 
Ammonium 
Acetate in 
H2O 
100% MeOH 62 mins 6 out of 11 
Negative Hypercarb 
Porous 
Graphite 
Carbon 3 
uM, 100 x 1 
mm 
0.1% 
Triethylamine 
in water 
0.1% 
Triethylamine 
in ACN 
62 mins 9 out of 11 
Table 6-1. Compilation of four additional chromatographic conditions tested for bile 
acid detection sensitivity and separation. 
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BA species. For ESI+, a Cadenza CD-C18 column (3.0 µm, 250 x 2 mm, Imtakt, Portland, OR) 
was selected for use due to its high 
steric selectivity, as CDCA and UDCA only differ by an inversion at a single stereocenter. The 
column was heated (55oC) for the entire gradient program, allowing for consistent and reliable 
retention times as well as avoidance of lipid content buildup on the column matrix that might 
have been leftover in the samples from earlier plasma preparation.513 The aqueous mobile 
phase solvent A consisted of a volumetric preparation of 1 L of ultrapure water with 1 mL of neat 
formic acid (100/0.1 v/v). Organic mobile phase solvent B was comprised of a volumetric 
preparation of 1 L of acetonitrile with 1 mL of neat formic acid (100/0.1 v/v). 
The gradient separation is described in Table 17. The injection volume of prepared biological 
samples was 8 µL. To minimize injector carry-over, a complete gradient wash cycle with a 
strong solvent (methanol) was performed sporadically throughout sample analysis as 
“blanks”. 
 
Time 
(min) 
%A %B Flow 
Rate 
(µL/min) 
Pressure 
 0 99 1 200 400 
3.5 99 1 200 400 
38 0 100 250 400 
40 0 100 250 400 
42 99 1 250 400 
45 99 1 250 400 
Table 6-2. Positive Ion ESI 
HPLC gradient conditions. 
Solvent A consisted of 100% / 
0.1% ultrapure water to neat 
formic acid. Solvent B 
consisted of 100% / 0.1% 
acetonitrile to neat formic acid. 
Pressure represents maximum 
instrument threshold. The 
column utilized with this 
gradient was a Cadenza CD-
C18 reverse phase (3.0 µm, 
250 x 2 mm). 
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For ESI-, a Kinetex EVO C18 column 
(1.7 µm, 150 x 2.1 mm) 
(Phenomenex, Torrance, CA) was selected for use for base stable capabilities along with 
high selectivity due to small particle size. The column was again heated to a constant 
temperature of 55oC for the entire duration of the chromatographic run. The aqueous mobile 
phase solvent A consisted of a volumetric preparation of 1 L of ultrapure water with 1 mL of 
triethylamine (TEA) (100/0.1 v/v) as a higher pH was observed to improve chromatographic 
separation of isobaric BA species. The organic mobile phase solvent B was prepared as a 
volumetric solution of 500 mL of ultrapure water, 375 mL of acetonitrile with 125 mL of 
methanol and an addition of 1 mL of TEA (50/37.5/12.5/0.1 v/v/v/v). The gradient separation 
is detailed in Table 6-3. The injection volume of patient samples was 8 µL. To minimize 
injector needle contamination, a complete wash cycle with a high polarity solvent (methanol) 
was performed occasionally throughout sample analysis as “blanks”. 
Time 
(min) 
%A %B Flow 
Rate 
(µL/min) 
Pressure 
0 99 1 70 400 
2 99 1 70 400 
7 50 50 70 400 
11 25 75 70 400 
32 0 100 70 400 
35 0 100 70 400 
37 99 1 70 400 
45 99 1 70 400 
Table 6-3. Negative Ion ESI HPLC 
gradient conditions. Solvent A 
consisted of 100% / 0.1% ultrapure 
water to triethylamine. Solvent B 
consisted of 
50%/37.5%/12.5%/0.1% water to 
acetonitrile to methanol to 
triethylamine. Pressure represents 
maximum instrument threshold. The 
column utilized with this gradient 
was a Kinetex EVO C18 reverse 
phase column (1.7 µm, 150 x 2.1 
mm), requiring a decreased flow 
rate. 
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MS/MS Conditions & Optimization 
As mentioned above, the highest sensitivity results were obtained with an Agilent 6460 series 
triple quadrupole mass spectrometer (QQQ). However, both positive and negative ESI 
methods were replicated and confirmed on an LCQ DecaXP Plus mass spectrometer 
(ThermoFisher, Waltham, MA). Mass spectrometry parameters for the QQQ were as follows: 
capillary voltage was set to 4000 V, gas flow was adjusted to 8 L/min, the gas temperature 
was 300 oC, the nebulizer pressure was set at 15 psi, and the delta electron multiplier voltage 
(EMV) was set to +200/-0 for ESI+ and +0/-200 for ESI-. All the 12 BA species in this 
assessment yielded characteristic fragments when subjected to collision-induced dissociation 
and were therefore assayed using multiple reaction monitoring (MRM). The noted transitions 
for each of the 12 standards and 1 deuterated internal standard are provided in Table 6-4 
(ESI+) and Table 4 (ESI-).  Source parameters of fragmentor voltage and collision energy 
were optimized for each bile acid transition by direct flow injection at the HPLC flow rate and 
appropriate solvent composition (HPLC MS/MS conditions listed above). These optimizations 
were automatically performed using Agilent MassHunter Optimization software, and tested in 
duplicate before finalizing the values, and are also included in Table 6-5 & 6-6.  
Method Validation 
The finalized method presented above was further tested according to certain parameters set 
forth by the FDA for bioanalytical method validation.514 Linearity was evaluated over a 
concentration range of 20 pM to 2 mM with a 5-point calibration curve. Samples designated 
as quality controls were prepared for each of the 12 species in MeOH/H2O (60/40 v/v) and 
utilized for both linearity assessment and matrix effect testing; QC1 (2mM) QC2 (200nM) 
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QC3 (20nM) and QC4 (2nM) QC5 (200pM). The limit of detection (LOD) was determined with 
a signal-to-noise (S/N) ratio greater than 3. Additionally, the lower limit of quantification 
(LLOQ) was determined with a S/N ratio greater than 5. Evaluation of the matrix effect from 
plasma biological fluids allowed for an assessment of reliability and selectivity of the 
proposed HPLC MS/MS method. This was accomplished by comparing the integrated peak 
area of the deuterated standard (CDCA-D4) in both spiked solvent (60% methanol) and in 
spiked plasma samples of fixed volumes. Potential for injector or column carry-over was 
tested by direct comparison of blank solvent samples versus QC1 and QC5.  
Compound Molecular 
Weight 
(g/mol) 
Monitoring 
Species 
Precursor 
Ion 
Product 
Ion 
Fragmentor 
(V) 
Collision 
Energy 
(V) 
TCA 515.7 (M+H)-H2O 498 462 75 12 
TCDCA 499.7 (M+H)-
2H2O 
464 125 125 44 
TDCA 499.7 (M+H) 500 464 105 8 
GCA 465.6 (M+H) 466 412 95 12 
GCDCA 449.6 (M+H)-
2H2O 
432 414 100 15 
CA 408.6 (M+H)-
2H2O 
373 355 95 12 
CDCA 392.6 (M+H)-
2H2O 
357 357 90 0 
DCA 392.6 (M+H)-
2H2O 
357 357 90 0 
LCA 376.6 (M+H)-H2O 359 177 75 16 
UDCA 392.6 (M+H)-
2H2O 
357 357 90 0 
BMCA 408.6 (M+H)+17 426 355 100 10 
C4 400.7 (M+H) 401 177 135 20 
CDCA-D4 396.6 (M+H)-
2H2O 
361 261 132 23 
Table 6-4. Positive Ion MRM transition monitoring species, product ions, and instrument 
source parameters. Bile acid acronyms can be found in Appendix 1. The majority of (M+H) 
ions were undetectable, or existed only at minimal levels, and dominating charged species 
consistently experience the loss of 1 or 2 water molecules. 
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Percent error of accuracy and precision of the described method were analyzed by 
measuring QC1, QC3, and QC5 on 3 intra-day (analyzed on the same day) replicates as well 
as an inter-day (measured on 3 separate days) replicate. Finally, the recovery of the 
deuterated standard (CDCA-D4) was evaluated. Control plasma was spiked with CDCA-D4 
before sample preparation, and additionally in a sample after preparation was complete. 
Recovery was calculated as: area under the peak of the pre-spiked sample divided by the 
area under the peak of the post-spiked sample. This was repeated in 3 replicates of fixed 
volume and concentration. 
 
Data Processing and Statistical Analysis 
Compound Molecular 
Weight 
(g/mol) 
Monitoring 
Species 
Precursor 
Ion 
Product 
Ion 
Fragmentor 
(V) 
Collision 
Energy 
(V) 
TCA 515.7 (M-H) 514 80 270 75 
TCDCA 499.7 (M-H) 498 80 280 80 
TDCA 499.7 (M-H) 498 80 270 70 
GCA 465.6 (M-H) 464 74 220 45 
GCDCA 449.6 (M-H) 448 74 200 45 
CA 408.6 (M-H) 407 289 290 40 
CDCA 392.6 (M-H) 391 391 240 0 
DCA 392.6 (M-H) 391 391 240 0 
LCA 376.6 (M-H) 375 369 190 11 
UDCA 392.6 (M-H) 391 391 240 0 
BMCA 408.6 (M-H)+46 452 406 110 5 
C4 400.7 (M-H) 399 177 155 18 
CDCA-D4 396.6 (M-H)+46 441 359 142 35 
Table 6-5. Negative Ion MRM transition monitoring species, product ions, and instrument 
source parameters. Bile acid acronyms can be found in Appendix 1. βMCA was 
undetectable in negative ESI. Product ions for glycine and taurine conjugates are classic 
fragments of these charged amino acids and consistent across species. 
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Raw data files were interpreted using MassHunter qualitative analysis software (Agilent). 
Integration of bile acid chromatographic peaks was accomplished both by automatic 
integration as well as manual integration in the case of the more difficult to detec t BA signals 
(LCA, GCA). 
In order to determine bile acid concentration in patient and control plasma samples, a 
standard curve of the previously measured QC samples was included with each sample 
batch, also eliminating the majority of errors that may occur due to batch effects. As the 
concentrations of each QC sample is known, linear regression was utilized to determine 
unknown sample concentrations by graphing integrative peak area vs. sample concentration. 
An example of the linear standard curve for all BAs can be seen in Figure 6-3. Dilution 
factors were taken into account to arrive at the final concentration of each BA in plasma.  
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Figure 6-3 
A. A representative BA calibration 
curve in positive mode detection; 
graph shows chenodeoxycholic acid 
(CDCA) which is the most dominant 
primary BA in humans. Six points in 
the lower range were examined, 0 nM, 
2 nM (0.785 ng/mL), 20 nM (7.85 
ng/mL), 80 nM (31.4 ng/mL), 120 nM 
(47.1 ng/mL), and 160 nM (62.8 
ng/mL). This curve was created for all 
12 species measured in the method 
and utilized for calculations of LOD 
and LLOQ. Linearity was high, with an 
R2 of 0.99. The standard curves were 
utilized in final concentration 
calculations of human samples. 
 
B. A representative BA calibration 
curve in positive mode detection; 
graph shows chenodeoxycholic acid 
(CDCA) which is the most dominant 
primary BA in humans. Eight points 
over a large range were examined, 0 
nM, 2 nM (0.785 ng/mL), 20 nM (7.85 
ng/mL), 80 nM (31.4 ng/mL), 120 nM 
(47.1 ng/mL), 160 nM (62.8 ng/mL), 
200 nM (78.5 ng/mL), and 2 uM (785 
ng/mL). This was also generated for 
all 12 BA species, to confirm accuracy 
and precision at higher 
concentrations, and that the ULOQ 
was not passed. 
 
C. A representative BA calibration 
curve in negative mode detection; 
graph shows chenodeoxycholic acid 
(CDCA) which is the most dominant 
primary BA in humans. Five points 
over a large range were examined, 0 
nM, 2 nM (0.785 ng/mL), 20 nM (7.85 
ng/mL, 200 nM (78.5 ng/mL), and 2 
uM (785 ng/mL). This was also 
generated for all 12 BA species, and 
higher concentrations were more 
accurate in the negative ion mode. 
Linearity was high at an R2 of 0.99, 
similar to that of ESI+.  
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Results and Discussion 
Chromatographic Optimization and Application 
In order to produce and maintain adequate chromatographic separation and overall peak shape 
for all BA species in positive ion detection mode, it was necessary to lower the pH of the mobile 
phases. Both 10 mM ammonium acetate and ~24 mM formic acid (or 0.1% v/v) solutions were 
tested in aqueous (water) and organic (acetonitrile or methanol) with the presented MRM 
method. While both were sufficient to achieve sharp peaks and stable retention times, it was 
found that the presence of ammonium acetate caused both predominant ammonium adducts in 
electrospray as well as bile salt build up in the column due to the high percentage of organic 
phase needed to move the compounds off. Formic acid addition did not produce formate 
adducts while still lowering the pH of both mobile phases to between 2-4 and positively 
impacted the sensitivity of the assay. These findings correlating pH and BA retention are 
consistent with previously published work.494, 515, 516  
  
In contrast, we found it was necessary to increase the pH during negative ion detection of BA 
species. This was mainly due to the fact that utilizing ammonium acetate or formic acid in a 
buffer would tend to protonate one of the various hydroxyl sites on the unconjugated bile acids 
and allow for easier coupling with acetate and formate adducts while hindering the ability to 
ionize the steroidal backbone efficiently. We found through the addition of 0.1% triethylamine 
(TEA) in both mobile phases, the pH increased sufficiently to allow for proper ion formation and 
unique fragmentation. This constituent also allowed for a greater magnitude of sensitivity as well 
as improved resolution for the isobaric BA species. This effect also has been reported in 
previous literature describing superior BA separation methods with high-pH anion exchange 
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chromatography.517 Partial addition of the stronger eluent methanol in the acetonitrile organic 
phase also helped to prevent bile salt formation in the column and machine.  
The sensitivity of both systems was found to be sufficient for the detection of selected BA 
species in normal human and rodent plasma despite a large concentration range in biological 
fluids. Although the majority of the bile acids observed in both healthy controls and disease 
sample analysis can be distinguished by the targeted method below, there are a multitude of 
both unidentified as well as additional secondary and tertiary species that could potentially 
act as differential markers of certain diseases. This warrants further translational exploration.  
Targeted MS/MS Analysis of 12 Bile Acid Species with Positive ESI 
Overall, 11 unique bile acid species and one bile acid precursor were targeted in a single 
HPLC-MS/MS method operating in the positive ion mode of detection. Utilization of the above 
optimized chromatographic conditions for ESI+ allowed for detection of all compounds in 
biological samples with a high 
level of separation. While 
MRM was implemented due to increased sensitivity and 
unique fragmentation options, chromatography and the 
Figure 6-4. Extracted ion 
chromatogram (EIC) of the 10 
human specific bile acids and 
their precursor (7α-H4C3 or 
C4) measured in one mixture, 
separated by the described 
HPLC method and positive 
ESI. All species give unique 
retention times with 
quantitative peaks, including 
isobaric compounds, during a 
45-minute gradient. As the 
column utilized is C18 reverse 
phased based, it can be 
concluded that 7α-H4C3 is the 
strongest retainer and most 
likely displays the highest non-
polar character. 
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length of the method alone was sufficient to separate even isobaric BA species. (Figure 6-4) 
Due to conjugation with either taurine or glycine which significantly alters the thermodynamic 
properties of a BA, we observed a decreased retention time for these species across the board, 
allowing for a facile distinction between conjugated and unconjugated variants. It is worth noting 
that although conjugated BA species do not comprise the majority of bile that is reabsorbed 
through the portal vein due to bile salt hydrolase activity in the ileum518, the amino acid addition 
has been shown to change the physiological activity of these molecules519 and is relevant in 
clinical applications. 
Combining superior LC separation with optimized MRM transitions offered significant 
sensitivity for the bile acids examined. Coupling this with consistent reproducibility allows us 
to confidently report positive-ion monitoring as a feasible approach for biological analysis of 
these compounds. 
 
Targeted MS/MS Analysis of 12 Bile Acid Species with Negative ESI 
Additionally, the same 11 BA species and BA precursor were targeted in a single HPLC-
MS/MS method operating in the negative ion mode of detection. As described above, 
differing chromatographic conditions were used for ESI- and adequately allowed for detection 
of all compounds in biological matrixes (specifically EDTA treated blood plasma). Alternating 
the variant of C18 particle column used in this polarity allowed for complete LC separation of 
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these molecules and produced unique retention times to that of positive ion detection (Figure 
6-5). MRM ions, fragmentations, and parameters for this method are listed in Table 6-5. 
 
Comparison of Positive Ion vs. Negative Ion MS Detection 
It is worth discussing the main differences between ESI+ and ESI- detection of bile acids, as 
both methods were sufficient for identification and quantification of all targeted species. The 
multitude of univariate mass spectrometry methods for the detection of bile acids was 
previously discussed in the introduction, and we are unaware of a report that discusses both 
applicable methods for immediate use in research endeavors. 
The most notable variance between positive and negative modes of detection is the bile acid 
ions and adducts that are formed and subsequently monitored. Comparing Figures, one can 
clearly see that the predominant fragment species in each mode are quite unique, and differ 
from the classically observed (M+H) and (M-H) peaks. While no significant difference in 
Figure 6-5. Extracted ion 
chromatogram (EIC) of 10 bile 
acids measured in one mixture, 
separated by the described HPLC 
method and negative ESI. All 
species give unique retention times 
with quantitative peaks, including 
isobaric compounds, during a 45-
minute gradient. As the column 
utilized is C18 reverse phased 
based, it can be concluded that β-
MCA (a rodent dominant BA) is the 
most polar bile acid measured, 
likely due to its unique 
stereochemistry at C-6. It can be 
seen that negative ESI detection 
produced slightly broader peaks 
than ESI+ with less defined 
retention times but is still suitable 
for sensitive measurement. 
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sensitivity based on peak integration was seen between these differing transition fragments, 
ESI+ tended to produce more robust signals and lower detectable ranges for all BA species; 
ESI- excelled at detecting toxic secondary bile acid species (i.e. LCA and DCA) that are not 
as dominant in peripheral blood. 
 
We were able to confidently confirm that BAs are susceptible to changes in pH, altering the 
ionization and detection patterns based on mobile phase selection. There are significant 
differences in this application for either ESI+ or ESI-. Greatest sensitivity was achieved with 
lower pH (acidic spiked) mobile phases in positive detection MS, while the opposite was true 
for negative detection, and a higher than neutral pH produced improved resolution. These 
differences can partially be explained by the steroidal backbone of the examined species, 
where hydroxyl substitutions greatly vary both the lipophilicity and hydrophilicty of BAs. This 
variation is ideal for specific method development that may include media or additional 
species that thrive in a particular pH, allowing for complete optimization.  
Method Validation 
To ensure the maximum signal detection for each bile acid species measured, optimization of 
MRM ion transitions was completed with Agilent MassHunter software. It was found that 
although isobaric variants CDCA, DCA, and UDCA produced unique fragments, a higher 
sensitivity was achieved when monitoring a loss of the same two water fragments with no 
collision energy, where separation was achieved through chromatography and retention time 
verification. Similar methodology was also used for internal standard (IS) monitoring, as it 
was a deuterated form of CDCA. This ensured specific and reproducible results across both 
method applications. According to FDA guidelines, the HPLC-MS/MS method was validated 
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for accuracy and precision on intra- and inter-day injections, as well as linearity in both 
detection ion modes. 
In positive ESI, the limit of detection (LOD) for the 12 compounds detected ranged between 
1.9-3.1 ng/mL for primary BAs (CA,CDCA), 3.6-11.6 ng/mL for secondary BAs 
(DCA,LCA,UDCA,BMCA), 0.73-5.6 ng/mL for conjugated BAs 
(GCA,GCDCA,TCA,TCDCA,TDCA) and was 15.4 ng/mL for C4,final concentration. ; in 
negative ESI the LOD’s ranged between 22.4-27.4 ng/mL for primary BAs,17.6-27.3 ng/mL 
for secondary, 12.3-24.0 ng/mL for conjugated BAs and was 26.8 ng/mL for C4. Linearity was 
explored over a broad range of concentrations as discussed above; 20 pM to 2 uM, due to 
the fact that there are various concentrations of BA present in bile, blood, urine, and feces, 
and although molarity concentrations can be utilized for reporting standard measurements, 
we found that individual BAs were better represented in final data using ng/mL, particularly 
for clinical applications. Tables 6-6 and 6-7 show the accuracy and precision of both intra- 
and inter-day measurements of the 11 BAs and 1 precursor targeted. As the limit of detection 
in measurement was approached, there was a marked decrease in accuracy for all species. 
However, negative ESI was superior in combating this variance, and further exploration of 
this effect would be warranted. While the range of extraction recovery of all analytes was 
averaged out to be 70.1%, the lowest percentage contributors are due to the more toxic, 
secondary BA species (particularly LCA) as the human body is efficient in removing these 
from the bloodstream before reabsorption and can experience stronger matrix effects.  520 
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Sample (+) Spiked (ng/mL) 
Measured 
(mean ± SD) 
Accuracy (%) 
Precision 
(RSD%) 
CA 
Intra-day 
8.17 10.8±0.7 112.9 6.9 
81.7 78.8±0.6 96.5 0.8 
817 817.3±5.9 100.0 0.7 
Inter-day 
8.17 14.0±2.1 171.0 15.4 
81.7 75.3±2.1 92.2 2.8 
817 817.6±0.2 100.1 0.0 
CDCA 
Intra-day 
7.85 11.6±2.1 117.7 18.4 
78.5 74.3±0.7 94.7 0.9 
785 785.4±21.2 100.0 2.7 
Inter-day 
7.85 13.1±1.7 167.0 12.8 
78.5 72.7±2.2 92.6 3.0 
785 785.5±13.3 100.1 1.7 
DCA 
Intra-day 
7.85 8.2±5.0 103.9 61 
78.5 78.2±1.2 99.6 1.5 
785 785.0±6.9 100.0 0.9 
Inter-day 
7.85 12.8±4.6 163.3 36.0 
78.5 73.0±4.5 93.0 6.2 
785 785.5±6.4 100.1 0.8 
LCA 
Intra-day 
7.53 5.7±0.0 76.1 0.0 
75.3 77.3±5.6 102.6 7.3 
753 752.8±5.4 100.0 0.7 
Inter-day 
7.53 13.4±5.4 178.1 40.4 
75.3 68.8±8.3 91.4 12.1 
753 753.6±4.7 100.1 0.6 
UDCA 
Table 6-6. Intra-day (same day in triplicate, n=3) and inter-day (3 separate days in triplicate, n=9) measured 
means (±standard deviation), accuracy, and precision for each of the 12 BA species measured in positive ion 
mode. The spiked concentrations are shown in ng/mL and vary based on the molecular weight of the compound, 
as original QC samples were prepared in molarities; 20 nM, 200 nM, 20 uM are the respective concentrations. 
Ng/mL concentrations were calculated using the calibration curve. Precision >35% for inter-day measurements 
is ideal, indicating acceptable machine variability and robust method application. It is worth noting that overall, 
samples closer to the LOD (20nM set) had lower accuracies across the board. This could be improved by fine 
tuning methods at lower concentrations. Both TCDCA and C4 were not detectable at the 20 nM concentration 
during this experiment, as this fell close to if not below the LOD. ESI+ provided the greater sensitivity and 
precision. 
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Intra-day 
7.85 9.4±0.3 120.0 3.2 
78.5 76.1±0.6 96.9 3.4 
785 785.2±10.2 100.0 12.7 
Inter-day 
7.85 12.7±3.5 162.3 27.8 
78.5 73.1±3.9 93.1 5.3 
785 785.5±6.9 100.1 0.9 
TCA 
Intra-day 
10.3 17.3±0.2 168.0 4.5 
103 95.3±2.5 92.5 2.6 
1030 1030.7±20.6 100.1 2.9 
Inter-day 
10.3 - - - 
103 93.6±3.6 90.9 3.9 
1030 1030.9±13.2 100.1 1.3 
TCDCA 
Intra-day 
9.97 - - - 
99.7 96.4±3.3 96.9 3.4 
997 997.3±127.0 100.0 12.7 
Inter-day 
9.97 12.0±8.6 120.0 71.7 
99.7 97.5±11.4 97.8 11.7 
997 997.2±72.6 100.0 7.3 
TDCA 
Intra-day 
9.97 11.8±0.7 118.5 6.0 
99.7 96.7±3.9 97.0 4.0 
997 997.2±6.1 100.0 0.6 
Inter-day 
9.97 14.4±2.7 144.3 18.5 
99.7 94.8±3.8 95.1 4.0 
997 997.4±19.0 100.0 1.9 
GCA 
Intra-day 
9.31 11.2±0.5 120.6 4.3 
93.1 89.9±0.6 96.6 0.7 
931 931.2 100.0 0.5 
Inter-day 
9.31 13.0±1.6 140.1 11.9 
93.1 89.0±1.4 95.6 1.6 
931 931.4± 100.0 1.3 
GCDCA 
Intra-day 
8.99 11.0±0.3 122.4 2.9 
89.9 86.6±0.6 96.3 0.7 
899 899.2±6.7 100.0 0.7 
Inter-day 
8.99 11.6±0.8 129.0 6.8 
89.9 87.0±0.6 96.8 0.7 
899 899.3±9.9 100.0 1.1 
BMCA 
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Intra-day 
8.17 9.8±0.7 119.4 7.4 
81.7 84.0±2.1 102.8 16.3 
817 817.2±7.0 100.0 0.9 
Inter-day 
8.17 10.2±3.0 125.1 29.8 
81.7 79.4±3.8 97.2 4.8 
817 817.2±5.9 100.0 0.7 
C4 
Intra-day 
8.01 - - - 
80.1 76.2±10.4 95.2 13.7 
801 803.2±47.3 100.3 5.9 
Inter-day 
8.01 - - - 
80.1 66.9±15.7 83.6 15.7 
801 802.2±52.2 100.1 6.5 
 
Sample (-) Spiked (ng/mL) 
Measured 
(mean ± SD) 
Accuracy (%) 
Precision 
(RSD%) 
CA 
Intra-day 
8.17 8.8±0.1 108.1 0.8 
81.7 81.0±5.1 99.1 6.3 
817 817.1±6.5 100.0 0.8 
Inter-day 
8.17 5.0±1.5 61.1 30.6 
81.7 85.2±5.9 104.3 7.0 
817 816.7±5.0 100.0 0.6 
CDCA 
Intra-day 
7.85 12.0±1.9 125.7 16.2 
78.5 73.9±1.7 94.2 2.3 
785 785.4±3.6 100.1 0.5 
Table 6-7. Intra-day (same day in triplicate, n=3) and inter-day (3 separate days in triplicate, n=9) measured 
means (±standard deviation), accuracy, and precision for each of the 12 BA species measured in negative ion 
mode. The spiked concentrations are shown in ng/mL and vary based on the molecular weight of the compound, 
as original QC samples were prepared in molarities; 20 nM, 200 nM, 20 uM are the respective concentrations. 
Ng/mL concentrations were calculated using the calibration curve. Precision >35% for inter-day measurements 
is ideal, indicating acceptable machine variability and robust method application. It is worth noting that overall, 
samples closer to the LOD (20nM set) had lower accuracies across the board. This could be improved by fine 
tuning methods at lower concentrations. Both TCDCA and TDCA were not seen at the lowest concentration 
(20nM). However, C4 still had stable measurements in this range, showing that negative ESI is preferable to 
measure this bile acid precursor, likely due to its unique chemical structure that differs from the typical steroid 
backbone of the other 11 bile acids. ESI- had slightly lower inter-day precision than ESI+ overall. 
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Inter-day 
7.85 9.7±6.4 124.2 65.4 
78.5 76.4±14.3 97.3 18.7 
785 785.2±38.4 100.0 4.9 
DCA 
Intra-day 
7.85 11.3±4.4 143.8 38.6 
78.5 74.7±0.2 95.2 0.2 
785 785.3±18.6 100.0 2.4 
Inter-day 
7.85 8.5±6.8 108.3 79.4 
78.5 77.8±14.6 99.1 18.7 
785 785.1±46.7 100.0 5.9 
LCA 
Intra-day 
7.53 13.3±3.9 134.0 29.0 
75.3 68.9±4.6 91.5 6.7 
753 753.6±2.4 100.1 0.3 
Inter-day 
7.53 8.9±4.2 117.5 47.5 
75.3 73.8±5.1 98.1 6.9 
753 753.1±2.4 100.0 0.3 
UDCA 
Intra-day 
7.85 11.3±1.6 89.3 14.0 
78.5 74.7±3.1 95.2 4.2 
785 785.3±8.7 100.0 1.1 
Inter-day 
7.85 8.3±3.0 106.3 35.9 
78.5 78.0±13.5 99.3 17.3 
785 785.0±7.6 100.0 1.0 
TCA 
Intra-day 
10.3 18.7±0.5 143.9 2.4 
103 123.5±8.1 95.0 6.6 
1030 1030.7±12.3 100.1 1.2 
Inter-day 
10.3 22.5±4.4 173.4 19.4 
103 119.2±9.0 91.7 7.6 
1030 1031.2±8.5 100.1 0.8 
TCDCA 
Intra-day 
9.97 10.7±1.0 107.0 9.7 
99.7 99.2±4.5 99.2 4.5 
997 1000.1±13.7 100.0 1.4 
Inter-day 
9.97 - - - 
99.7 110.4±4.3 110.4 3.9 
997 999.1±19.8 99.9 2.0 
TDCA 
Intra-day 
9.97 10.8±0.7 108.0 6.5 
99.7 98.8±9.6 99.1 9.8 
997 997.1±18.5 100.0 1.9 
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Finally, to confirm the scientific application of this analytical method, plasma samples from a 
pediatric autistic population (n=14) that had been taking the antipsychotic medication 
Risperidone (RSP) 521  were processed and measured according to the ESI+ parameters 
described above. These samples represent a unique challenge for method validation, as 
many of them were over 15 years old at the time of measurement, having been stored long 
Inter-day 
9.97 - - - 
99.7 112.0±8.0 112.3 7.1 
997 995.9±18.1 99.9 1.8 
GCA 
Intra-day 
9.31 8.2±1.5 88.5 18.3 
93.1 94.3±5.8 101.3 6.2 
931 930.9±4.2 100.0 0.5 
Inter-day 
9.31 5.7±2.9 61.8 50.6 
93.1 97.0±5.7 104.2 5.9 
931 930.6±9.8 100.0 1.1 
GCDCA 
Intra-day 
8.99 9.7±0.3 108.2 2.7 
89.9 89.1±5.3 99.1 6.0 
899 899.1±7.2 100.0 0.8 
Inter-day 
8.99 6.7±2.6 74.6 38.7 
89.9 92.4±4.6 102.8 5.0 
899 898.8±7.9 100.0 0.9 
BMCA 
Intra-day 
8.17 10.0±0.5 117.6 5.4 
81.7 79.6±0.5 97.5 0.7 
817 817.2±8.8 100.0 1.1 
Inter-day 
8.17 7.4±2.3 90.2 30.6 
81.7 82.6±2.1 101.1 2.5 
817 816.9±6.5 100.0 0.8 
C4 
Intra-day 
8.01 8.5±0.1 108.1 0.8 
80.1 77.8±5.0 99.1 6.3 
801 785.1±6.3 100.0 0.8 
Inter-day 
8.01 10.7±4.8 136.7 44.9 
80.1 75.3±24.8 96.0 32.9 
801 785.3±9.5 100.0 1.2 
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term at -80°C. It is also important to quantitate BAs in child populations such as these, as 
current data is limited, but has the potential to represent critical clinical indications early in 
life. The children in the study underwent an 8-week time course of RSP, at which point their 
final fasting BA concentrations were measured. The average concentrations of the 5 main 
bile acids that exist in plasma can be seen in Table 6-8. Interestingly, overall significant 
changes were observed in BA concentrations before and after taking this medication. This 
alone demonstrates the clinical importance of better understanding enterohepatic circulation 
patterns and contributors through targeted analytical methods.  
 
n = 28, Following Treatment 
All values in ng/mL 
Bile Acid Average Median Min Max 
CA 16.81 13.5 1.86 51.09 
CDCA 25.91 18.23 5.04 65.22 
DCA 39.94 35.6 6.99 78.79 
UDCA 42.92 18.79 6.2 150.52 
TCA 8.81 4.62 1.35 47.02 
 
Table 6-8. Fasting plasma BA concentrations of pediatric patients (aged 4-17 years old) 
following 8 weeks of risperidone pharmaceutical treatment, displaying the average, median, 
minimum, and maximum concentrations for each of the 5 main BA species occurring in 
humans as a test for method application. Values are represented in ng/mL, and sample 
preparation allowed for detection below the limit of quantitation from liquid concentration 
before injection. 
 
211 
 
Conclusion 
Increasing awareness and importance of bile acids as signaling molecules in both basic and 
translational research spurs a need for reliable and facile quantitative methods. BA diversity 
and challenging chemical properties make fit-for-purpose mass spectrometry the most 
straightforward approach to many related quantitative and qualitative measurements. 
Targeted detection through reversed-phase HPLC coupled with MS allows for sensitive and 
reliable determination of unconjugated, glycine, and taurine conjugated BAs in human and 
rodent plasma fluids in either positive or negative ion modes. 
 
Measurement of these species, along with the indicative precursor 7a-hydroxycholest-4-en-3-
one can generate detailed profiles that have the potential to be vital components of clinical 
testing for disease states including metabolic syndrome, inflammation, psychiatric disorders, 
and liver problems. We believe having a wide array of equipment and procedural choices 
when developing a targeted bile acid MS/MS detection workflow will be invaluable for 
translational and clinical research alike. It is the hope that this understudied field of BAs and 
their related biological and pathological mechanisms will become more accessible to many 
laboratories. 
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MxH Case Study #1: A Putative Development Pathway; Microbiome – Bile Acid Cross 
Talk in the Biological Mechanism of Psychotropic-Induced Weight Gain* 
*This work is currently unpublished. 
Lauren Seaman, Chadi Calarge, Kym Faull, Jude McElroy, Gerhard Helleman, James 
McCracken, Erika Nurmi 
 
Introduction 
Antipsychotic (AP) medications are critical for the stabilization of psychotic, mood, and 
behavioral disorders.522 APs are prescribed to 1-2% of adults (~7M)523 and 0.8-1.2% of youth 
(~1M).524, 525 Prescribing rates have been steadily rising for decades (increasing 750% in the 
first decade of the millennium),526 and is greatest in the demographic groups most vulnerable to 
adverse effects—the underprivileged, elderly and very young.527-530 While effective, 
antipsychotics carry serious risks—most commonly, weight gain and cardiometabolic 
abnormalities, which affect up to 60% of patients531 and present a major obstacle to long-term 
treatment.532-534 An increased susceptibility to and magnitude of AIWG has been repeatedly 
documented in children.533, 535, 536 Within a period of only 11 weeks, youth starting risperidone 
(RSP) may gain up to 3 kg. Associated abnormalities such as central obesity, insulin resistance, 
dyslipidemia, and systemic inflammation537-539 reach sufficient magnitude in childhood to trigger 
and accelerate atherosclerosis.537, 539-543 Cardiovascular disease accounts for the largest 
proportion of premature deaths in the severely mentally ill, whose life expectancy is dwarfed by 
213 
 
that of the general population by as much as 20 years—a gap that has increased over recent 
decades, paralleling antipsychotic prescribing.544, 545 
 
Little is known about the mechanism of AIWG and its subsequent influence on metabolic 
syndrome (MS). Differential risk across the drug class is not explained by simple receptor 
binding profiles at contributing sites such as the muscarinic system, but other mechanistic 
links are lacking. A few supported risk genes explain only a small percentage of the risk.62, 546, 
547 Novel, testable hypotheses are sorely needed that examine how these APs and other 
similar psychotropic medications interact with our underlying biology. We asked ourselves 
where a logical place to begin the search for fundamental links to AIWG might be and began 
to uncover relevant research in opposite situations – bariatric surgery patients who were 
losing significant amounts of weight.  
While it has long been suggested that the various benefits of bariatric surgery are simply a 
result of mechanical restriction of the stomach and malabsorption of nutrients caused by 
intestinal changes, contemporary studies are beginning to uncover more contributing factors. 
Based on alterations in the flow and anatomic routing of ingested nutrients following surgery, 
hypotheses have emerged implicating bile acids as key molecules in this avenue of weight-
loss.548 Classically viewed as the simple “dish-detergent” molecules of the digestive system, 
bile acids (BAs) are quickly gaining recognition as critical metabolic signaling compounds, 
hormone regulators, and disease state clinical biomarkers. BAs are the major component of 
bile and are synthesized from cholesterol through a hepatic cytochrome p450 7A1 (CYP7A1) -
mediated enzymatic pathway.479 They are powerful dietary lipid emulsifiers, allowing for 
solubilization and subsequent digestion of fats and oils through a mixed-micellular surfactant 
process.480 
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BAs have been found to regulate lipid, glucose and cellular energy homeostasis by acting as 
signaling molecules at nuclear hormone receptors in the liver and intestines known as 
farnesoid X (FXR).549 Systemic levels of BAs are significantly elevated in patients following 
both major bariatric procedures, Roux-en-Y gastric bypass and sleeve gastrectomy, 
suggesting a critical role for these molecules in the mechanism of weight regulation. 
Interestingly, in a study of human BA profiles, total plasma BA concentrations were higher in 
both obese and diabetic subjects than in healthy controls550, indicating there are complex 
interactions between the host and these regulatory compounds that can change how they 
affect metabolic states. This can potentially be delineated by the differing agonist and 
antagonist properties of various primary and secondary BAs at FXR. Primary (1o) BAs (cholic 
acid [CA] and chenodeoxycholic acid [CDCA]) are potent agonists for FXR, while the 
secondary (2o) BA ursodeoxycholic acid (UDCA) is an FXR antagonist.   
As the binding potential for BAs changes in accordance to their relative lipophilicity and 
hydrophilicity, this study aims to measure the concentrations of a set of primary and 
secondary BAs in a specific population that has undergone treatment with an antipsychotic 
medication utilizing high performance liquid chromatograph tandem mass spectrometry 
(HPLC-MS), and test whether or not the relative makeup of a person’s bile acid pool can 
provide us with significant biological clues to explain how weight-gain following treatment 
occurs on a molecular level. A better understanding of this complex mechanism will provide 
the foundation for targeted treatment and drug development strategies for pharmaceutical-
induced and, potentially, other-cause weight gain and metabolic dysfunction. 
 
Materials and Methods 
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Collection of Human Plasma & Vital Metrics 
Samples were collected from pediatric patients with autism spectrum disorder, n=30, after 
initiating and sustaining a second-generation antipsychotic Risperidone (RSP) treatment for 
an 8-week trial, fasting at two timepoints: baseline and after 2 months on medication.  Blood 
was initially taken into Vacutainer blood collection tubes (Becton, Dickinson and Company, 
Franklin Lakes, NJ) which were treated with 7-10 mg of K2EDTA to prevent erythrocyte 
clotting. Venous blood samples were stored immediately at 4oC until further processing could 
occur – within 1 week. All specimens were centrifuged at 2000xg, 4oC for 10 minutes in a 
Beckman Coulter Allegra 6R (Beckman Coulter, Indianapolis, IN) to separate red blood cells 
from what is deemed “blood plasma”. This resulting plasma sample was aliquoted into  500 µL 
fractions for long term storage at -80oC.  
All participants underwent baseline clinical evaluation by the study psychiatrist including 
general health, diet, and body measurements (height, weight, body mass index [BMI]. At both 
visits, repeated body measurements, medication dose and adherence since the prior 
session, any new treatments received (with special focus on antibiotics), and the occurrence 
and reason for any protocol deviations were recorded. 
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Compound 
R1 
(α) 
R2 
(α) 
R3 
(β) 
R4 
(α) 
R5 
Type of  
BA 
Cholic acid (CA) H OH H OH OH 1o 
Chenodeoxycholic acid 
(CDCA) 
H OH H H OH 1o 
Deoxycholic acid (DCA) H H H OH OH 2o 
Lithocholic acid (LCA) H H H H OH 2o 
Ursodeoxycholic acid 
(UDCA) 
H H OH H OH 2o 
Taurocholic acid (TCA) H OH H OH NHCH2CH2SO3H 2o 
Figure 6-6. Structure variations and substitutions of the 6 bile acid species measured with 
their corresponding abbreviations. For bile acids as a whole, tauro-conjugates have the 
amino acid taurine connected by the N terminus at the R5 position. Glyco-conjugates have 
glycine connected by the N terminus at the R5 position.  
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Chemical Materials for Mass Spectrometry Analysis 
All organic solvents used in biological sample preparation and mobile phases were prepared 
with LC-MS grade solvents and chemicals obtained from Sigma-Aldrich (St. Louis, MO). This 
included methanol, acetonitrile, formic acid, triethylamine, and ammonium acetate. 6 bile acid 
standards (cholic acid, taurocholic acid, chenodeoxycholic acid, deoxycholic acid, 
ursodeoxycholic acid, and lithocholic acid) were also purchased from Sigma-Aldrich (St. 
Louis, MO). Additionally, one deuterated internal standard (chenodeoxycholic acid-2,2,4,4-d4 
[CDCA-D4]), which was chosen due to its predominance in the human bile acid pool 512 and 
shared molecular weight with two other unique BAs, was also procured from Sigma-Aldrich 
(St. Louis, MO). The structures of all the BA species measured can be seen in Figure 6-6. 
 
Plasma Sample Preparation 
Prior to BA profiling analysis, samples were thawed at 4oC, and 100 µL aliquots were 
transferred to 1.5 mL Eppendorf microcentrifuge tubes (Eppendorf, Hauppauge, NY), spiked 
with an internal standard (CDCA-D4, in a final concentration of 5 pmol/µL [5 uM] (5 µL 
addition of 20 pmol/µL in methanol). For a liquid-liquid based extraction, 300 µL of 100% 
methanol was added (1:3 v/v), before 1 min of high speed vortexting, followed by a 15-minute 
incubation at room temperature (RT). Following centrifugation (16,000xg, 5 min, RT) the 
resulting supernatant was transferred to a clean microcentrifuge tube. This supernatant was 
dried down in a vacuum centrifuge (Savant SpeedVac Concentrator, ThermoFisher, 
Waltham, MA) for 2 hours, and the pellet was re-dissolved in 20 µL of 60/40% MeOH/H2O. A 
final round of high speed vortexing for 30 seconds, accompanied by centrifugation (16,000xg, 
5 min, RT), provided a clear supernatant which was transferred to 300 µL polypropylene 
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HPLC vials (American Chromatography Supplies, Vineland, NJ) for subsequent analytical 
examination. 
HPLC-MS Analysis – Positive ESI Conditions 
Analysis was performed by an Agilent 1260 Infinity high performance liquid chromatograph 
(HPLC) (Agilent, Santa Clara, CA) coupled to an Agilent 6460 triple quadrupole mass 
spectrometer equipped with an electrospray ionization source operating in the positive ion 
mode (ESI+) for targeted detection options. The conditions described below were developed 
by our lab for a personalized method and produced the most sensitive and reliable BA 
detection results in-house. 
The chromatographic method was reverse-phase in nature, utilizing a long alkyl chain 
stationary phase (C18) paired with a mobile phase system to facilitate both dampening of 
adduct effects, elution of widely varying hydrophobicity levels, as well as separation of 
isobaric BA species. For ESI+, a Cadenza CD-C18 column (3.0 µm, 250 x 2 mm, Imtakt, 
Portland, OR) was selected for use due to its high steric selectivity, as CDCA and UDCA only 
differ by an inversion at a single stereocenter. The column was heated (55oC) for the entire 
gradient program, allowing for consistent and reliable retention times as well as avoidance of 
lipid content buildup on the column matrix that might have been leftover in the samples from 
earlier plasma preparation.513 The aqueous mobile phase solvent A consisted of a volumetric 
preparation of 1 L of ultrapure water with 1 mL of neat formic acid (100/0.1 v/v). Organic 
mobile phase solvent B was comprised of a volumetric preparation of 1 L of acetonitrile with 
1 mL of neat formic acid (100/0.1 v/v). The injection volume of prepared biological samples 
was 8 µL. To minimize injector carry-over, a complete gradient wash cycle with a strong 
solvent (methanol) was performed sporadically throughout sample analysis as “blanks”.  
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All the 6 BA species in this assessment yielded characteristic fragments when subjected to 
collision-induced dissociation and were therefore assayed using multiple reaction monitoring  
(MRM). The finalized method presented above was further tested according to certain 
parameters set forth by the FDA for bioanalytical method validation for properties such as 
linearity, limit of detection, limit of quantitation, precision, and accuracy. 514 
 
Data Processing and Statistical Analysis 
Raw data files were interpreted using MassHunter qualitative analysis software (Agilent). 
Integration of bile acid chromatographic peaks was accomplished both by automatic 
integration as well as manual integration in the case of the more difficult to detect BA signals 
(LCA). 
In order to determine bile acid concentration in patient and control plasma samples, a 
standard curve of the previously measured QC samples was included with each sample 
batch, also eliminating the majority of errors that may occur due to batch effects. As the 
concentrations of each QC sample is known, linear regression was utilized to determine 
unknown sample concentrations by graphing integrative peak area vs. sample concentration. 
Dilution factors were taken into account to arrive at the final concentration of each BA in 
plasma. 
 
Results 
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First and foremost, it is important to quantitate BAs in child populations such as the ones 
described above, as current data is limited, but has the potential to represent critical clinical 
indications early in life, particularly in the case of monitoring and attenuating psychotropic 
side effects.  The children in the study initiated and sustained an 8-week time course of RSP, 
at which point their final fasting BA concentrations were measured. The average 
concentrations of the 5 main bile acid that exist in plasma (LCA, a toxic secondary BA 
species, was too low of a concentration to reliably detect across samples) can be seen in 
Table 6-8. 
In this pilot dataset of 30 children from the RUPP RSP trial, we also observed marked 
changes in the total BA pool and diversity, with predominant increases in 1° BAs. Primary  
BAs were significantly more pronounced in those with high versus low AIWG (p=0.01, Fig. 
35A). This pattern was replicated in 4 subjects started on RSP with moderate weight gain 
recruited at Baylor College of Medicine, a collaborator’s site, with a 1° BA increase of 960 
nmol/L, similar to 1,374 nmol/L in the RUPP sample.  
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Figure 6-7. RSP-Induced BA Changes. A. 1° BAs increase to 
a greater degree (p=0.01) in those with (green) compared to 
those without (blue) weight gain. B. In those with BA changes 
on RSP (12/28), the ratio of CDCA change to UDCA change 
differentiates those with (green) and without (blue) AIWG 
(p=0.001). All 28 subjects shown. Units are nmol/L. 
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Both CDCA and UDCA measures at baseline and 8 weeks were available for 28/30 RUPP 
participants. 12 of these 28 displayed a significant change (from baseline to 8 weeks) in 
either CDCA or UDCA (>0.5 SD). In this subset showing BA change with RSP, the ratio of 
the change in CDCA to the change in UDCA differentiated those with AIWG 
(∆CDCA/∆UDCA>1) from those without (∆CDCA/∆UDCA<1). This algorithm correctly predicts 
AIWG status in 11/12 (92%) participants whose ratios change (p=0.001, Fig. 35B), with a 
sensitivity of 100% and specificity of 86%. Sex, age, race/ethnicity, and RSP dose/plasma 
level were tested but did not contribute to BA differences. Test-Retest reliability of CDCA, 
UDCA, and 1° BA repeated measurements in the same individual (N=2) were precise within 4 
nmol/L. 
 
Discussion 
While previous studies have described AIWG and resulting metabolic syndrome (MS), and 
even searched for genes conferring risk, mechanistic approaches are lacking. As far as we 
are aware, this examination of peripheral bile acids in pediatric patients taking psychotropic 
medications is the first to demonstrate that significant changes are occurring in the BA pool 
following treatment. There are multiple factors that make these findings potentially so 
significant. Within the last few decades, it has been discovered that bile acids and bile salts 
have the ability to activate specific nuclear receptors, expressed in liver and GI tract cells, 
such as farnesoid X receptor (FXR) and G protein coupled receptor TGR5.11 Binding and 
subsequent activation of these receptors alter the expression of multiple genes that encode 
protein or enzyme products involved in the regulation of glucose, fatty acids, metabolism, bile 
acid synthesis, metabolism, and even energy metabolism.486, 551, 552 In more recent years, it 
has also been shown that bile acids can stimulate the expression of endocrine L-cells553 
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which are implicated in secretion of satiety hormones peptide YY (PYY) and glycogen-like 
protein 1 (GLP-1). This provides elucidative connections for BA quantification and the 
biological mechanism of AIWG/MS. 
We can strengthen these tenuous links by examining a similarly growing field of study – the 
gut microbiome. Recent evidence has fueled a growing enthusiasm for the role of the 
collective bacterial population in the human gastrointestinal tract in host metabolism and 
energy harvest,554 glucose homeostasis,491 and pharmaceutical breakdown.555 Preclinical 
studies of the antipsychotics olanzapine (OLZ) and RSP link AIWG with obesogenic 
microbiome changes in mice, including an increased Firmicutes to Bacteroidetes (F/B) phyla 
ratio.556-559 Moreover, preclinical studies have also demonstrated that gut bacteria are 
necessary for AIWG. In the only translational study published to date, our team confirmed 
that AIWG is associated with microbiome changes in children.560 
The relationship between the microbiome and BA pool is bidirectional. The microbiome 
regulates BA synthesis and reabsorption and shapes the BA pool.561 Both gram positive and 
negative bacteria produce intracellular enzymes such as bile salt hydrolase and hydroxysteroid 
dehydrogenase (HSDH) that can deconjugate taurine and glycine adduct bile salts562 as well as 
hydroxylate 1° BAs to form 2° and 3° forms.563 This deconjugation and epimerization results in 
an increase in BA hydrophilicity, affecting membrane permeability and efficiency of lipid 
solubilization. While almost all BAs are natural ligands for the hepatic FXR receptor, binding 
affinity and activity are substantially altered by BA modifications.564 For example, the 1° BA 
CDCA is hepatically synthesized and excreted into the intestinal lumen in bile. Gut bacteria then 
convert CDCA to UDCA, which has opposing effects on downstream FXR signaling.565-569  
 
Since FXR signaling is promoted by 1° BAs (CDCA and CA) but inhibited by the 2° BA UDCA, 
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the microbiome could influence metabolism by shifting the balance between these BA species. 
Conversely, BAs alter intestinal bacterial composition by moderating oxidative and pH stress in 
the small bowel and chelating vital cellular ions, thus promoting or inhibiting the growth of certain 
species.476 Direct antimicrobial effects result from detergent-like disruption of 
bacterial membranes561 and indirect effects are  mediated by FXR activation, triggering 
upregulation of genes involved in epithelial mucosal defense.482 
 
We hypothesize that a ∆CDCA/∆UDCA<1 could occur when epimerase+ bacteria are 
unavailable to convert CDCA to UDCA, resulting in excess CDCA and AIWG. Therefore, we 
believe future experiments should examine whether relative abundance of a key bacterial 
species (B. fragilis) that can catalyze the first step in epimerization was affected by RSP 
exposure. In Figure 6-8, we have proposed a potential active biological mechanism of AIWG. 
The data presented here, while preliminary, provide the foundation for a potentially targetable 
and biological based model of AIWG. Further research is needed to replicate findings in 
larger samples, clarify links between microbiome and BA, and determine whether 
associations are causal or simply an epiphenomenon or downstream effect. Some 
weaknesses of the current student include the small sample size of participants, and while 
power  was sufficient to generate statistically meaningful results, future studies that aim to 
affix the microbiome and bile acids would benefit from at least double the sample population 
(n=60+) to help delineate downstream affects. 
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It is also worth noting that addition of more bile acid species in the analytical quantification 
would be desirable for continuing work. This study was only able to reliable detect and 
measure 5 major human BAs, however there are close to 150 unique compounds in human 
bile.494 Conversely, as more compounds are added to a MS analysis, it could potentially 
result in issues with multiple testing, spurious associations, and the need for a larger 
population size. These secondary bile acid species are produced through structural 
modifications of primary BAs in the small intestines and colon following interaction with 
present microbial populations. Various enzymes produced by these bacterial species have 
the capabilities to deconjugate, hydroxylate, dehydroxylate, and epimerize 491, 496 both primary 
and secondary BAs altering their chemical properties and binding affinities, indicating 
Figure 6-8. Proposed Model of AIWG/MS. RSP impacts BA and gut microbial composition, favoring 
more obesogenic profiles. These pathways promote FXR signaling, negatively impacting lipid and 
glucose homeostasis, adiposity, and BMI. A protective mechanism whereby CDCA is converted to 
UDCA by epimerase+ gut bacteria counteracts this pathway; UDCA blocks FXR signaling, thus 
opposing AIWG/MS. The balance between these two pathways dictates metabolic response to RSP. 
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microbial importance in host enterohepatic circulation and overall metabolic homeostasis, 
and quantifying additional variants has the potential to yield even more insightful biological 
connections to AIWG. Our team has already begun to add 10 additional BA species to the 
bioanalytical method described above for future studies. 
Finally, in order to disentangle direct BA involvement with AIWG/MS, downstream biomarkers 
for FXR activation would be an ideal target to assay in later work on this topic. FXR signaling 
results in secretion of gut-derived FGF19 and subsequent suppression of precursors of 
hepatic BA synthesis (7α-hydroxycholesterol and 7α-hydroxy-4- cholesten-3-one [C4]). Both 
of these factors can be measured successfully in blood to provide additional insight on the 
direction of the proposed mechanism.  
Conclusion 
Antipsychotics have revolutionized treatment of several severe medical conditions; therefore, 
their use is necessary despite serious side effects. We have shown that RSP treatment 
results in unfavorable bile acid changes which are significantly linked with AIWG in pediatric 
populations. This drug exposure resulted in BA pool alterations that can dif ferentiate those 
who experience AIWG from those without and has the prospective to guide clinical care 
moving forward. Additionally, due to an evolving understanding of the gut microbiome’s 
involvement with host metabolism, we have proposed an extended hypothesis and 
theoretical model for bile acid-microbiome cross talk based on chemistry and function. 
Further research is needed to replicate findings in larger samples, clarify links between 
microbiome and BA, and determine whether associations are causal or simply an 
epiphenomenon or downstream effect. Ultimately, the identification of an easily measurable 
biomarker of AIWG risk could provide clinical guidance. If proven, highly actionable treatment 
targets are clear, and potential treatments are immediately available. 
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Chapter 6 Wrap-Up 
Chapter 7 will directly continue from the conclusions of the above case study, wrapping up 
my dissertation as a whole, and presenting the current, larger replication project to validate 
my preliminary findings. 
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Chapter 7  
Future Directions, Conclusions, and Final Thoughts 
 
 
Future Directions 
 
Based on the encouraging and intriguing preliminary results just discussed in Chapter 6, and 
with the help and leadership of my PI, Dr. Nurmi, we decided to write and submit a R21 
research proposal grant to the NIH to explore our putative biological pathway of antipsychotic-
induced weight gain further. Below you fill find this document, that was just recently accepted 
and funded by the National Institute of Child Health and Human Development (NICHD). It is 
ongoing, and I will be continuing to serve as a research assistant on this grant and perform the 
pertinent bile acid measurements and statistical and quantitative analysis as we accumulate 
enough participants. I am beyond excited at the prospect this study holds to inform the world of 
adverse treatment side effects following psychotropic medication, which I will discuss further in 
the conclusions following.  
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Current Study and Future Directions : The role of bile acid-microbiome cross-talk in 
psychotropic-induced weight gain and cardiometabolic dysfunction* 
*This is a submitted and funded R21 grant proposal. 
 
I. SIGNIFICANCE.  
A. Antipsychotic-Induced Weight Gain (AIWG) & Metabolic Syndrome.  
 
Antipsychotic (AP) medications are critical for the stabilization of psychotic, mood, and behavioral 
disorders.522 APs are prescribed to 1-2% of adults (~7M)523 and 0.8-1.2% of youth (~1M).524, 525 
Prescribing rates have been steadily rising for decades (increasing 750% in the first decade of 
the millennium),526 and is greatest in the demographic groups most vulnerable to adverse 
effects—the underprivileged, elderly and very young.527-530 While effective, antipsychotics carry 
serious risks—most commonly, weight gain and cardiometabolic abnormalities, which affect up 
to 60% of patients531 and present a major obstacle to long-term treatment.532-534 An increased 
susceptibility to and magnitude of AIWG has been repeatedly documented in children.533, 535, 536 
Within a period of only 11 weeks, youth starting risperidone (RSP) may gain up to 3 kg. Associated 
abnormalities such as central obesity, insulin resistance, dyslipidemia, and systemic 
inflammation537-539 reach sufficient magnitude in childhood to trigger and accelerate 
atherosclerosis.537, 539-543 Cardiovascular disease accounts for the largest proportion of premature 
deaths in the severely mentally ill, whose life expectancy is dwarfed by that of the general 
population by as much as 20 years—a gap that has increased over recent decades, paralleling 
antipsychotic prescribing.544, 545 
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Despite this increase, very little is known about the mechanism of AIWG/MS. Differential risk 
across the drug class is not explained by simple receptor binding profiles, but other biological 
mechanistic links are lacking. A few supported risk genes explain only a small percentage of the 
risk.62, 546, 547 Novel, testable hypotheses are sorely needed. 
 
B. The Gut Microbiome & AIWG.  
Recent evidence has fueled a growing enthusiasm for the role of the collective bacterial 
population in the human gastrointestinal tract in host metabolism and energy harvest,570 glucose 
homeostasis,571 and pharmaceutical breakdown.572 Preclinical studies of the antipsychotics 
olanzapine (OLZ) and RSP link AIWG with obesogenic microbiota changes in mice, including an 
increased Firmicutes to Bacteroidetes (F/B) phyla ratio.573-576 Moreover, preclinical studies have 
also demonstrated that gut bacteria are necessary for AIWG.573-576 In fact, AIWG is absent in 
germ-free mice but can be induced by microbiome transplant.573 Similar F/B changes, increased 
adiposity, and inflammation were reported in OLZ-treated rats and could be prevented by co-
administration of an antibiotic cocktail that effectively sterilized the gut.575.574 Similarly, mice 
receiving RSP developed AIWG, mediated by decreased energy expenditure and transferrable 
by fecal transplant.576  
 
In the only translational study published to date, our team confirmed that AIWG is associated 
with microbiome changes in RSP-treated children.577 In line with preclinical studies, RSP 
treatment was associated , cross-sectionally, with elevated F/B ratio and a host of differences in 
the metabolic potential of the gut microbiota (Fig. 7-1a).578 Concurrently, a small longitudinal 
study of children enrolled within days (mean=3.2, s.d.=5.2) of starting RSP substantiated these 
findings. Within 1-3 months of RSP initiation, the F/B ratio had begun to increase, appearing to 
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plateau by 5-6 months (Fig. 7-1b). Importantly, the F/B ratio was positively correlated with the 
magnitude of AIWG (Fig. 7-1c). 
 
 
 
 
 
 
 
 
C. Bile Acids Regulate Energy Balance.  
While BAs were traditionally assigned the simple role of lipid surfactants aiding in fat absorption, 
they are now considered steroid hormones with a regulatory role in energy balance via tropism 
for specific hepatic, intestinal, and adipose tissue nuclear receptors.551, 553, 579 Primary (1°) BAs, 
chenodeoxycholic acid (CDCA) and cholic acid (CA), are synthesized from cholesterol in the 
liver.580 1° BAs are potent agonists for the liver nuclear receptor farnesoid X (FXR), involved in 
lipid and glucose homeostasis, while the secondary (2°) BA ursodeoxycholic acid (UDCA) acts 
as an FXR antagonist.565-569 In a study of human BA profiles, total plasma BA concentrations were 
higher in both obese and diabetic subjects than in healthy controls.550 Specifically, the 1° BAs 
Figure 7-1a. Cross-Sectional RSP-Related Microbiome 
Changes. Phyla-level differences between controls (green) 
and chronic RSP–treated subjects with AIWG (yellow) and 
without (blue) reveal phyla changes similar to those seen in 
obesity (increased F/B ratio).7-1b. Prospective RSP-
Associated F/B Increase. By 1-3 mo., relative abundance 
of F (blue) vs. B (red) diverges, with maximum increase in 
F/B ratio at 5-6 mo. 7-1c. F/B ratio predicts AIWG. BMI (z-
score) change is positively correlated with F (blue) to B (red) 
relative abundance. 
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CDCA and CA were associated with insulin resistance550 and CDCA was positively correlated 
with BMI. Rodent and human data suggest that oral CDCA treatment, once used to dissolve 
gallstones, results in unfavorable lipid changes (increased total cholesterol/LDL581 and decreased 
HDL).582 Conversely, the secondary BA UDCA has been shown to promote positive lipid changes 
and reduce inflammation.583-586 UDCA also reduces intestinal absorption of more toxic 1° BAs.587 
Furthermore, BA sequestrants, which disrupt BA enterohepatic circulation, lower plasma glucose 
and long-term glucose regulation marker HbA1c in hyperlipidemia clinical trials.588 
 
The relationship between the microbiome and BA pool is bidirectional. The microbiome regulates 
BA synthesis and reabsorption and shapes the BA pool.561 Both gram positive and negative 
bacteria produce intracellular enzymes such as bile salt hydrolase and hydroxysteroid 
dehydrogenase (HSDH) that can deconjugate taurine and glycine adduct bile salts562 as well as 
hydroxylate 1° BAs to form 2° and 3° forms.563 This deconjugation and epimerization results in an 
increase in BA hydrophilicity, affecting membrane permeability and efficiency of lipid 
solubilization. While almost all BAs are natural ligands for the hepatic FXR receptor, binding 
affinity and activity are substantially altered by BA modifications.564 For example, the 1° BA CDCA 
is hepatically synthesized and excreted into the intestinal lumen in bile. Gut bacteria then convert 
CDCA to UDCA, which has opposing effects on downstream FXR signaling.565-569 Rodent studies 
highlight the importance of signaling through the FXR receptor as a mechanism for microbiome 
effects on energy balance. Data from germ-free and antibiotic treated mice suggest that the 
microbiome promotes diet-induced obesity through FXR signaling,589, 590 and FXR deficiency 
reduces weight and improves glucose homeostasis in mouse models of obesity.591 Following 
bariatric surgery in rodents, hepatic FXR expression is decreased.554 However, beneficial 
metabolic effects can be achieved by reducing or increasing signaling in a context-specific 
manner. Since FXR signaling is promoted by 1° BAs (CDCA and CA) but inhibited by the 2° BA 
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UDCA, the microbiome could influence metabolism by shifting the balance between these BA 
species. 
Conversely, BAs alter intestinal bacterial composition by moderating oxidative and pH stress in 
the small bowel and chelating vital cellular ions, thus promoting or inhibiting the growth of certain 
species.476 Direct antimicrobial effects result from detergent-like disruption of 
bacterial membranes561 and indirect effects are  mediated by FXR activation, triggering 
upregulation of genes involved in epithelial mucosal defense.482 
 
D. Preliminary Data:  
 
In a pilot dataset of 30 children from the RUPP RSP trial who had initiated and sustained RSP 
treatment for an 8 week trial,107, 521, 592 we observed marked changes in the total BA pool and 
diversity, with predominant increases in 1° BAs. 1° BAs were significantly more pronounced in 
those with high versus low AIWG (p=0.01, Fig. 6-7a). This pattern was replicated in 4 subjects 
started on RSP with moderate weight gain recruited by Dr. Calarge, co-investigator,577 with a 1° 
BA increase of 960 nmol/L, comparable to 1,374 nmol/L in the RUPP sample. Both CDCA and 
UDCA measures at baseline and 8 weeks were available for 28/30 RUPP participants. 12 of these 
28 displayed a significant change (from baseline to 8 weeks) in either CDCA or UDCA (>.5 SD). 
Of note, the ratio of the change in CDCA to the change in UDCA differentiated those with AIWG 
(∆CDCA/∆UDCA>1) from those without (∆CDCA/∆UDCA<1). This pattern correctly predicts 
AIWG status in 11/12 (92%) participants whose ratios change (p=0.001, Fig. 6-7b), with a 
sensitivity of 100% and specificity of 86%. Sex, age, race/ethnicity, and RSP dose/plasma level 
did not contribute to BA differences. Test-Retest reliability of CDCA, UDCA, and 1° BA repeated 
measurements in the same individual (N=2) were precise within 4 nmol/L.  
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We hypothesized that a ∆CDCA/∆UDCA<1 could occur when epimerase+ bacteria are 
unavailable to convert CDCA to UDCA, resulting in excess CDCA and AIWG. Therefore, using 
data from the prospectively followed RSP-treated children enrolled by Dr. Calarge,577 we 
examined whether relative abundance of a key bacterial species (B. fragilis) that can catalyze the 
first step in epimerization was affected by RSP exposure. As predicted, the relative abundance of 
B. fragilis decreased over 200-fold after 1-3 months of RSP exposure.  
 
In order to explore whether these effects are specific to AIWG, we tested a small pilot sample of 
children taking SSRIs. Ten youth were selected, 5 with moderate (>1 Z-score) SSRI-induced 
weight gain (SIWG) and 5 without. Remarkably, the trends were in the same direction, with 
individuals with greater weight gain showing greater elevation in 1° BA and ∆CDCA/∆UDCA>1. 
However, given the small sample size, the differences were not significant. . Using this ratio, 
SIWG status can be correctly predicted in 6/8 (75%) of individuals with BA change on an SSRI.  
In summary, our preliminary data suggests that alterations to the BA balance may contribute to 
AIWG, a link that to our knowledge has not been previously investigated. We have shown that 
RSP-exposed children exhibit substantial changes in their BA pool, with opposite patterns of 1° 
vs. 2° BAs seen in youth at risk versus protected from AIWG. It is possible that antipsychotic 
drugs may impact BA synthesis and metabolism directly, as both first and second generation 
antipsychotics concentrate in bile,573 slow enterohepatic BA circulation, and can trigger hepatic 
cholestasis, resulting in a reduced flow and clearance of BAs and toxic accumulation of 1° 
BAs.593, 594 However, based on previous data supporting an essential role for the microbiome in 
AIWG and the fact that the key regulator of UDCA levels is bacterial conversion from CDCA, we 
propose to test a model of AIWG based on altered BA-microbiome interaction. 
 
E. Scientific Premise.  
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Integrating the prior literature reviewed above and our own pilot data, we hypothesize that (Aim 
1A) RSP treatment increases 1° BAs and that resistance to these changes is conferred by the 
ability of epimerase+ gut microbiota to convert 1° (CDCA) to the 2° (UDCA) BA, which opposes 
the downstream effects of 1° BAs at the FXR receptor. We further propose that those who 
experience significant AIWG can be differentiated from those who are protected based on RSP-
induced changes in: (Aim 1A) CDCA/UDCA>1, (Aim 1B) increased FXR activity and (Aim 2A) 
loss of epimerase+ bacterial species in the gut, reflecting an impaired ability to convert CDCA to 
UDCA to compensate for increasing CDCA. While preclinical studies from three independent 
groups, in both mice and rats exposed to two different antipsychotics, report consistent effects 
on the microbiome, translation from rodent to human is inherently problematic. Our data 
examining RSP-induced microbiome changes in humans, although unique, are largely based on 
a cross-sectional study and very small longitudinal sample. Time course of changes is not well 
defined. BAs are gaining support as a hormonal signal involved in energy balance; however, our 
pilot data, while in agreement with our theoretical model based on BA chemistry and function, is 
also based on a small sample.  
 
These data, while preliminary, provide the foundation for a compelling model of AIWG (Fig. 37). 
Further research is needed to replicate findings in larger samples, clarify links between 
microbiome and BA, and determine whether associations are causal or simply an 
epiphenomenon or downstream effect. Understanding the role BAs play in AIWG will serve 
several functions. It will lead to the identification of an easily measurable biomarker of AIWG risk 
could provide clinical guidance. If proven, highly actionable treatment targets are clear, and 
potential treatments are immediately available. UDCA is available orally as a gallstone 
treatment and epimerase+ bacteria are a chief component of probiotics. Developing approaches 
that may be relevant include drugs directly impacting FXR signaling and prebiotic strategies 
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used to shape microbial populations. The mechanisms involved in AIWG/MS may be relevant to 
other drug classes and will likely inform our overarching concept of normal and dysregulated 
metabolic balance. 
 
 
II. INNOVATION.  
 
While previous studies have described AIWG/MS, and even searched for genes conferring risk, 
mechanistic approaches are lacking. Our team’s prior work represents the only published 
examination of the role of the microbiome in AIWG in humans. We developed and will 
implement our own BA measurement assay, the details of which we will publish. An 
appreciation of the role of BAs as signaling molecules is just beginning to emerge. This project 
would be the first to include BA signaling pathways in the study of AIWG and the first to 
integrate BA and microbiome changes. Uniting preclinical and clinical data and integrating 
microbiome and BA findings, we propose to test a novel potential mechanism contributing to 
AIWG. This model has compelling hooks to actionable treatment targets and aligns with the 
goals of precision medicine. 
 
Figure 7-2. Proposed Model of 
AIWG/MS. RSP impacts BA and gut 
microbial composition, favoring more 
obesogenic profiles. These pathways 
promote FXR signaling, negatively 
impacting lipid and glucose 
homeostasis, adiposity, and BMI. A 
protective mechanism whereby CDCA 
is converted to UDCA by epimerase+ 
gut bacteria counteracts this pathway; 
UDCA blocks FXR signaling, thus 
opposing AIWG/MS. The balance 
between these two pathways dictates 
metabolic response to RSP. 
236 
 
III. APPROACH: METHODS 
 
Study Design and Procedures.  
 
60 unmedicated youth initiating RSP treatment within clinical programs at UCLA and BCM will 
be recruited, screened, and consented for participation in order to provide 52 subjects with 
complete data (additional 15% to account for attrition). UCLA will recruit 20 subjects and BCM 
10 subjects during each study year. Subjects will be paid $50 at each of 4 collection visits and 
$30 for providing written dietary information on 5 non-visit weeks. 
 
Assessments:  
 
All participants will undergo baseline clinical evaluation by the study psychiatrist including 
general health, and diet and anthropometric measurements (height, weight, blood pressure, 
body mass index [BMI], waist circumference, skinfold body fat) will be taken following standard 
procedures. The Pubertal Developmental Scale (PDS), a psychometrically sound child self-
report yielding a continuous pubertal change score and a five-level categorical classification of 
pre- to post-pubertal, will be administered.595 At each visit, repeated body measurements, 
medication dose and adherence since the prior session, any new treatments received (especially 
antibiotics), and the occurrence and reason for any protocol deviations will be recorded. Fasting 
STUDY OVERVIEW 
1. Recruit: children 
starting RSP as part of 
naturalistic treatment for 
any diagnosis 
UCLA: 20 participants/Y 
BCM: 10 participants/Y 
2. Collect (baseline, 1-, 2-, 
& 6-mo f/u): blood (fasting), 
stool, diet tracking, height, 
weight, waist circumference, 
skinfold body fat, med 
changes (including RSP 
dose, antibiotics, other 
meds) 
3. Analyze: 
Blood: BAs, 
lipids, glc 
Stool:  
Microbiome, 
epimerase 
activity, BAs 
 
4. Expected Results:  
Aim 1A: 1° BAs will increase & AIWG will 
be predicted by changes in CDCA/UDCA 
Aim 1B: Downstream markers of FXR 
signaling will increase, moreso in AIWG+. 
Aim 2A: Epimerase+ bacterial species 
will decrease in AIWG+ vs. AIWG- 
Aim 2B: Explore time course 
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blood and stool samples will be collected prior to initiation of RSP treatment and at 1-, 2- and 6-
months on RSP. 
 
Several factors support the feasibility of our recruitment target. UCLA and BCM are leading 
regional centers for the evaluation and treatment of youngsters with pediatric mental illness. The 
UCLA Child Psychiatry Division has served as home to numerous funded clinical studies and 
draws referrals from a catchment of over 16 million. The clinical operations (inpatient, partial, 
outpatient hospital services) are housed in close proximity to the research sites. At both sites, 
RSP is the antipsychotic most commonly prescribed to children and teens given the superior 
evidence base for clinical treatment of psychosis, mood stabilization, aggression, impulsivity, 
tics, OCD, and other developmental disorders. Recruiting will be facilitated by announcements 
at faculty meetings and fellow didactics; emails to faculty and fellows; and outreach to social 
work, nursing and support staff. Study staff will be available continuously on call (during 
business hours Mon. through Fri. when clinics operate and recruitment will occur) to meet with 
potential participants following their treatment visit. We have successfully completed recruitment 
for multiple funded pediatric trials, supported by a vibrant community outreach/referral network 
including UCLA-affiliated community clinics, primary care physicians, mental health providers, 
schools, churches, community organizations and centers, and an active and expanding web and 
social media presence. Of note, the ethnic minority participation rate for our similar studies is 
~40%. 
AIM 1: Methods. Whole blood will be collected in EDTA-treated Vacutainer tubes (Becton 
Dickinson, Franklin Lakes, NJ) and centrifuged at 4C at 2000 rpm for 10 minutes within 24 hours 
of collection to separate plasma. Plasma will be stored at -80C until processing. BAs will be 
measured in plasma samples using a solid-phase extraction method. We will measure the 
principal BAs found in humans, including 1°, 2°, and conjugated BAs:579, 596 Specifically, we will 
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measure CA, CDCA, UDCA, deoxycholic acid (DCA), and lithocholic acid (LCA) and their taurine 
(T) and glycine (G) conjugates (TCA, TCDCA, TDCA, TUDCA, TLCA, GCDCA, GDCA, GCA, 
GLCA), iso-epimers (isoLCA, isoDCA) and precursors (7-hydroxycholesterol, 7-hydroxy-4-
cholesten-3-one [C4]). A Cadenza CD-C18 high efficiency column (Imtak, Portland, OR) that is 
specifically designed with unique ligand density provides excellent steric selectivity for 
chromatographic separation. Separated BAs will be analyzed with an Agilent 6460 Triple 
Quadrupole LC/Mass Spectrometer with Standard ESI Source (Agilent Technologies, Santa 
Clara, CA) in the positive-ion mode. Quantitative data will be analyzed in the multiple reaction 
monitoring mode by using optimal parameters for each individual BA. In our pilot studies, the 
lower limit of quantification was 0.5 nmol/L for all BAs. Downstream indicators of FXR signaling 
and measures of inflammation (cytokine panel) will be quantified by commercially available ELISA 
assays (ThermoFisher). FXR signaling results in secretion of gut-derived FGF19 and subsequent 
suppression of prescursors of hepatic BA synthesis (7-hydroxycholesterol and 7-hydroxy-4-
cholesten-3-one [C4]). 
 
AIM 1A. To measure changes to BA composition longitudinally during 8 weeks of RSP 
treatment and compare BA pool composition in those with and without AIWG.  
 
Hypothesis: 1° BAs will increase with RSP exposure, with greater increases in those with AIWG. 
In those with RSP-induced BA changes, ∆CDCA/∆UDCA ratio>1 will identify participants who 
gain clinically significant weight compared to ∆CDCA/∆UDCA ratio<1 in those protected from 
weight gain.  
 
Analytic Plan 1A: Levels of 1° BAs will be calculated at individual time points and analyzed 
using a repeated measures mixed linear model. Covariates such as dose, age, sex, and 
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race/ethnicity will be included in the model. Sex-specific effects will be considered. Change in 
CDCA and UDCA will be calculated at individual time points. Participants with significant 
changes in either measure (>.5 SD) will be analyzed for ∆CDCA/∆UDCA ratio and ratio>1 will 
be used to predict AIWG status. Actual versus predicted assignments will be compared using a 
Chi Square test. Sex-specific effects will be considered.  
Power 1A: The effect size for increases in 1° BA’s determined in the pilot study is large (d=.74). 
The proposed sample size (n=52), with 3 within subject measurement points and 2 groups and 
assuming a within-subject autocorrelation of r=.50), provides sufficient power (81%) to detect 
changes of this magnitude. The proposed UDCA/CDCA ratio rule is only applicable to 
participants that show significant changes in those values in response to antipsychotics. Based 
on the preliminary data, ~50% of the sample is expected to change. In our pilot, the proportion 
of participants with ratio>1 who have AIWG is 100%, while those with ratio <1 who have AIWG 
is only 14%. The minimum sample size to detect a difference in proportions of this magnitude 
with sufficient power (80%) is n=14, requiring a total sample size of n=28 to be recruited to 
account for the 50% of the participants without BA changes. As these estimated proportions are 
based on small samples, this is likely to underestimate the required sample size, but as the 
sample size available (n=52) is nearly twice the estimate, we are confident that this aim is 
sufficiently powered. Additional analyses of the baseline microbiome of participants resistant to 
changes in CDCA and UDCA will be explored to assess potential protective factors for future 
study. 
 
AIM 1B. To bolster the evidence for the proposed mechanism, we will compare 
downstream markers of FXR signaling in those with and without AIWG.  
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Hypothesis: Downstream indicators of BA-induced FXR signaling will reveal suppression of BA 
synthesis and increased secreted FGF19 reflecting increased FXR activity overall. We expect 
greater FXR signaling in those with versus those without AIWG.  
 
Analytic Plan 1A: Blood levels of these markers at the three visits will be analyzed using a 
repeated measures mixed linear model. AIWG+ or – group status will be added to the model as 
a between subject variable to test for differential effects. Covariates such as dose, age, sex, and 
race/ethnicity will be included in the model. Sex-specific effects will be considered. Power 1B: 
Given the large effects seen in BA increase (d=.74) and existing literature showing that CDCA 
produces large effects on downstream markers of FXR activity in contrast to UDCA,597, 598 we 
anticipate that downstream markers will be altered by a greater magnitude than BAs themselves 
(see Power 1A), and thus the study is powered to detect these effects. 
Alternative Approach: If pilot findings do not replicate, FXR signaling indicators may provide 
clues to an alternative mechanism. Additionally, the relationship of other BAs with AIWG can be 
explored in this larger, better-powered study. 
 
AIM 2: Methods. Stool samples will be collected prior to initiation of RSP treatment and at 1-, 2- 
and 6-months on RSP. Samples will be freshly collected and transported to the Nurmi laboratory 
where they will be aliquoted and frozen within 30 minutes. If patients are unable to provide stool 
samples at the time of their visit, collection kits will be sent home with parents. Samples 
provided in a home setting will be placed on provided dry ice and picked up within 24 hours in a 
frozen state. All stabilized samples will be stored at -80C until DNA extraction. Extracted DNA 
will be subjected to multiplex paired-end whole genome sequencing on an Illumina HiSeq 
instrument (Illumina, San Diego, CA) in the UCLA microbiome core. Computational analysis will 
be performed using Qiime 2 to identify OTUs and relative abundances and to perform diversity 
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analyses. The CDCA to UDCA conversion requires two steps that can be formed by distinct but 
co-located bacteria. The first step is performed by species expressing 7-hydroxysteroid 
deyhydrogenase (HSDH) that can form oxo derivatives (ketones) of CDCA, including 
Escherichia coli, Bacteroides fragilis and Pseudomonas species. The second step is performed 
by species expressing 7-HSDH that reduces ketones to epimerized hydroxyls, including 
Collinsella aerofaciens and Ruminococcus gnavus. Bacteria that contain both − and -HSDHs 
include Clostridium limosum, and Clostridium baratii. The specific enzyme sequences are 
available for these species. The low level of homology (~50-80%) between species will allow us 
to differentiate which epimerizing bacteria are present through their enzymatic sequence 
signature. A further confirmatory functional assay will measure epimerase activity by culture of 
stool samples, followed by addition of CDCA to culture medium and LCMS measurement of 
UDCA and LCA.507, 579, 599, 600 Fresh stool samples collected can be used for both analyses. 
 
 
AIM 2A. To measure longitudinal changes in the gut microbiota during 8 weeks of RSP 
treatment and compare relative abundance of epimerase+ bacterial species in those with 
and without AIWG.  
 
Hypothesis: Epimerase+ bacterial species will be depleted in those with vs. without AIWG.  
 
B. Fragilis vs. E. Coli 7a-HSDH Alignment Representative Excerpt  
(54% identity, p<4e-12) 
R. Gnavus vs. C. Aerofaciens 7b-HSDH Alignment Representative Excerpt  
(68% identity, p<4.7e-100) 
Figure 7-3. Representative Genetic 
sequence of B. Fragilis and R. 
Gnavus. Both of these bacterial 
species produce the specific 7-βHSDH 
enzyme needed to epimerize CDCA to 
UDCA. 
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Analytic Plan 2A: The change in relative abundance of epimerase+ bacteria will be assessed 
based on both OTUs and enzyme activity using a repeated measures linear mixed model. 
Covariates such as dose, age, sex, and race/ethnicity will be included in the model. Sex-specific 
effects will be considered.  
Power 2A: The proposed sample size (n=52, ~26 expected in each group [AIWG+ and AIWG-], 
with 3 within subject measurement points and 2 groups) provides sufficient power (81%) to 
detect differences in the relative abundance of epimerase+ bacteria of the same magnitude as 
observed in the pilot data (d=.71 difference at study endpoint under the assumption that both 
groups are equivalent at study beginning and a within-subject autocorrelation of r=.50). 
Alternative Approach: If pilot findings do not replicate, other microbiome-AIWG relationships can 
be explored in this larger, better-powered study. 
 
Exploratory Aim 2B. To measure the time course of gut microbiota and BA composition 
changes during RSP exposure to help clarify the mechanism of AIWG and facilitate the 
identification of early biomarkers.  
 
Given that the earliest data previously collected for BA and microbiome changes were 8 weeks 
from baseline, the mid-point and 6-month follow-up assessments will help resolve the order and 
timing of BA and microbiome peak changes, as well as changes relative to one another. Since a 
longer time period will likely result in greater rates of attrition, loss to follow-up, RSP 
discontinuation, concomitant drug addition, and antibiotic prescription, we expect a much 
smaller of subjects to provide useable data for a 6-month follow-up, hence this timepoint will be 
observational and analyses will be exploratory. 
 
Rigor and Reproducibility:  
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Scientific Premise of Proposed Research (see Significance section).  
 
Rigorous Experimental Design.  
Our methods have been validated by our own prior work and independent published data. 
Multiple approaches have been enlisted to protect against bias, including independent, blinded 
data analysis and sound statistical methods. In order to facilitate transparency, we have 
described in detail our experimental protocol and other methods. Similarly, we will share the 
study design details, analytic methods, and trial data with the scientific community. 
 
Consideration of Sex and Other Relevant Biological Variables.  
Given that major indications for antipsychotic treatment in youth have a male bias, extra efforts 
will be made to recruit female subjects to ensure representation, especially in light of previous 
data indicating that female rodents are at greater risk of microbiome and metabolic effects. 
Inclusion of females will enable us to robustly test for sex effects. In our pilot studies, sex, age, 
race/ethnicity, and RSP dose/plasma level were not significant contributors to our models. 
 
Authentication of Key Biological and/or Chemical Resources. Our methodological approaches 
have been selected with attention to prior validation and shared acceptance by the field. We will 
ensure transparency in data sharing and continue to apply new methods to our data as they 
emerge to improve interpretation. 
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Timeline Preaward Y1 Y2 (mo 1-
8) 
Y2 (mo 9-11) Y2 (mo 12) 
UCLA Update IRB, 
consents, 
announcements 
 
Recruiting 
& 
Collection  
N (2/mo) 
=24 
Recruiting 
& 
Collection  
N (2/mo) 
=16 
Sample 
Processing, 
Data Analysis, 
Interpretation 
Manuscript 
preparation, 
data sharing 
BCM N (1/mo) 
=12 
N=1/mo) 
=8 
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Overall Dissertation Conclusions 
 
Precision medicine is an emerging approach for disease treatment and prevention that heavily 
weighs individual variability in genes, environment, and lifestyle for each person. It is in stark 
contrast to a one-size-fits-all approach in which both doctors and drug developers focus on 
empirical data and what works best for the “average” person in the general population. The 
importance of these techniques is so high, in 2016, President Barack Obama backed an 
initiative to fund precision medicine and accelerate this type of technology into everyday life. 
Personalized medicine has the potential to tailor therapy and inform targeted drug design for the 
best therapeutic responses and highest safety margins to overall ensure better patient care. 
Earlier diagnoses, informative risk assessments, and optimal treatments are pieces of human 
healthcare that should not be overlooked, and have the utmost potential to improve the quality 
of life for many people. 
 
By leveraging the tools and techniques I described throughout this dissertation, I feel I have had 
the opportunity to truly explore the potential that precision medicine has to change the 
landscape of scientific research and pharmaceutical manufacturing. I would like to take this 
opportunity to briefly summarize the salient findings I have presented, and touch on how I feel 
they all fit snugly together in the puzzle that is psychiatric health. 
 
We began our journey in the field of pharmacokinetics (PK), where I was able to learn a vast 
amount of both didactic knowledge and hands-on techniques for evaluating how drugs are 
processed by the human body and what this could mean for downstream effects and 
diagnostics. PK Case Study #1 was entitled CYP2D6, brain structure, and cognitive function in 
methamphetamine dependence and utilized functional genotyping at a pertinent metabolic 
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enzyme to assess whether or not MA addicts were more susceptible to neurodegredation based 
on variation at this locus’. Our data strongly support the hypothesis that CYP2D6 extensive 
metabolizers are more vulnerable to methamphetamine-induced neurotoxic effects than those 
with impaired enzymatic activity, resulting from common gene polymorphisms. This could be 
due to the fact that MA metabolites are more toxic to the underlying neurocircuitry and neuronal 
cells than the parent compound, and future toxicity studies can now address this issue. A clearly 
defined genetic risk factor such as this has the potential to be utilized by clinicians for both early 
intervention and individualized treatment planning, while also aiding in the development of harm 
reduction strategies, a lynchpin of personalized medicine. 
 
PK Case Study #2, Genetic Determinants of Risperidone Pharmacokinetics in Children with 
Autism Spectrum Disorder (ASD): Relationship to Treatment Outcomes and Side Effects, was 
my first exposure to the deleterious pharmaceutical side effect that is antipsychotic-induced 
weight gain. I was unaware back then of the implications, but this project is what truly piqued my 
interested in regard to defining pathways and mechanisms that are more closely related to our 
underlying biology, and through our examinations of the same liver based enzymatic genotype, 
we were able to understand how drug metabolites can also play a critical role in individual 
patient outcomes. The CYP2D6 poor metabolizer genotype group displayed 702% higher 
risperidone (RSP) and 133% higher total active moiety concentrations and RSP metabolism 
appears to be handled by different CYP metabolic pathways across ancestry. These data add to 
extant knowledge of moderators of RSP pharmacokinetics in humans, and while the entire 
picture is still somewhat poorly understood, this study may eventually help to identify patients 
who would benefit most from RSP therapy or are at highest risk for adverse outcomes. 
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From these promising roots in pharmacokinetics, I was able to make a smooth transition to the 
yin of this yang, pharmacodynamics (PD). Focusing efforts on how already known xenobiotic 
substances affect the human body is of great importance when considering new modality 
conception and synthesis further down the line. The comprehension I gained during my 
research in this field changed how I approach solving more complex enigmas related to a 
variety of human disease, and truly helped me learn a large amount of invaluable neurobiology. 
PD Case Study #1 was the Effect of Cigarette Smoking on a Marker for Neuroinflammation: A 
[11C]DAA1106 Positron Emission Tomography Study, a paper I was able to publish with 
fantastic collaborators and experts in the field. When activated, microglia increase the 
expression of translocator protein (TSPO) 18 kDa, thereby making the TSPO expression a 
marker for neuroinflammation, and we examined this diagnostic effect directly through 
radiochemistry in combination with genetics in a high-risk population. Cigarette smokers have 
less [11C]DAA1106 binding than non-smokers throughout the brain, indicating less TSPO 
availability, and though several explanations for this finding are possible, a straightforward one 
is that smoking results in global impairment of microglial activation which could lead to 
compromised wound healing throughout the body. As nicotine dependence is an immense and 
wide-spread public health issue, future research could examine the time course of recovery of 
TSPO availability upon smoking cessation and the interplay between smoking, 
neuroinflammation, and the progression of substance use disorder as well as other diseases 
thought to be mediated by neuroinflammation. 
 
And some of this future research came with a related pharmacodynamic study, seen in PD 
Case Study #2: Effect of overnight smoking abstinence on a marker for microglial activation: a 
[11C]DAA1106 positron emission tomography study. Again utilizing Using positron emission 
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tomography scanning, our group recently demonstrated that smokers in the satiated state had 
16.8% less binding of the radiotracer [11C]DAA1106 (a radioligand for TSPO) in the brain than 
nonsmokers. These results in overnight abstinent smokers are similar to those in satiated 
smokers, indicating that chronic cigarette smoking leads to global impairment of microglial 
activation which persists into early abstinence. Both studies were significant in the fact that they 
brought me the opportunity to discover more about theranostic platforms such as brain imaging, 
and how these can be implemented in cutting edge research to make informed choices of 
receptors in both investigatory science as well as drug delivery mechanisms. 
 
In order to lay the final brick in my formidable foundation of precision medicine repertoire, I had 
to dive deep into the world of genomic technology. At the end of the day, the true backbone of 
personalized medicine lies in DNA based understanding, applications, and manipulations. I was 
fortunate enough to participate in both major forms of human genetic evaluations currently used 
in medicine – candidate gene and genome-wide studies. GT Case Study #1 was titled 
Cholinergic Genetic Variation Moderates Smoking-Induced Striatal Dopamine Release and 
focused on a subset of nicotinic acetylcholine receptor encoding candidate genes to inform 
direct dopamine (DA) release variation in nicotine consumption. Findings at nicotinic α4 and α7 
cholinergic receptor subunits are consistent with animal and in vitro studies implicating these 
subunits in DA-mediated reinforcement associated with smoking. Correlation of these variants 
with behavioral endophenotypes suggests substantial effects on dependence and craving. 
Overall, a comprehensive understanding of genetic moderators of nicotine reward and 
dependence risk may facilitate the development and individualization of successful treatment 
strategies. 
 
249 
 
GT Case Study #2: Polygenic Contributions to Decision-Making on a Laboratory Test of 
Reward-Based Risk-Taking was one of the more critical projects that I had to the chance to 
develop and participate in due to its usage of genome-wide association studies and polygenic 
risk scores, two of the most pertinent genomic approaches. Heightened risk-taking behavior has 
been linked to neuropsychiatric disorders, such as Attention Deficit-Hyperactive Disorder 
(ADHD), addictions, and mood disorders, and our findings confirm a heritable, polygenic 
component to risky decision-making explaining 11% of the variance in balloon analog risk task 
(BART) performance. We demonstrated for the first time that polygenic scores derived from a 
genome-wide association study of a risk-taking phenotype successfully predict the same 
phenotype in an independent sample and revealed shared genetic underpinnings with 
categorical bipolar diagnosis. This is a succinct and effective biomarker, one of the true 
hallmarks of precision medicine. Having the confidence and grasp on the genomic technology 
involved in disentangling biomarkers such as this will be indispensable in my future career. 
 
As I moved forward and began to apply these principles to environmental factors, the story of 
my research began to take an entirely new shape. We do not live in a vacuum, and to not 
consider how profoundly the world around us affects our health on a cellular level would be 
foolish. Due to Dr. Nurmi’s strong connections with a top researcher in the field of childhood 
attachment, I was able to work on understanding how our genes and the environment interact to 
engender various disease states as well as treatment outcomes. The first endeavor, GxE Case 
Study #1: Interactive effects of attachment and FKBP5 genotype on school-aged children's 
emotion regulation and depressive symptoms, was a wonderful way to expose me to the 
intricate workings of gene-environment interactions. Research demonstrates that child 
attachment insecurity and genetic factors are each associated with elevated risk for emotion 
dysregulation and psychopathology but had not been considered in tandem. Higher levels of 
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overcontrol predicted lower child attachment security only in FKBP5 minor allele carriers, and 
these findings can be conceptualized in a differential susceptibility framework, where the FKBP5 
minor allele confers either risk or resilience, depending on the parenting environment. 
 
Following up with the same encouraging team, I worked on GxE Case Study #2: Interaction 
between the Opioid Receptor OPRM1 Gene and Mother-Child Language Style Matching 
Prospectively Predicts Children's Separation Anxiety Disorder Symptoms. Psychiatric disorders 
tend to be particularly distressing in children and adolescents, and this is especially true for 
anxiety-based disorders, yet they remain largely underexplored in this population. There is also 
considerable evidence of genetic risk for anxiety, including possession of the OPRM1 minor 
allele, 118G, and the interaction between mother-child language style matching and OPRM1 
genotype significantly predicted separation anxiety disorder (SAD) symptoms beyond the main 
effects of the two variables in our study. Greater knowledge of the factors that contribute to the 
development of SAD can inform both treatment and preventative measures, and this could point 
toward the importance of testing whether interventions designed to strengthen the parent-child 
relationship reduce the risk of developing SAD symptoms in children who carry the minor 
OPRM1 allele. As precision medicine pushes the agenda of implementing standard patient 
genotyping, studies such as these provide cardinal information on how these new and strange 
health data can be utilized and tailored based on each person’s unique situation. 
 
And finally, we come to the apogee of my doctoral research career. Through serendipitous 
events that I will discuss briefly in my final thoughts following this section, I came to discover the 
fascinating world that is that surrounding the human gut microbiome. Over the last 10 years, 
scientists have begun to unearth the almost limitless potential the gut microbiota and 
microbiome bring to elucidating human disease pathophysiology. I knew immediately when I 
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first began reading about this symbiotic presence contained within all of us that I wanted to 
incorporate it in my PhD project; so I set out to accomplish just that. The final chapter of my 
story highlights the blood, sweat, and tears that I poured into my work on bile acid and gut 
microbiome crosstalk. I stumbled into the world of bioanalytics ignorant and bright eyed, but 
quickly realized the true potential it has to inform us about biochemical moieties that could 
influence disease and adverse drug side effects. My original method: Fit-For-Purpose HPLC-
MS/MS Targeted Detection and quantitation of 11 Bile Acids and Their Biological Precursor, 7-
alpha-hydroxycholest-4-en-3-one was a labor of love, and it plays a pivotal role in my proposed 
research study. Classically, bile acids (BA) are defined as our body’s simple detergent 
molecules. They are produced in our liver from the catabolism of cholesterol and stored in the 
gallbladder. Due to their steroidal backbone, they can act as hormones and have significant 
regulatory effects in host energy metabolism. They accomplish this through binding at various 
nuclear receptors in the gut and liver, namely FXR (farnesoid X receptor) and PXR (pregnagane 
X receptor) but also G-protein coupled receptors (such as TGR5). These have serious 
downstream impact on glucose and lipid homeostasis, as well as pathway functions in disease 
states such as cirrhosis and cancer tumorogenesis. I identified an unmet need in the mass spec 
quantification of these compounds in human matrices and was able to develop a novel method 
for their robust detection. I am still adding additional bile acids to this method as I write this, and 
it has the potential for even more growth in the future! 
 
The real dessert came when I had the opportunity to apply this bioanalytic method to actual 
patient samples in my microbiota-host interaction Case Study #1: A Putative Development 
Pathway; Microbiome – Bile Acid Cross Talk in the Biological Mechanism of Psychotropic-
Induced Weight Gain. I assembled a top tier collaborative research team to aid me in my quest 
to better understand the biochemical circuitry and pathways involved in the complex weight gain 
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and metabolic syndrome that plagues the majority of patients taking psychotropic medications. 
Differential risk across the drug class is not explained by simple receptor binding profiles at 
contributing sites such as the muscarinic system, but other mechanistic links are lacking.  We 
observed marked changes in the total BA pool and diversity, with predominant increases in 
1° BAs. Primary BAs were significantly more pronounced in those with high versus low 
antipsychotic-induced weight gain (AIWG), and in this subset showing BA change with 
antipsychotic treatment, the ratio of the change in CDCA to the change in UDCA 
differentiated those with AIWG (∆CDCA/∆UDCA>1) from those without (∆CDCA/∆UDCA<1).  
Because of these strong biomarker-based findings, but the paucity of understanding on why 
this might be, we began to pull in previous data from collaborators in the same populations 
involving the gut microbiota composition. We crafted an expositive mechanism of 
psychotropic-induced weight gain leverage both of these salient factors, and with the help of 
the incredible scientists around me, I drafted a replication project grant proposal to link bile 
acid changes to gut microbiota shifts in individuals experience the deleterious effects of 
weight gain following antipsychotic medication treatment, which is currently in progress and 
explained in the future directions above this blurb. Encouragingly, a recent paper published in 
Nature Medicine reveals that metformin, a medication commonly used to treat antipsychotic-
induced weight gain, acts through the microbiome-bile acid signaling pathway that we 
identified in our study, further validating our hypothesis.601, 602 This opens the door to very 
personalized and patient centered treatment approaches, and even hopefully one day, informed 
and specific biological targets for future drug design in these areas, as I believe we have 
brought yet another piece of the AIWG puzzle to the table, and hopefully clinical implementation 
might not be far away. 
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My Final Thoughts 
 
I believe I had a truly unique and inspiring graduate school experience. There was a defining 
moment in my undergraduate career when it hit me that chemistry was my calling. I had been a 
psychology major for three years, intending to continue on to medical school to become a 
psychiatrist. Pursuing the chemistry requirements for this goal led me to discover my love and 
talent for this versatile and fascinating subject. As my chemistry professors recognized my 
aptitude and excitement, they urged me to switch my major. The decision to alter my path 
crystallized when I realized that using chemistry to design new therapeutics was the way I could 
best contribute my talents towards healing and medicine.  
 
As I pursued my studies here at UCLA, completing chemistry graduate courses and teaching 
undergraduate chemistry labs, I considered how my science might have real-world impact. 
However, I was met with an unfortunate situation; the year I matriculated, there were an 
abundance of students in the organic chemistry discipline. Combined with a tepid funding 
environment, most of the labs I was initially interested in being a part of were full or not taking 
more students due to this lack of resources. I struggle for close to a year to find somewhere that 
I might belong in the scientific community and was beginning to feel hopeless when I stumbled 
across the laboratory of Dr. Erika Nurmi. I realized that my background in organic chemistry would 
provide a solid foundation for translational research. The many opportunities to integrate my 
chemistry background with translational projects in psychiatry and clinical medicine drew me to 
her unique style of research, as she is a neuroscience PhD but also an actively practicing 
psychiatrist. To me, she has always been Wonder Woman. Not only does she attempt to do it all 
in terms of teaching, guiding new students, treating patients, running clinics, provoking novel 
research, and challenging the status quo of women in science, but she also made time to be my 
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mentor in this crazy journey. She helped me form the beautiful story that I presented to you today, 
and I could not be prouder of what I’ve accomplished under her nourishing wings.  
 
As my research has progressed, I have come to appreciate the need for biologically based, 
personalized treatments for a myriad of debilitating disorders. Specifically, in the field of 
psychiatry, targeted drug therapies are lacking, and those pharmaceuticals currently in use show 
wide variability in efficacy across individuals. I have found my niche in a personalized medicine 
field known as pharmacomicrobiomics, which aims to capture the gut microbiome’s interaction 
with human ingested xenobiotics and pharmaceuticals. My flagship dissertation project presented 
in chapters 6 and 7 embodies my passion about this subject, as I have strong personal ties to 
metabolic syndrome. My entire life I have struggled with my weight; I was obese before I even 
knew what the word medically meant. When I moved to California to attend graduate school, I left 
everything I had ever known behind on the East coast, and that negatively impacted my health 
even more. I reached almost 400 pounds my second year of education here at UCLA, and beyond 
anything else, I knew I NEVER wanted anyone else to ever feel the way that I felt in that moment. 
I spent sleepless nights and countless hours researching the gut microbiota and how they might 
influence obesity, weight-gain, weight-loss, and associated diseases. While my own journey 
swept me through losing over 230 pounds over the next 3 years, I couldn’t not confer this 
knowledge to the research community. Even if it only helped one person in the future, I knew it 
was vital that I incorporate the human microbiota and microbiome into a meaningful scientific 
study. 
 
 
My personal dissertation project and culmination of the tools and techniques I previously 
examined begins to elucidate a direct biological link to the unexplored partners of the gut 
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microbiome and bile acids. This work specifically aims to confirm the link between microbiome 
changes and antipsychotic-induced weight gain, to further define concrete biological mechanisms 
underlying this serious adverse event, and to ideally present clinically relevant biomarkers for the 
advancement of future research and treatment. I believe that my unique training and skillset offer 
a unique perspective to the pharmacomicrobiomics and precision medicine disciplines. Through 
my initial undergraduate and graduate education, I have developed the organic and analytical 
chemistry skills for a future in targeted drug design; however, the second phase of my graduate 
training provides me the necessary understanding of brain and gut biology that will inform my 
choice of drug targets. Insights about the underpinnings of complex pharmaceutical responses 
revealed by mechanistic and genetic studies, such as those I have begun to examine, will provide 
rich future opportunities to unite my inner chemist and biologist in the development of novel 
therapeutics to improve overall health and quality of life.  
 
 
While my choice to incorporate learning a whole new field into my training has made this trajectory 
lengthy and challenging, my project has already delivered publishable results that have generated 
great enthusiasm in my field. I plan to complete the confirmatory analyses that will solidify this 
project even as I move away to the next phase of my scientific career. It will also pave the way 
for this endeavor, as I integrate my interests in clinical biomarkers, psychopathology, and 
effective, individualized treatments. My work has the potential to solve a problem that has 
perplexed the field for many years, will have clear clinical implications and will highlight viable 
treatment strategies for implementation work. After completion of my doctorate, I hope to pursue 
a scientific position in the pharmaceutical industry where I can leverage the knowledge and skills 
I have acquired during my graduate training to design, develop, and deliver precision therapeutics 
for psychiatric disease. 
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I hope to not only become a shining member of the biotechnology industry with my unique 
approach to solving scientific perplexities that I garnered from the precision medicine tool box I 
put together over the last six years, but I also strive to bring passion and compassion into my 
work. This planet is a beautiful place, and life is a wonderful experience. We all deserve the best 
care, the most happiness, and the brightest of futures. I want to provide that for people that may 
have lost hope along the way. I want to transform the way we approach the treatment of grievous 
diseases. I want to change the world. And while it may sound like I’m auditioning for Miss America; 
I am beyond content to instead be receiving the title of Dr. Lauren Seaman. Thank you for your 
time and for being a part of my story. 
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